<?xml version="1.0" encoding="utf-8"?><Summary xmlns:msxsl="urn:schemas-microsoft-com:xslt" xmlns:scripts="urn:local-scripts"><Span Class="Summary-Title">Genetics of Breast and Ovarian Cancer</Span><ul><li Class="Summary-SummaryTitle-Level1"><a href="#Section_1"><Span class="Summary-SummarySection-Title-Level1">Introduction</Span><br /><br /></a></li><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_2"><Span class="Summary-SummarySection-Title-Level2">General Information</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_6"><Span class="Summary-SummarySection-Title-Level2">Family History as a Risk Factor for Breast Cancer</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_11"><Span class="Summary-SummarySection-Title-Level2">Family History as a Risk Factor for Ovarian Cancer</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_15"><Span class="Summary-SummarySection-Title-Level2">Autosomal Dominant Inheritance of Breast/Ovarian Cancer Predisposition</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_22"><Span class="Summary-SummarySection-Title-Level2">Difficulties in Identifying a Family History of Breast Cancer Risk</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_25"><Span class="Summary-SummarySection-Title-Level2">Other Risk Factors for Breast Cancer</Span></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_338"><Span class="Summary-SummarySection-Title-Level3">Age</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_339"><Span class="Summary-SummarySection-Title-Level3">Reproductive and Menstrual History
</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_340"><Span class="Summary-SummarySection-Title-Level3">Hormone Therapy</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_341"><Span class="Summary-SummarySection-Title-Level3">Radiation Exposure</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_342"><Span class="Summary-SummarySection-Title-Level3">Lifestyle Factors</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_343"><Span class="Summary-SummarySection-Title-Level3">History of Breast Disease</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_344"><Span class="Summary-SummarySection-Title-Level3">Other Factors</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_56"><Span class="Summary-SummarySection-Title-Level2">Other Risk Factors for Ovarian Cancer</Span></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_345"><Span class="Summary-SummarySection-Title-Level3">Age</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_346"><Span class="Summary-SummarySection-Title-Level3">Demographic</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_347"><Span class="Summary-SummarySection-Title-Level3">Reproductive
</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_348"><Span class="Summary-SummarySection-Title-Level3">Surgical History
</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_66"><Span class="Summary-SummarySection-Title-Level2">Models for Prediction of Breast Cancer Risk</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_89"><Span class="Summary-SummarySection-Title-Level2">Introduction</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_95"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA1</Span></Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_97"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA2</Span></Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_99"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> Function</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_110"><Span class="Summary-SummarySection-Title-Level2">Mutations in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span></Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_113"><Span class="Summary-SummarySection-Title-Level2">Prevalence and Founder Effects</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_117"><Span class="Summary-SummarySection-Title-Level2">Penetrance of Mutations</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_79"><Span class="Summary-SummarySection-Title-Level2">Models for Prediction of the Likelihood of a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> Mutation</Span></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_652"><Span class="Summary-SummarySection-Title-Level3">Population Estimates of the Likelihood of Having a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> Mutation</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_125"><Span class="Summary-SummarySection-Title-Level2">Role of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> in Sporadic Cancer</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_129"><Span class="Summary-SummarySection-Title-Level2">Molecular Correlations</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_136"><Span class="Summary-SummarySection-Title-Level2">Pathology/Prognosis of Breast Cancer</Span><br /><br /></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_759"><Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">BRCA1</Span></Span><br /><br /></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_766"><Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">BRCA2</Span></Span><br /><br /></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_408"><Span class="Summary-SummarySection-Title-Level2">Pathology/Prognosis of Ovarian Cancer</Span><br /><br /></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_784"><Span class="Summary-SummarySection-Title-Level3">Pathology</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_785"><Span class="Summary-SummarySection-Title-Level3">Prognosis</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_144"><Span class="Summary-SummarySection-Title-Level2">Li-Fraumeni Syndrome</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_756"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">CHEK2</Span></Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_148"><Span class="Summary-SummarySection-Title-Level2">Cowden’s Syndrome</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_150"><Span class="Summary-SummarySection-Title-Level2">Ataxia Telangiectasia</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_153"><Span class="Summary-SummarySection-Title-Level2">Peutz-Jeghers Syndrome</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_157"><Span class="Summary-SummarySection-Title-Level2">Background</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_159"><Span class="Summary-SummarySection-Title-Level2">Summary of Evidence</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_161"><Span class="Summary-SummarySection-Title-Level2">Significance</Span><br /><br /></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_349"><Span class="Summary-SummarySection-Title-Level3">Cytochrome p450 Enzymes</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_351"><Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">N-acetyl transferase 1</Span> and <Span Class="Protocol-GeneName">N-acetyl transferase 2</Span></Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_352"><Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">Glutathione S-transferase</Span></Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_177"><Span class="Summary-SummarySection-Title-Level2">Breast Cancer</Span><br /><br /></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_355"><Span class="Summary-SummarySection-Title-Level3">Screening</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_360"><Span class="Summary-SummarySection-Title-Level3">Prevention</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_389"><Span class="Summary-SummarySection-Title-Level2">Ovarian Cancer</Span><br /><br /></a></li></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_390"><Span class="Summary-SummarySection-Title-Level3">Screening</Span></a></li></ul></ul><ul><ul><li Class="Summary-SummaryTitle-Level3"><a href="#Section_395"><Span class="Summary-SummarySection-Title-Level3">Prevention</Span></a></li></ul></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_272"><Span class="Summary-SummarySection-Title-Level2">Introduction</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_276"><Span class="Summary-SummarySection-Title-Level2">Anticipated and Actual Interest in Genetic Testing</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_285"><Span class="Summary-SummarySection-Title-Level2">What People Bring to Genetic Testing: Impact of Risk Perception, Health Beliefs, and Personality Characteristics</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_290"><Span class="Summary-SummarySection-Title-Level2">Genetic Counseling for Hereditary Predisposition to Breast Cancer</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_298"><Span class="Summary-SummarySection-Title-Level2">Emotional Outcomes of Individuals</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_303"><Span class="Summary-SummarySection-Title-Level2">Family Effects</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_308"><Span class="Summary-SummarySection-Title-Level2">Cultural/Community Effects</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_310"><Span class="Summary-SummarySection-Title-Level2">Ethical Concerns </Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_313"><Span class="Summary-SummarySection-Title-Level2">Psychological Aspects of Medical Interventions</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_602"><Span class="Summary-SummarySection-Title-Level2">Psychosocial Outcome Studies</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_327"><Span class="Summary-SummarySection-Title-Level2">Interventions: Psychological</Span></a></li></ul><ul><li Class="Summary-SummaryTitle-Level2"><a href="#Section_332"><Span class="Summary-SummarySection-Title-Level2">Behavioral Outcomes</Span></a></li></ul></ul><a name="Section_1">
        <Span class="Summary-SummarySection-Title-Level1">Introduction</Span><br /><br />

<a name="Section_2"><Span class="Summary-SummarySection-Title-Level2">General Information</Span>
<a name="Section_3" /><P __id="_3">Among women, breast cancer is the most commonly diagnosed cancer after
nonmelanoma skin cancer, and is the second leading cause of cancer deaths after
lung cancer.  In 2005, an estimated 212,930 new cases will be diagnosed, and
40,870 deaths from breast cancer will occur.<a href="#Reference1.1">1</a> (Refer to the PDQ summary on <SummaryRef href="CDR0000062787">Breast Cancer Treatment</SummaryRef> for more information on breast cancer rates, diagnosis, and management.)</P>
<a name="Section_4" /><P __id="_4">A possible genetic contribution to breast cancer risk is indicated by the
increased incidence of breast cancer among women with a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=302456&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000302456&amp;version=HealthProfessional&amp;language=English');  return(false);">family history</a> of
breast cancer, and by the observation of rare families in which multiple family
members are affected with breast cancer, in a pattern compatible with <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339338&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339338&amp;version=HealthProfessional&amp;language=English');  return(false);">autosomal
dominant</a> inheritance of cancer susceptibility.
</P>
<a name="Section_5" /><P __id="_5">Formal studies of families (<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=425374&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000425374&amp;version=HealthProfessional&amp;language=English');  return(false);">linkage analysis</a>) have subsequently proven the
existence of autosomal dominant forms of breast cancer, and have led to the
identification of several highly <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339344&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339344&amp;version=HealthProfessional&amp;language=English');  return(false);">penetrant</a> <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=HealthProfessional&amp;language=English');  return(false);">genes</a> of major effect as the cause
of inherited cancer risk in many cancer-prone families.  (Refer to the PDQ
summary   <SummaryRef href="CDR0000062838">Cancer Genetics Overview</SummaryRef> for more information on linkage
analysis.) <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46063&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=HealthProfessional&amp;language=English');  return(false);">Mutations</a> in these genes are rare and are estimated to account for no more
than 5% to 10% of breast cancer cases overall.  It is likely that other
background genetic factors contribute to the etiology of breast cancer.
</P>
</a>
<a name="Section_6"><Span class="Summary-SummarySection-Title-Level2">Family History as a Risk Factor for Breast Cancer</Span>
<a name="Section_7" /><P __id="_7">In cross-sectional studies of adult populations, 5% to 10% of women have a
mother or sister with breast cancer, and about twice as many have either a
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460150&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460150&amp;version=HealthProfessional&amp;language=English');  return(false);">first-degree relative</a> or a second-degree relative with breast cancer.<a href="#Reference1.2">2</a><a href="#Reference1.3">3</a><a href="#Reference1.4">4</a><a href="#Reference1.5">5</a>  The risk
conferred by a family history of breast cancer has been assessed in both
case-control and cohort studies, using volunteer and population-based samples,
with generally consistent results.<a href="#Reference1.6">6</a>  In a pooled analysis of 38 studies, the
relative risk of breast cancer conferred by a first-degree relative with breast
cancer was 2.1 (95% confidence interval CI, 2.0-2.2).<a href="#Reference1.6">6</a>
</P>
<a name="Section_8" /><P __id="_8">Risk varies with the age at which the affected relative was diagnosed: the
younger the affected relative, the greater the risk posed to
relatives.<a href="#Reference1.2">2</a><a href="#Reference1.3">3</a><a href="#Reference1.4">4</a><a href="#Reference1.6">6</a><a href="#Reference1.7">7</a><a href="#Reference1.8">8</a>  This effect was strongest for women younger than 50 years who had a
first-degree relative affected before age 50 years (RR = 3.3; 95% CI, 2.8-3.9).<a href="#Reference1.6">6</a> 
</P>
<a name="Section_9" /><P __id="_9">The number of affected relatives and the closeness of their biologic
relationship are also important factors.<a href="#Reference1.3">3</a><a href="#Reference1.4">4</a><a href="#Reference1.6">6</a>  In general, the greater the
number of affected relatives and the closer the biologic relationship, the
greater the risk.<a href="#Reference1.3">3</a><a href="#Reference1.4">4</a><a href="#Reference1.6">6</a>  The number of female relatives in the family
influences both the utility of the family history as a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460214&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460214&amp;version=HealthProfessional&amp;language=English');  return(false);">risk assessment</a> tool as well as the significance of the family history.  In families
with few women, it may be difficult to identify a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=256553&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000256553&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic susceptibility</a> to
breast or other female cancers.  If a family has many
female members, the proportion of affected relatives may be a more
important indicator of risk than the number of affected relatives.
</P>
<a name="Section_10" /><P __id="_10">Studies of family history of ovarian cancer suggest an association with
breast cancer risk.  A first-degree relative with ovarian cancer confers a
modest risk of breast cancer. The odds ratio (OR) derived from a case-control
study based on the Utah Cancer Registry was 1.27 (95% CI, 0.91-1.77),<a href="#Reference1.9">9</a> and
other studies have found no evidence of increased risk.<a href="#Reference1.7">7</a><a href="#Reference1.10">10</a>  When the Utah
data were analyzed according to a family history score (based on
characteristics that included number of relatives with ovarian cancer, their
age at diagnosis, and biologic relatedness), however, the OR for women
with a score of 5 or higher (3% of the population) was 1.60 (95% CI,
1.03-2.43); for women with scores of 2.0 to 4.9 (12% of the population),
the OR was 1.15 (95% CI, 1.01-1.36).<a href="#Reference1.9">9</a>  The presence of both breast and
ovarian cancer in a family increases the likelihood that a cancer-predisposing
mutation is present.<a href="#Reference1.11">11</a><a href="#Reference1.12">12</a> 
</P>
</a>
<a name="Section_11"><Span class="Summary-SummarySection-Title-Level2">Family History as a Risk Factor for Ovarian Cancer</Span>
<a name="Section_12" /><P __id="_12">In the United States the lifetime risk for developing ovarian cancer is
approximately 1/70, or 1.4%, accounting for an estimated 22,220 new cases and 16,210 deaths in 2005.<a href="#Reference1.1">1</a>  Although reproductive, demographic, and lifestyle
factors affect risk of ovarian cancer, the single greatest ovarian cancer risk
factor is a family history of the disease.  A population-based case-control
study evaluated the degree of aggregation of epithelial ovarian cancer in
families.  In this study of nearly 3,000 ovarian cancer cases and controls, a
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460148&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460148&amp;version=HealthProfessional&amp;language=English');  return(false);">familial</a> clustering of ovarian cancer was noted.  The OR for ovarian
cancer in relatives of ovarian cancer cases compared with controls was 3.6 for
first-degree relatives and 2.9 for second-degree relatives.<a href="#Reference1.13">13</a>
</P>
<a name="Section_13" /><P __id="_13">Pooled estimates of relative risk from 7 case-control studies, including the
Cancer and Steroid Hormone (CASH) study, were derived.  The estimated OR for ovarian cancer was 3.1 (95% CI, 2.1-4.5) for a woman with a single
first-degree relative with ovarian cancer, and 4.6 (95% CI, 1.1-18.4) for a
woman with 2 or 3 relatives with ovarian cancer; this translates into lifetime
probabilities of ovarian cancer of 5.0% and 7.2%, respectively.<a href="#Reference1.14">14</a>
</P>
<a name="Section_14" /><P __id="_14">An analysis of published case-control and cohort studies in ovarian cancer that
included nearly 18,000 women was performed.  In this series, the relative risk
of ovarian cancer for women with a first-degree family history of ovarian
cancer was 3.1, which is consistent with that reported by others.  In this
study, the relative risk to mothers of ovarian cancer cases was substantially
lower than the relative risk to sisters and daughters.  The lower cancer risk
to mothers observed in this study is not easily explained.<a href="#Reference1.15">15</a>
</P>
</a>
<a name="Section_15"><Span class="Summary-SummarySection-Title-Level2">Autosomal Dominant Inheritance of Breast/Ovarian Cancer Predisposition</Span>
<a name="Section_16" /><P __id="_16">Autosomal dominant inheritance of breast/ovarian cancer is characterized by transmission of
cancer <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460153&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460153&amp;version=HealthProfessional&amp;language=English');  return(false);">predisposition</a> from generation to generation, with a 50% risk to offspring of
inheriting the predisposing genetic alteration.  The
susceptibility may be inherited through either the mother’s or the father’s
side of the family.
</P>
<a name="Section_726" /><a name="ListSection" /><UL __id="_726" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Inheritance risk of 50%. When a parent carries an autosomal dominant genetic predisposition, each child has a 50% chance of inheriting the predisposition. Although the risk of inheriting the predisposition is 50%, it is important to remember that not everyone with the predisposition will develop cancer because of incomplete penetrance and/or gender-restricted or gender-related expression.</LI><br /><br /><LI class="Protocol-IL-Bullet">Both males and females can inherit and transmit an autosomal dominant   
cancer predisposition.  Thus, the mutant gene can be passed on to either  
male or female children.  In the case of breast cancer, the cancer     
risk is manifested primarily in women; males with the inherited  
breast cancer predisposition (especially <Span Class="Protocol-GeneName">BRCA2</Span>-related) may develop breast cancer as well, but it is still rare in this setting.  A male who        
inherits a cancer predisposition and shows no evidence of it can still
pass the altered gene on to his sons and daughters.
</LI><br /><br /></UL><a name="END_ListSection" /><a name="Section_17" /><P __id="_17">Once this dominant inheritance pattern has been established through analysis of
family history (<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44868&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044868&amp;version=HealthProfessional&amp;language=English');  return(false);">pedigree</a> analysis), the task becomes one of determining a
diagnosis of a specific cancer susceptibility <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339343&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339343&amp;version=HealthProfessional&amp;language=English');  return(false);">syndrome</a>, since the
susceptibility can be because of different genetic syndromes for any given type of
cancer, such as breast cancer.
</P>
<a name="Section_18" /><P __id="_18">Thus far, the syndromes most strongly associated with an autosomal dominant inheritance
of breast cancer risk are hereditary breast and ovarian cancer due to <Span Class="Protocol-GeneName">BRCA1</Span> or
<Span Class="Protocol-GeneName">BRCA2</Span> mutations, <SummaryRef href="CDR0000062855#_144">Li-Fraumeni syndrome</SummaryRef> due to <Span Class="Protocol-GeneName">TP53</Span> mutations, and <SummaryRef href="CDR0000062855#_148">Cowden's syndrome</SummaryRef> due to <Span Class="Protocol-GeneName">PTEN</Span> mutations.<a href="#Reference1.16">16</a> Mutations in each of these genes produce different
clinical <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460203&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460203&amp;version=HealthProfessional&amp;language=English');  return(false);">phenotypes</a> of characteristic malignancies and, in some instances,
associated nonmalignant abnormalities.  The specific phenotypic characteristics
are discussed later in this section.
</P>
<a name="Section_19" /><P __id="_19">Other genetic syndromes that may include breast cancer as an associated
feature include <SummaryRef href="CDR0000062855#_150">ataxia telangiectasia</SummaryRef> (AT) and <SummaryRef href="CDR0000062855#_153">Peutz-Jeghers syndrome</SummaryRef>.  Ovarian
cancer has also been associated with basal cell nevus (Gorlin) syndrome,
<SummaryRef href="CDR0000062890#_117">multiple endocrine neoplasia type 1</SummaryRef> (MEN1), and <SummaryRef href="CDR0000062863#_120">hereditary nonpolyposis colon
cancer</SummaryRef> (HNPCC).<a href="#Reference1.16">16</a>  In addition, a variety of other genes have alterations that
probably produce effects that are less recognizable as autosomal dominant
genetic syndromes.  Some of these are discussed in the <SummaryRef href="CDR0000062855#_156">Genetic Polymorphisms
and Breast Cancer Risk</SummaryRef> section of this summary.
</P>
<a name="Section_20" /><P __id="_20">The family characteristics that suggest hereditary breast and ovarian cancer predisposition include the following: 
</P>
<a name="Section_21" /><a name="ListSection" /><UL __id="_21" class="Protocol-UL">


<LI class="Protocol-IL-Bullet">Cancers that typically occur at an earlier age than in
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339347&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339347&amp;version=HealthProfessional&amp;language=English');  return(false);">sporadic</a> cases (defined as cases not associated with genetic risk).
</LI><br /><br />
<LI class="Protocol-IL-Bullet">Two or more primary
cancers in a single individual.  These could be multiple
primary cancers of the same type (e.g., bilateral breast cancer) or
primary cancer of different types (e.g., breast and ovarian cancer in
the same individual).
</LI><br /><br /><LI class="Protocol-IL-Bullet">Cases of male breast cancer.</LI><br /><br /><LI class="Protocol-IL-Bullet">Possible increased risk of other selected cancers
and benign features for males and females. (Refer to the <SummaryRef href="CDR0000062855#_88">Major Genes</SummaryRef> section of this summary for more information.)</LI><br /><br /></UL><a name="END_ListSection" />
<a name="Section_789" /><P __id="_789">Besides the characteristics outlined above, breast and ovarian cancers occurring in <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460132&amp;version=HealthProfessional&amp;language=English');  return(false);">carriers</a> generally do not differ dramatically from sporadic cases occurring in noncarriers and thus far have no known pathognomonic features.  [Refer to the <SummaryRef href="CDR0000062855#_136">Pathology/Prognosis of Breast Cancer</SummaryRef> and <SummaryRef href="CDR0000062855#_408">Pathology/Prognosis of Ovarian Cancer</SummaryRef> sections for more information.]</P></a>
<a name="Section_22"><Span class="Summary-SummarySection-Title-Level2">Difficulties in Identifying a Family History of Breast Cancer Risk</Span>
<a name="Section_23" /><P __id="_23">When using family history to assess risk, the accuracy and completeness of family history data must be taken into account.  A reported family history may be
erroneous, or a person may be unaware of relatives affected with cancer.  In
addition, small family sizes and premature deaths may limit the information
obtained from a family history.  In the case of breast cancer, cancer on the
paternal side of the family usually involves more distant relatives than on the
maternal side and thus may be more difficult to obtain.
</P>
<a name="Section_24" /><P __id="_24">A comparison of self-reported family history to data from the Utah Population
Database indicates a sensitivity of 83% (95% CI, 66%-93%) for reported family
history of breast cancer; a measure of overall agreement between the reported
family history and the database (kappa score) was 0.63 (95% CI, 0.52-0.73),
indicating moderate agreement.<a href="#Reference1.17">17</a>  Family history was less accurate for most
other cancers, e.g., the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=322883&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000322883&amp;version=HealthProfessional&amp;language=English');  return(false);">sensitivity</a> of a family history of ovarian cancer was
60% (95% CI, 17%-93%), with a kappa score of 0.36 (95% CI, 0.26-0.48).<a href="#Reference1.17">17</a>  In a
Canadian study, accuracy of a reported family history of breast cancer was
assessed through review of the medical records of relatives reported as
affected for a consecutive series of women with breast cancer and for a
population-based sample of women without breast cancer.<a href="#Reference1.18">18</a>  Among cases, 16%
reported a first-degree relative with breast cancer; 91% of verifiable
histories were confirmed.  Among controls, 9% reported a first-degree relative
with breast cancer; 97% of verifiable histories were confirmed.<a href="#Reference1.18">18</a> 
</P>
</a>
<a name="Section_25"><Span class="Summary-SummarySection-Title-Level2">Other Risk Factors for Breast Cancer</Span>
<a name="Section_26" /><P __id="_26">Other risk factors for breast cancer include age, reproductive and menstrual history, hormone therapy, radiation exposure, mammographic breast density, lifestyle factors, and history of breast disease.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef>
for more information.)  Relatively few studies have addressed the effect of
these risk factors in women who are genetically susceptible to breast cancer. 
</P>
<a name="Section_338">

<Span class="Summary-SummarySection-Title-Level3">Age</Span>


<a name="Section_28" /><P __id="_28">Cumulative risk of breast cancer increases with age, with most breast cancers
occurring after age 50 years.<a href="#Reference1.19">19</a>  In women with a genetic susceptibility, breast
cancer tends to occur at an earlier age than in sporadic cases.  </P><a name="Section_963" /><P __id="_963">However, the
frequency of genetic mutations related to breast cancer risk is small even
among women with breast cancer at an early age.  In 2 of the largest population-based series of breast cancer patients from the United Kingdom, 5.9% of 234 women diagnosed younger than age 35 had a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation, and 4.1% of those diagnosed between ages 36 to 45 were positive.<a href="#Reference1.20">20</a></P><a name="Section_29" /><P __id="_29">In cancer-prone families, the mean age of breast cancer diagnosis among women
carrying <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations is in the 40s.<a href="#Reference1.21">21</a>  Estimates of risk
obtained using the Claus model, a statistical model based on data from the
Cancer and Steroid Hormone Study (discussed further below), also suggest an
earlier age of onset in women who have a mother or sister affected with breast
cancer at an early age.<a href="#Reference1.22">22</a> 
</P>
</a>



<a name="Section_339">

<Span class="Summary-SummarySection-Title-Level3">Reproductive and Menstrual History
</Span>


<a name="Section_31" /><P __id="_31">Breast cancer risk increases with early menarche and late menopause, and is
reduced by early first full-term pregnancy.  In the Nurses’ Health Study, these
factors influenced breast cancer risk only among women who did not have a
mother or sister with breast cancer.<a href="#Reference1.23">23</a>  In women with known mutations of the
<Span Class="Protocol-GeneName">BRCA1</Span> gene, however, a protective effect has been seen with early age at first
live birth, and also with parity of 3 or more.<a href="#Reference1.24">24</a><a href="#Reference1.25">25</a>  In a study of 1,200 case-control pairs of women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations, parity per se was not associated with breast cancer risk in <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, but women with more than 4 children had a 38% lower risk compared with nulliparous carriers.<a href="#Reference1.26">26</a>  In contrast,<a href="#Reference1.26">26</a> among <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers, increased parity was associated with a significant increase in the risk of breast cancer before age 50, and this increase was greatest in the 2-year period following a pregnancy. Some of these studies also found
a higher rate of cancer and earlier age at cancer diagnosis in recent birth
cohorts of women with <Span Class="Protocol-GeneName">BRCA1</Span> mutations, compared with older relatives.  This
difference was only partially explained by differences in reproductive history,
suggesting that other factors may also influence risk in this genetically
susceptible group.<a href="#Reference1.24">24</a><a href="#Reference1.25">25</a>  Early menarche has been associated with increased risk among <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers but appeared not to influence risk in <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.<a href="#Reference1.27">27</a> 
In both the general population and <Span Class="Protocol-GeneName">BRCA1</Span> carriers, some evidence exists of a slight-to-moderate reduction in breast cancer risk with breastfeeding for at least one year.<a href="#Reference1.28">28</a><a href="#Reference1.29">29</a></P>
</a>


<a name="Section_340">

<Span class="Summary-SummarySection-Title-Level3">Hormone Therapy</Span>


<a name="Section_33" /><P __id="_33">Oral contraceptives may produce a slight increase in breast cancer risk among
long-term users, but this appears to be a short-term effect.  A meta-analysis
of data from 54 studies identified a relative risk (RR) of 1.24 (95% CI, 1.15-1.33)
for current users; 10 or more years after stopping, no difference was seen.<a href="#Reference1.30">30</a> 
Further, the cancers diagnosed in women who had ever used hormonal
contraceptives were less advanced than those in nonusers, raising the
possibility that the small excess among users was due to increased detection. 
Breast cancer risk associated with hormonal contraceptive use did not appear to
vary with family history of breast cancer.<a href="#Reference1.30">30</a>
</P><a name="Section_34" /><P __id="_34">Oral contraceptives are sometimes recommended for ovarian cancer prevention in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers, but studies of their effect on breast cancer risk have been inconsistent. In a small study of Jewish women with <i>in situ</i> or invasive breast cancer
occurring before age 40 years, those with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations (14 of 50, or 28%)
had a higher likelihood of long-term oral contraceptive use before their first
pregnancy.  This result was interpreted to suggest a higher risk of breast
cancer with oral contraceptive use in women carrying such mutations.<a href="#Reference1.31">31</a>
 In a case-control study of more than 1,300 pairs of women, each case was matched to a woman with a mutation in the same gene, born within 2 years of the case, and in the same country, who had not developed cancer. Oral contraceptive use was associated with a statistically significant 20% (CI, 2%-40%) increase in risk of breast cancer among <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, particularly if use: </P><a name="Section_691" /><a name="ListSection" /><UL __id="_691" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Began before 1975, a period when estrogen doses were relatively high (38% increase, 95% CI, 11%-72%).</LI><LI class="Protocol-IL-Bullet">Began before age 30 years (29% increase, 95% CI, 9%-52%).</LI><LI class="Protocol-IL-Bullet">Lasted for 5 or more years (33% increase, 95% CI, 11%-60%).<a href="#Reference1.32">32</a></LI></UL><a name="END_ListSection" /><a name="Section_697" /><P __id="_697">There was no increased risk  associated with use among <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.</P><a name="Section_902" /><P __id="_902">In contrast, a population-based study of 47 <Span Class="Protocol-GeneName">BRCA1</Span>- and 36 <Span Class="Protocol-GeneName">BRCA2</Span>-mutation carriers with breast cancer, matched to population controls without mutations, found no increased risk associated with current use of low-dose contraceptive pills for <Span Class="Protocol-GeneName">BRCA2</Span> (OR = 1.02), and a significantly reduced risk for <Span Class="Protocol-GeneName">BRCA1</Span> (OR = 0.22; 95% CI, 0.10-0.49).<a href="#Reference1.33">33</a></P><a name="Section_35" /><P __id="_35">Data exist from both observational and randomized clinical trials regarding the association between postmenopausal hormone
replacement therapy (HRT) and breast cancer.  A meta-analysis of data from 51
observational studies indicated a relative risk of breast cancer of 1.35 (95% CI, 1.21-1.49)
for women who had used HRT for 5 or more years after menopause.<a href="#Reference1.34">34</a>  Another observational study, published after the meta-analysis, also observed a significant increased risk for long-term use in a nested case-control study from Puget Sound.<a href="#Reference1.35">35</a>
</P><a name="Section_674" /><P __id="_674">The Women's Health Initiative (WHI), a randomized controlled trial of about 160,000 postmenopausal women, investigated the risks and benefits of strategies that may reduce the incidence of heart disease, breast and colorectal cancer, and fractures, including dietary interventions and 2 trials of hormone therapy. The estrogen-plus-progestin arm of the study, which randomized more than 16,000 women to receive combined hormone therapy or placebo, was halted early because health risks exceeded  benefits.<a href="#Reference1.36">36</a><a href="#Reference1.37">37</a> One of the adverse outcomes prompting closure was a significant increase in both total (245 vs. 185 cases) and invasive (199 vs. 150 cases) breast cancers (RR = 1.24; 95% CI, 1.02-1.5, <i>P</i> &lt;.001) in women randomized to receive estrogen and progestin.<a href="#Reference1.37">37</a> HRT-related breast cancers had adverse prognostic characteristics (more advanced stages and larger tumors) compared with cancers occurring in the placebo group, and HRT was also associated with a substantial increase in abnormal mammograms.<a href="#Reference1.37">37</a></P><a name="Section_36" /><P __id="_36">The association between HRT and breast cancer risk among women with a family history of breast cancer has not been consistent; some studies suggest risk is particularly elevated among women with a family history, while others have not found evidence for an interaction between these factors.<a href="#Reference1.38">38</a><a href="#Reference1.39">39</a><a href="#Reference1.40">40</a><a href="#Reference1.41">41</a><a href="#Reference1.42">42</a> <a href="#Reference1.34">34</a> 
The increased risk of breast cancer associated  with HRT use in the large meta-analysis did not differ significantly between subjects with and without a family history. The WHI study has not reported analyses stratified on breast cancer family history, and subjects have not been systematically tested for <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations.<a href="#Reference1.37">37</a> Short-term use of hormones for treatment of menopausal symptoms appears to
confer little or no breast cancer risk.<a href="#Reference1.34">34</a><a href="#Reference1.43">43</a>  No data exist regarding the
effect of hormone replacement use on breast cancer risk among carriers of <Span Class="Protocol-GeneName">BRCA1</Span>
or <Span Class="Protocol-GeneName">BRCA2</Span> mutations.
</P>
</a>





<a name="Section_341">

<Span class="Summary-SummarySection-Title-Level3">Radiation Exposure</Span>


<a name="Section_38" /><P __id="_38">Observations in  survivors of the atomic bombings of Hiroshima and Nagasaki and in women who have received
therapeutic radiation treatments to the chest and upper body document increased
breast cancer risk as a result of radiation exposure.  The significance of this
risk factor in women with a genetic susceptibility to breast cancer is unclear. 
In a case report of a family with multiple cases of breast cancer in a single
generation, the cancers were associated with repeated fluoroscopic exposure in
childhood.<a href="#Reference1.44">44</a>  Lymphocytes from affected family members demonstrated reduced
efficiency of repair of x-ray-induced <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45671&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045671&amp;version=HealthProfessional&amp;language=English');  return(false);">DNA</a> breaks, suggesting that the breast
cancers could have resulted from a genetic susceptibility to the mutagenic
effect of radiation exposure.<a href="#Reference1.44">44</a>  A small follow-up study found evidence of
suboptimal repair of x-ray-induced DNA breaks in 12 of 17 women at increased
breast cancer risk due to a positive family history, compared with 6 of 19
control subjects (OR 5.2; 95% CI, 1.04-28.57).<a href="#Reference1.45">45</a>  
</P><a name="Section_39" /><P __id="_39">In vitro studies of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> function suggest a possible role for these
genes in repair of x-ray-induced DNA damage.  Human cancer cells containing mutated <Span Class="Protocol-GeneName">BRCA1</Span> are hypersensitive to ionizing radiation via transcription-coupled DNA repair mechanisms.<a href="#Reference1.46">46</a>  </P><a name="Section_872" /><P __id="_872">While human tumor cells deficient in the BRCA2 protein
also demonstrate deficiencies in the repair of radiation-induced DNA breaks,
cells that carry a single mutated copy of <Span Class="Protocol-GeneName">BRCA2</Span> have normal
repair.<a href="#Reference1.47">47</a>  These preliminary data suggest that increased sensitivity to
radiation could be a cause of cancer susceptibility in carriers of <Span Class="Protocol-GeneName">BRCA1</Span> and
<Span Class="Protocol-GeneName">BRCA2</Span> mutations.  Since <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers are heterozygotes, however, radiation
sensitivity might occur only after a somatic mutation has damaged the normal copy
of the gene.</P><a name="Section_40" /><P __id="_40">Increased sensitivity to radiation has also been postulated as a source of
increased breast cancer risk among carriers of mutations in the <Span Class="Protocol-GeneName">ATM</Span> gene.<a href="#Reference1.48">48</a><a href="#Reference1.49">49</a>
</P><a name="Section_41" /><P __id="_41">Radiation sensitivity has also been reported in Li-Fraumeni syndrome (LFS) and
is associated with a greatly increased rate of multiple primary malignancies in
persons with this disorder (57% cumulative probability of second malignancy 30
years after diagnosis of a first cancer).<a href="#Reference1.50">50</a>  Breast cancer is the most common
tumor in LFS families, occurring at an average age of 37 years.<a href="#Reference1.51">51</a>  
</P><a name="Section_42" /><P __id="_42">The possibility that genetic susceptibility to breast cancer occurs via a
mechanism of radiation sensitivity raises questions about radiation exposure. 
It is possible that diagnostic radiation exposure, including mammography, poses
more risk in genetically susceptible women than in women of average risk. 
Therapeutic radiation could also pose carcinogenic risk.  A cohort study of
<Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers treated with breast-conserving therapy,
however, showed no evidence of increased radiation sensitivity or sequelae in
the breast, lung, or bone marrow of mutation carriers.<a href="#Reference1.52">52</a>  Conversely,
radiation sensitivity could make tumors in women with genetic susceptibility to
breast cancer more responsive to radiation treatment.  Empiric data are needed
to address these questions.
</P>
</a>






<a name="Section_342">

<Span class="Summary-SummarySection-Title-Level3">Lifestyle Factors</Span>


<a name="Section_44" /><P __id="_44">Several lifestyle factors are associated with breast cancer risk.  These
lifestyle factors include weight gain, obesity, fat intake, and level of
physical activity.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef>
for more information.)
</P><a name="Section_45" /><P __id="_45">Weight gain and being overweight are commonly recognized risk factors for
breast cancer, with overweight women most commonly observed to be at increased
risk of postmenopausal breast cancer and at reduced risk of premenopausal
breast cancer.  Sedentary lifestyle may also be a risk factor.  These factors
have not been evaluated in women with a positive family history of breast
cancer or in carriers of cancer-predisposing mutations.  Similarly, alcohol
consumption and a high-fat diet may be associated with an increased risk.
</P>
</a>



<a name="Section_343">

<Span class="Summary-SummarySection-Title-Level3">History of Breast Disease</Span>


<a name="Section_47" /><P __id="_47">Benign breast disease (BBD) is a risk factor for breast cancer, independent of
the effects of other major risk factors for breast cancer (age, age at
menarche, age at first live birth, and family history of breast cancer).<a href="#Reference1.53">53</a>  
The risk of developing breast cancer varies by the result of the breast biopsy
(i.e., type of benign breast disease).  The risk among women with atypical
hyperplasia is 2.5 to 5.3 times that among women with nonproliferative BBD. 
Women who have proliferative disease without atypia are at a 1.6-fold to 
1.9-fold risk.<a href="#Reference1.54">54</a><a href="#Reference1.55">55</a><a href="#Reference1.56">56</a>  Even among women with fibroadenomas who have no evidence
of proliferative disease, breast cancer risk is increased 40% to 90% over an
average of 22 years of follow-up.<a href="#Reference1.57">57</a>
</P><a name="Section_48" /><P __id="_48">In several studies, the association between types of BBD and breast cancer
differed in certain subgroups.  For example, a study found that the association
between atypical hyperplasia and breast cancer was stronger among premenopausal
women (OR = 5.9) than among postmenopausal women (OR = 2.3).<a href="#Reference1.56">56</a>  In this
study, the association of proliferative BBD (with or without atypia) with
breast cancer was stronger among women who reported a positive family history
of breast cancer (mother or sister) than among women who reported no such
history, confirming the stronger relationship that was reported in another
study between atypical hyperplasia and breast cancer among women with a
positive family history of breast cancer.<a href="#Reference1.54">54</a>
</P><a name="Section_49" /><P __id="_49">A meta-analysis of 6 studies found evidence for a cumulative risk of breast
cancer of 19% by age 50 years for women with both a positive family history (mother
or sister with breast cancer) and a previous breast biopsy showing atypical
hyperplasia.<a href="#Reference1.58">58</a>  No studies have assessed the predictive value of atypical
hyperplasia in women carrying autosomal dominant cancer-predisposing mutations.
</P><a name="Section_50" /><P __id="_50">An increased risk of breast cancer has also been demonstrated for women who
have increased density of breast tissue as assessed by mammogram.<a href="#Reference1.59">59</a><a href="#Reference1.60">60</a>  This
increased risk occurs in both premenopausal and postmenopausal women.<a href="#Reference1.60">60</a> 
Compared with women with no visible breast density, a breast density of 75% or
greater is associated with an approximately 5-fold increase in risk (95% CI,
3.6-7.1).<a href="#Reference1.60">60</a> 
Some observational studies suggest the possibility of a genetic contribution to breast density.<a href="#Reference1.61">61</a><a href="#Reference1.62">62</a><a href="#Reference1.63">63</a></P><a name="Section_51" /><P __id="_51">Women with a previous primary breast cancer have a 3-fold to 4-fold
increase in risk of a second breast cancer in the contralateral breast.<a href="#Reference1.64">64</a> 
Most studies report an annual risk of development of a second breast cancer of
0.5% to 0.7%.<a href="#Reference1.65">65</a>  While the risk of contralateral breast cancer persists for
up to 30 years after the original diagnosis, the median interval between
primary breast cancer and contralateral disease is approximately 4 years.<a href="#Reference1.66">66</a>  
</P><a name="Section_52" /><P __id="_52">Although risk is similar following invasive and <i>in situ</i> ductal cancer, it is
higher for women with a family history of breast cancer, and for those with a
lobular histology in the original cancer.<a href="#Reference1.67">67</a>  Lobular carcinoma <i>in situ</i>
(LCIS), which is often an incidental finding in breast biopsies, is associated
with an increased risk of subsequent invasive cancer.  Long-term follow-up
studies of women diagnosed with LCIS report relative risks of developing breast
cancer ranging from 7 to 12.  Risks are higher for women diagnosed at a younger
age, and for those with a family history of breast cancer.  Subsequent breast
cancers are most often of ductal histology, and occur equally in either breast,
suggesting that LCIS is a marker of risk rather than a precancerous lesion
itself.<a href="#Reference1.68">68</a> 
</P>
</a>







<a name="Section_344">

<Span class="Summary-SummarySection-Title-Level3">Other Factors</Span>


<a name="Section_54" /><P __id="_54">Other risk factors, including those that are only weakly associated with breast
cancer and those that have been inconsistently associated with the disease in
epidemiologic studies (e.g., cigarette smoking), may be important in subgroups
of women defined according to genotype.  For example, some studies have
suggested that certain N-acetyl transferase <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339337&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339337&amp;version=HealthProfessional&amp;language=English');  return(false);">alleles</a> may influence female
smokers’ risk of developing breast cancer.<a href="#Reference1.69">69</a>  One study <a href="#Reference1.70">70</a> found a reduced risk of breast cancer among <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers who smoked, but an expanded follow-up study failed to find an association.<a href="#Reference1.71">71</a> 
</P>
</a>



</a>
<a name="Section_56"><Span class="Summary-SummarySection-Title-Level2">Other Risk Factors for Ovarian Cancer</Span>
<a name="Section_57" /><P __id="_57">Other risk factors for ovarian cancer include age, demographics, and
reproductive and surgical history.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062771">Prevention of
Ovarian Cancer</SummaryRef> for more information.)  Relatively few studies have addressed
the effect of these risk factors in women who are genetically susceptible to
ovarian cancer.
</P>
<a name="Section_345">

<Span class="Summary-SummarySection-Title-Level3">Age</Span>


<a name="Section_59" /><P __id="_59">Risk for ovarian cancer increases as a woman gets older.  Before age 30 years, the risk of developing ovarian cancer is remote; even in hereditary
cancer families, epithelial ovarian cancer is virtually nonexistent before age
20 years.  Ovarian cancer incidence rises in a linear fashion from age 30 years to age 50 years and continues to increase, though at a slower rate, thereafter.  The
highest incidence is found in the eighth decade of life, with a rate of 57
cases per 100,000 women aged 75 to 79 years, compared with 16 cases
per 100,000 women aged 40 to 44 years.<a href="#Reference1.72">72</a>
</P>
</a>


<a name="Section_346">

<Span class="Summary-SummarySection-Title-Level3">Demographic</Span>


<a name="Section_61" /><P __id="_61">Ovarian cancer incidence varies significantly depending on country of birth,
and ranges from a high of 14.9 cases per 100,000 women in Sweden to a low of
2.7 cases per 100,000 women in Japan.<a href="#Reference1.73">73</a>  Incidence in the United States is
13.3 cases per 100,000 women.  Immigration appears to alter the risk to match
that of the host country.  Offspring of Japanese immigrants to the United
States have an increased risk of developing ovarian cancer that approaches
the rate among women born in the United States, indicating a possible role for
dietary and environmental factors.
</P>
</a>


<a name="Section_347">

<Span class="Summary-SummarySection-Title-Level3">Reproductive
</Span>


<a name="Section_63" /><P __id="_63">Nulliparity is associated with an increased risk of ovarian cancer.  Risk may also be increased among women who have used fertility drugs, especially those who remain nulligravid.<a href="#Reference1.74">74</a> A small subset from a large retrospective cohort study did not confirm a strong link between infertility drugs and ovarian cancer risk.<a href="#Reference1.75">75</a> Evidence is growing that the use of menopausal HRT is associated with an increased risk of ovarian cancer, particularly in long-time users and users of sequential estrogen-progesterone schedules.<a href="#Reference1.76">76</a><a href="#Reference1.77">77</a>  In a prospective study of 329 incident ovarian cancer cases in the Breast Cancer Detection Demonstration Project, use of estrogen only was associated with a significant 60% increased risk of ovarian cancer, and the risk increased with increasing duration of use.<a href="#Reference1.78">78</a>   In the WHI, 38 incident ovarian cancers were identified, and the hazard ratio for those taking estrogen plus progestin was 1.6 (95% CI, 0.8-3.2) compared with the placebo group.<a href="#Reference1.79">79</a>  No data exist regarding risk either in those with a family history of breast or ovarian cancer or in <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers. Data on the role of age at menarche and age at menopause are inconsistent.</P>
</a>


<a name="Section_348">

<Span class="Summary-SummarySection-Title-Level3">Surgical History
</Span>


<a name="Section_65" /><P __id="_65">Bilateral tubal ligation and hysterectomy have also been reported to be
associated with reduced ovarian cancer risk.<a href="#Reference1.74">74</a><a href="#Reference1.80">80</a><a href="#Reference1.81">81</a>
A retrospective study and a prospective study have reported a &gt;90% reduction in risk of ovarian cancer in women with documented <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations who chose prophylactic (risk-reducing) oophorectomy.  In this same population, prophylactic removal of the ovaries also resulted in a nearly 50% reduction in the risk of subsequent breast cancer.<a href="#Reference1.82">82</a><a href="#Reference1.83">83</a> For further information on these studies refer to the <SummaryRef href="CDR0000062855#_382">Ovarian Ablation</SummaryRef> section of this summary.</P>
</a>


</a>
<a name="Section_66"><Span class="Summary-SummarySection-Title-Level2">Models for Prediction of Breast Cancer Risk</Span>
<a name="Section_634" /><P __id="_634">Models to predict an individual’s lifetime risk for developing breast cancer are available.  In addition, models exist to predict an individual’s likelihood of having a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation. For further information on these models refer to the <SummaryRef href="CDR0000062855#_79">Models for Prediction of the Likelihood of a BRCA1 or BRCA2 Mutation </SummaryRef> section of this summary. Not all models can be appropriately applied for all patients.   Each model is  appropriate only when the patient’s characteristics and family history are similar to the study population on which the model was based.  The table, <SummaryRef href="CDR0000062855#_671">Characteristics of the Gail and Claus Models</SummaryRef>, summarizes the salient aspects of the risk assessment models and is designed to aid in choosing the one that best applies to a particular individual.</P><a name="Section_635" /><P __id="_635">Two models for predicting breast cancer risk, the Claus model <a href="#Reference1.22">22</a> and the Gail model,<a href="#Reference1.53">53</a> are widely used in research studies and clinical <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44961&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044961&amp;version=HealthProfessional&amp;language=English');  return(false);">counseling</a>. Both have limitations, and the risk estimates derived from the 2 models may differ for an individual patient. These models, however, represent the best methods currently available for individual risk assessment.</P><a name="Section_636" /><P __id="_636">It is important to note that these models will significantly underestimate breast cancer risk for women in families with hereditary breast cancer susceptibility syndromes.  In those cases, Mendelian risks would apply.  A 3-generation cancer family history is taken before applying any model. (Refer to the PDQ summary on <SummaryRef href="CDR0000062865">Elements of Cancer Genetics Risk Assessment and Counseling</SummaryRef> for more information on <SummaryRef href="CDR0000062865#_18">Taking a Family History</SummaryRef>.)  Generally, the Claus or Gail models should not be used for families with 1 of the following characteristics:</P><a name="Section_637" /><a name="ListSection" /><UL __id="_637" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Three individuals with breast or ovarian cancer (especially when 1 or more breast cancers are diagnosed before age 50 years).</LI><LI class="Protocol-IL-Bullet">A woman who has both breast and ovarian cancer.</LI><LI class="Protocol-IL-Bullet"><a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460127&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460127&amp;version=HealthProfessional&amp;language=English');  return(false);">Ashkenazi Jewish</a> ancestry with at least 1 case of breast or ovarian cancer (as these families are more likely to have a hereditary cancer susceptibility syndrome).</LI></UL><a name="END_ListSection" /><a name="TableSection"><a name="Section_671"><table Rules="all" Frame="border" Border="1" valign="top" cellspacing="0" cellpadding="5" width="100%"><span class="Summary-Table-Caption"><b>Table 1. Characteristics of the Gail and Claus Models*</b></span><div name="EnlargePlaceholder" align="right" /><COLGROUP><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /></COLGROUP><THEAD><tr class="Summary-Table-Head"><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b /> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Gail Model</b> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Claus Model</b> 
									</td></tr></THEAD><TFOOT><tr><td colspan="3" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>*Adapted from Domcheck et al.,<a href="#Reference1.84">84</a> Rubenstein et al.,<a href="#Reference1.85">85</a> and Rhodes.<a href="#Reference1.86">86</a></i></td></tr></TFOOT><TBODY><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Data derived from</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Breast Cancer Detection Demonstration Project (BCDDP) Study  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Cancer and Steroid Hormone (CASH) Study  </td></tr><tr><td rowspan="5" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Study population</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">2,852 cases, age ≥35 years   </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">4,730 cases, age 20-54 years  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><i>In situ</i> and invasive cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Invasive cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">3,146 controls  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">4,688 controls  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Caucasian  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Caucasian  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Annual breast <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460216&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460216&amp;version=HealthProfessional&amp;language=English');  return(false);">screening</a>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Not routinely screened  </td></tr><tr><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Family history characteristics</b>  </td><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">First-degree relatives with breast cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">First-degree or second-degree relatives with breast cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Age of onset in relatives  </td></tr><tr><td rowspan="6" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Other characteristics</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Current age   </td><td rowspan="6" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Current age   </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Age at menarche  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Age at first live birth  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Number of breast biopsies  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Atypical hyperplasia in breast biopsy  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Race (included in the most current version of the Gail model)  </td></tr><tr><td rowspan="4" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Strengths</b></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Incorporates:   </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Incorporates:   </td></tr><tr><td rowspan="3" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Risk factors other than family history  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Paternal as well as maternal history   </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Age at onset of breast cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Family history of ovarian cancer  </td></tr><tr><td rowspan="7" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Limitations</b> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Underestimates risk in hereditary families   </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">May underestimate risk in hereditary families  </td></tr><tr><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Number of breast biopsies without atypical hyperplasia may cause inflated risk estimates  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">May not be applicable to all combinations of affected relatives  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not include risk factors other than family history  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not incorporate:  </td><td rowspan="4" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Paternal family history of breast cancer or any family history of ovarian cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Age at onset of breast cancer in relatives  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">All known risk factors for breast cancer <a href="#Reference1.86">86</a>  </td></tr><tr><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Best application</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">For individuals with no family history of breast cancer or 1 first-degree relative with breast cancer at ≥age 50 years  </td><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">For individuals with 0, 1, or 2 first-degree or second-degree relatives with breast cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">For determining eligibility for chemoprevention studies  </td></tr></TBODY></table><br /></a></a><a name="Section_640" /><P __id="_640">The Gail model has been found to be reasonably accurate at predicting breast cancer risk in large groups of white women who undergo annual screening mammography.<a href="#Reference1.87">87</a><a href="#Reference1.88">88</a><a href="#Reference1.89">89</a><a href="#Reference1.90">90</a><a href="#Reference1.91">91</a>  While the model is reliable in predicting the number of breast cancer cases expected in a group of women from the same age-risk strata, it is less reliable in predicting risk for individual patients.  Risk can be overestimated in:</P><a name="Section_641" /><a name="ListSection" /><UL __id="_641" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Noncompliant women (i.e., not compliant with screening).<a href="#Reference1.87">87</a><a href="#Reference1.88">88</a></LI><LI class="Protocol-IL-Bullet">Women in the highest risk strata.<a href="#Reference1.90">90</a></LI></UL><a name="END_ListSection" /><a name="Section_642" /><P __id="_642">Risk could be underestimated in the lowest risk strata.<a href="#Reference1.90">90</a>   Earlier studies <a href="#Reference1.87">87</a><a href="#Reference1.88">88</a> suggested risk was overpredicted in younger women and underpredicted in older women.  More recent studies <a href="#Reference1.89">89</a><a href="#Reference1.90">90</a> using the modified Gail model (which is 
currently used) found it performed well in all age groups.  Further studies are needed to establish the validity of the Gail model in minority populations.<a href="#Reference1.91">91</a></P><a name="Section_644" /><P __id="_644">A study of 491 women aged 18 to 74 years with a family history of breast cancer compared the most recent Gail model to the Claus model 
in predicting breast cancer risk.<a href="#Reference1.92">92</a>  The 2 models were positively correlated (r = .55).  The Gail model estimates were higher than the Claus model estimates for most participants.  Presentation and discussion of both the Gail and Claus models risk estimates may be useful in the counseling setting. </P><a name="Section_645" /><P __id="_645">The Gail model is the basis for the <a Class="Protocol-ExternalRef" href="http://bcra.nci.nih.gov/">Breast Cancer Risk Assessment Tool</a>, a computer program that is available from the NCI by calling the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237, or TTY at 1-800-332-8615). This version of the Gail Model estimates only the risk of invasive breast cancer.</P></a>


        
       <a name="ReferenceSection"><p><Span Class="Summary-ReferenceSection">
							References
						</Span><ol><li><a name="Reference1.1" />American Cancer Society.: Cancer Facts and Figures 2005. Atlanta, Ga: American Cancer Society, 2005.  <a Class="Protocol-ExternalRef" href="http://www.cancer.org/docroot/STT/stt_0.asp">Also available online.</a> Last accessed November 1, 2005. 
			<A /><br /><br /></li><li><a name="Reference1.2" />Yang Q, Khoury MJ, Rodriguez C, et al.: Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol 147 (7): 652-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9554604&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.3" />Colditz GA, Willett WC, Hunter DJ, et al.: Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA 270 (3): 338-43, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8123079&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.4" />Slattery ML, Kerber RA: A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 270 (13): 1563-8, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8371466&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.5" />Johnson N, Lancaster T, Fuller A, et al.: The prevalence of a family history of cancer in general practice. Fam Pract 12 (3): 287-9, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8536831&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.6" />Pharoah PD, Day NE, Duffy S, et al.: Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71 (5): 800-9, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9180149&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.7" />Negri E, Braga C, La Vecchia C, et al.: Family history of cancer and risk of breast cancer. Int J Cancer 72 (5): 735-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9311586&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.8" />Hemminki K, Vaittinen P: Familial breast cancer in the family-cancer database. Int J Cancer 77 (3): 386-91, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9663600&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.9" />Kerber RA, Slattery ML: The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 155 (9): 905-12, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7726698&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.10" />Auranen A, Pukkala E, Mäkinen J, et al.: Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer 74 (2): 280-4, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8688336&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.11" />Couch FJ, DeShano ML, Blackwood MA, et al.: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336 (20): 1409-15, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9145677&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.12" />Shattuck-Eidens D, Oliphant A, McClure M, et al.: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (15): 1242-50, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333265&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.13" />Schildkraut JM, Thompson WD: Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 128 (3): 456-66, 1988. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3414654&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.14" />Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80 (4): 700-7, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1407898&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.15" />Stratton JF, Pharoah P, Smith SK, et al.: A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105 (5): 493-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9637117&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.16" />Lindor NM, Greene MH: The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 90 (14): 1039-71, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672254&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.17" />Kerber RA, Slattery ML: Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146 (3): 244-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9247008&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.18" />Parent ME, Ghadirian P, Lacroix A, et al.: The reliability of recollections of family history: implications for the medical provider. J Cancer Educ 12 (2): 114-20, 1997 Summer. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9229275&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.19" />Feuer EJ, Wun LM, Boring CC, et al.: The lifetime risk of developing breast cancer. J Natl Cancer Inst 85 (11): 892-7, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8492317&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.20" />Peto J, Collins N, Barfoot R, et al.: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91 (11): 943-9, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10359546&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.21" />Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (3): 676-89, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9497246&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.22" />Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73 (3): 643-51, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8299086&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.23" />Colditz GA, Rosner BA, Speizer FE: Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J Natl Cancer Inst 88 (6): 365-71, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8609646&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.24" />Narod S, Lynch H, Conway T, et al.: Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet 341 (8852): 1101-2, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8097005&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.25" />Narod SA, Goldgar D, Cannon-Albright L, et al.: Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64 (6): 394-8, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8550241&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.26" />Cullinane CA, Lubinski J, Neuhausen SL, et al.: Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117 (6): 988-91, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15986445&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.27" />Kotsopoulos J, Lubinski J, Lynch HT, et al.: Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16 (6): 667-74, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16049805&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.28" />Collaborative Group on Hormonal Factors in Breast Cancer.: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.29" />Jernström H, Lubinski J, Lynch HT, et al.: Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96 (14): 1094-8, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15265971&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.30" />Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347 (9017): 1713-27, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8656904&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.31" />Ursin G, Henderson BE, Haile RW, et al.: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57 (17): 3678-81, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9288771&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.32" />Narod SA, Dubé MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (23): 1773-9, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12464649&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.33" />Milne RL, Knight JA, John EM, et al.: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14 (2): 350-6, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15734957&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.34" />Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (9084): 1047-59, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10213546&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.35" />Chen CL, Weiss NS, Newcomb P, et al.: Hormone replacement therapy in relation to breast cancer. JAMA 287 (6): 734-41, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11851540&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.36" />Writing Group for the Women's Health Initiative Investigators.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-33, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.37" />Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (24): 3243-53, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.38" />Schuurman AG, van den Brandt PA, Goldbohm RA: Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control 6 (5): 416-24, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8547539&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.39" />Steinberg KK, Thacker SB, Smith SJ, et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265 (15): 1985-90, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1826136&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.40" />Sellers TA, Mink PJ, Cerhan JR, et al.: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127 (11): 973-80, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412302&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.41" />Stanford JL, Weiss NS, Voigt LF, et al.: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274 (2): 137-42, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7596001&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.42" />Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168 (5): 1473-80, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8498430&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.43" />Gorsky RD, Koplan JP, Peterson HB, et al.: Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 83 (2): 161-6, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8290175&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.44" />Helzlsouer KJ, Harris EL, Parshad R, et al.: Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer 64 (1): 14-7, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7665242&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.45" />Helzlsouer KJ, Harris EL, Parshad R, et al.: DNA repair proficiency: potential susceptiblity factor for breast cancer. J Natl Cancer Inst 88 (11): 754-5, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8637030&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.46" />Abbott DW, Thompson ME, Robinson-Benion C, et al.: BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274 (26): 18808-12, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10373498&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.47" />Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90 (13): 978-85, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9665145&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.48" />Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 66 (6 Suppl): S177-82, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7836845&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.49" />Kastan M: Ataxia-telangiectasia--broad implications for a rare disorder. N Engl J Med 333 (10): 662-3, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7637733&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.50" />Hisada M, Garber JE, Fung CY, et al.: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90 (8): 606-11, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9554443&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.51" />Kleihues P, Schäuble B, zur Hausen A, et al.: Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150 (1): 1-13, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9006316&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.52" />Pierce LJ, Strawderman M, Narod SA, et al.: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18 (19): 3360-9, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11013276&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.53" />Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (24): 1879-86, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2593165&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.54" />Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312 (3): 146-51, 1985. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3965932&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.55" />Carter CL, Corle DK, Micozzi MS, et al.: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 128 (3): 467-77, 1988. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3414655&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.56" />London SJ, Connolly JL, Schnitt SJ, et al.: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267 (7): 941-4, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1734106&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.57" />Dupont WD, Page DL, Parl FF, et al.: Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331 (1): 10-5, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8202095&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.58" />Unic I, Stalmeier PF, Peer PG, et al.: A review on family history of breast cancer: screening and counseling proposals for women with familial (non-hereditary) breast cancer. Patient Educ Couns 32 (1-2): 117-27, 1997 Sep-Oct. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9355579&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.59" />Boyd NF, Byng JW, Jong RA, et al.: Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87 (9): 670-5, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7752271&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.60" />Byrne C, Schairer C, Wolfe J, et al.: Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87 (21): 1622-9, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7563205&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.61" />Pankow JS, Vachon CM, Kuni CC, et al.: Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst 89 (8): 549-56, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9106643&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.62" />Boyd NF, Lockwood GA, Martin LJ, et al.: Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 91 (16): 1404-8, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10451446&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.63" />Vachon CM, King RA, Atwood LD, et al.: Preliminary sibpair linkage analysis of percent mammographic density. J Natl Cancer Inst 91 (20): 1778-9, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10528030&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.64" />Kelsey JL, Gammon MD: The epidemiology of breast cancer. CA Cancer J Clin 41 (3): 146-65, 1991 May-Jun. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1902137&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.65" />Singletary SE, Taylor SH, Guinee VF, et al.: Occurrence and prognosis of contralateral carcinoma of the breast. J Am Coll Surg 178 (4): 390-6, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8149039&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.66" />Cook LS, White E, Schwartz SM, et al.: A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States) Cancer Causes Control 7 (3): 382-90, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8734833&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.67" />Habel LA, Moe RE, Daling JR, et al.: Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225 (1): 69-75, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8998122&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.68" />Bodian CA, Perzin KH, Lattes R: Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 78 (5): 1024-34, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8780540&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.69" />Ambrosone CB, Freudenheim JL, Graham S, et al.: Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276 (18): 1494-501, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8903261&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.70" />Brunet JS, Ghadirian P, Rebbeck TR, et al.: Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 90 (10): 761-6, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9605646&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.71" />Ghadirian P, Lubinski J, Lynch H, et al.: Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer 110 (3): 413-6, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15095307&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.72" />Amos CI, Struewing JP: Genetic epidemiology of epithelial ovarian cancer. Cancer 71 (2 Suppl): 566-72, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8420678&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.73" />Heintz AP, Hacker NF, Lagasse LD: Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol 66 (1): 127-35, 1985. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3892386&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.74" />Whittemore AS, Harris R, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136 (10): 1184-203, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1476141&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.75" />Brinton LA, Lamb EJ, Moghissi KS, et al.: Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 103 (6): 1194-203, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15172852&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.76" />Rodriguez C, Patel AV, Calle EE, et al.: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (11): 1460-5, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11255422&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.77" />Riman T, Dickman PW, Nilsson S, et al.: Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94 (7): 497-504, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11929950&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.78" />Lacey JV Jr, Mink PJ, Lubin JH, et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (3): 334-41, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117398&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.79" />Anderson GL, Judd HL, Kaunitz AM, et al.: Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (13): 1739-48, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14519708&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.80" />Tortolero-Luna G, Mitchell MF: The epidemiology of ovarian cancer. J Cell Biochem Suppl 23: 200-7, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8747397&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.81" />Hankinson SE, Hunter DJ, Colditz GA, et al.: Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270 (23): 2813-8, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8133619&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.82" />Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.83" />Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.84" />Domchek SM, Eisen A, Calzone K, et al.: Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21 (4): 593-601, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586794&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.85" />Rubinstein WS, O'Neill SM, Peters JA, et al.: Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Huntingt) 16 (8): 1082-94; discussion 1094, 1097-9, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12201647&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.86" />Rhodes DJ: Identifying and counseling women at increased risk for breast cancer. Mayo Clin Proc 77 (4): 355-60; quiz 360-1, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11936931&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.87" />Bondy ML, Lustbader ED, Halabi S, et al.: Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86 (8): 620-5, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8003106&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.88" />Spiegelman D, Colditz GA, Hunter D, et al.: Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 86 (8): 600-7, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145275&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.89" />Rockhill B, Spiegelman D, Byrne C, et al.: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93 (5): 358-66, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11238697&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.90" />Costantino JP, Gail MH, Pee D, et al.: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91 (18): 1541-8, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10491430&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.91" />Bondy ML, Newman LA: Breast cancer risk assessment models: applicability to African-American women. Cancer 97 (1 Suppl): 230-5, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12491486&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference1.92" />McTiernan A, Kuniyuki A, Yasui Y, et al.: Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 10 (4): 333-8, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11319173&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li></ol></p></a></a><a name="Section_88">
        <Span class="Summary-SummarySection-Title-Level1">Major Genes</Span><br /><br />

<a name="Section_89"><Span class="Summary-SummarySection-Title-Level2">Introduction</Span>
<a name="Section_90" /><P __id="_90">Epidemiologic studies have clearly established the role of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=302456&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000302456&amp;version=HealthProfessional&amp;language=English');  return(false);">family history</a> as an
important risk factor for both breast and ovarian cancer.  After gender and
age, a positive family history is the strongest known predictive risk factor
for breast cancer.  In most cases an extensive family history (more than 4
relatives in the same biologic line affected) is not present.  In some
families, however, inherited factors are clearly the major component of an
individual’s cancer risk.  We now know that some of these “cancer families” can
be explained by specific <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46063&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=HealthProfessional&amp;language=English');  return(false);">mutations</a> in single cancer <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460209&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460209&amp;version=HealthProfessional&amp;language=English');  return(false);">susceptibility genes</a> .  The
recent isolation of several of these genes associated with a significantly
increased risk of breast/ovarian cancer make it possible to identify families
who carry mutations in these <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=HealthProfessional&amp;language=English');  return(false);">genes</a>.  Mutation <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460132&amp;version=HealthProfessional&amp;language=English');  return(false);">carriers</a> who have a risk of
developing breast cancer that may exceed 50% comprise no more than 5% to 10%
of all breast cancer cases.
</P>
<a name="Section_91" /><P __id="_91">Hereditary breast cancer is characterized by early age at onset (on average 
5-15 years earlier than in  <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339347&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339347&amp;version=HealthProfessional&amp;language=English');  return(false);">sporadic</a> cases), bilaterality, vertical transmission
through both maternal and paternal lines, and familial association with tumors
of other organs, particularly the ovary and prostate gland.<a href="#Reference2.1">1</a><a href="#Reference2.2">2</a><a href="#Reference2.3">3</a> 
</P>
<a name="Section_92" /><P __id="_92">The clinical evidence of an <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339338&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339338&amp;version=HealthProfessional&amp;language=English');  return(false);">autosomal dominant</a> inherited predisposition to
breast cancer has been supported by segregation analysis, a statistical
genetics method to determine whether a particular trait follows a Mendelian pattern
of inheritance.  (For more information on criteria of autosomal dominant
inheritance, refer to the <SummaryRef href="CDR0000062855#_15">Autosomal Dominant Inheritance of Breast/Ovarian Cancer Predisposition</SummaryRef> section of this summary.)
</P>
<a name="Section_93" /><P __id="_93">A 1988 study reported the first quantitative evidence that breast cancer
segregated as an autosomal dominant trait in some families.<a href="#Reference2.4">4</a>  When
segregation analysis was applied to the Cancer and Steroid Hormone (CASH) data
set, goodness-of-fit tests of genetic models provided additional evidence for
the existence of a rare autosomal dominant <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339337&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339337&amp;version=HealthProfessional&amp;language=English');  return(false);">allele</a> associated with increased
susceptibility to breast cancer.<a href="#Reference2.5">5</a>
</P>
<a name="Section_94" /><P __id="_94">The search for genes associated with hereditary susceptibility to breast cancer
has been facilitated by the study of large <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460158&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460158&amp;version=HealthProfessional&amp;language=English');  return(false);">kindreds</a> with multiple affected
individuals, and has led to the identification of several susceptibility genes,
including <Span Class="Protocol-GeneName">BRCA1</Span>, <Span Class="Protocol-GeneName">BRCA2</Span>, <Span Class="Protocol-GeneName">TP53</Span>, and <Span Class="Protocol-GeneName">PTEN/MMAC1</Span>.    
</P>
</a>
<a name="Section_95"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA1</Span></Span>
<a name="Section_96" /><P __id="_96">In 1990, a susceptibility gene for breast cancer was mapped by genetic <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460161&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460161&amp;version=HealthProfessional&amp;language=English');  return(false);">linkage</a>
to the long arm of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46470&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046470&amp;version=HealthProfessional&amp;language=English');  return(false);">chromosome</a> 17, in the interval 17q12-21.<a href="#Reference2.6">6</a>  The linkage
between breast cancer and <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46129&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046129&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic markers</a> on chromosome 17q was soon confirmed
by others, and evidence for the coincident transmission of both breast and
ovarian cancer susceptibility in linked families was observed.<a href="#Reference2.1">1</a>  The <Span Class="Protocol-GeneName">BRCA1</Span>
gene was subsequently identified by positional <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460134&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460134&amp;version=HealthProfessional&amp;language=English');  return(false);">cloning</a> methods, and has been
found to contain 24 <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460146&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460146&amp;version=HealthProfessional&amp;language=English');  return(false);">exons</a> that encode a protein of 1,863 amino acids.  <Span Class="Protocol-GeneName">BRCA1</Span>
appears to be responsible for disease in 45% of families with multiple cases of
breast cancer only, and in up to 90% of families with both breast and ovarian
cancer.<a href="#Reference2.7">7</a>
</P>
</a>
<a name="Section_97"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA2</Span></Span>
<a name="Section_98" /><P __id="_98">A second breast cancer susceptibility gene, <Span Class="Protocol-GeneName">BRCA2</Span>, was localized to the long
arm of chromosome 13 through <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=425374&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000425374&amp;version=HealthProfessional&amp;language=English');  return(false);">linkage studies</a> of 15 families with multiple cases
of breast cancer that were not linked to  <Span Class="Protocol-GeneName">BRCA1</Span>.  Mutations in <Span Class="Protocol-GeneName">BRCA2</Span> are thought
to account for approximately 35% of multiple case breast cancer families, and
are also associated with male breast cancer, ovarian cancer, prostate cancer,
and pancreatic cancer.<a href="#Reference2.8">8</a><a href="#Reference2.9">9</a>  <Span Class="Protocol-GeneName">BRCA2</Span> is also a large gene with 27 exons that
encode a protein of 3,418 amino acids.<a href="#Reference2.10">10</a>  While not homologous genes, both
<Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> have an unusually large exon 11 and translational start sites
in exon 2.  Like <Span Class="Protocol-GeneName">BRCA1</Span>, <Span Class="Protocol-GeneName">BRCA2</Span> appears to behave like a tumor suppressor gene,
with loss of the unmutated allele found in tumor specimens.  
</P>
</a>
<a name="Section_99"><Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> Function</Span>
<a name="Section_100" /><P __id="_100">Most <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations are predicted to produce a truncated protein product, and thus loss of protein function.  Because inherited breast/ovarian cancer is an autosomal dominant condition, persons with a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation on 1 copy of chromosome 17 or 13 also carry a normal allele on the other paired chromosome. 
In most breast and ovarian cancers that have been studied from mutation carriers, however, the
normal allele is deleted, resulting in loss of all function.  This finding strongly suggests that <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> are in
the class of tumor suppressor genes, i.e., genes whose loss of function can
result in neoplastic growth.<a href="#Reference2.11">11</a><a href="#Reference2.12">12</a>
</P>
<a name="Section_101" /><P __id="_101">Additional evidence that <Span Class="Protocol-GeneName">BRCA1</Span> is a tumor suppressor gene is that
overexpression of the BRCA1 protein leads to tumor growth suppression in vitro and in a mouse model, in a fashion
similar to the tumor suppressor gene <Span Class="Protocol-GeneName">TP53</Span> and the <Span Class="Protocol-GeneName">retinoblastoma (RB)</Span> gene.<a href="#Reference2.13">13</a> 
While this provides a conceptual framework for understanding the role of
mutations in cancer progression, it does little to indicate how these genes
normally function to prevent cancer.
</P>
<a name="Section_102" /><P __id="_102">However, a variety of evidence now points to <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> being directly involved in the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45671&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045671&amp;version=HealthProfessional&amp;language=English');  return(false);">DNA</a> repair process.  Several strategies are used to evaluate gene function.  These include comparing the
sequence and structure of the protein product to other known genes; determining the tissues, cell types, and stages of the cell cycle in which the protein is expressed; and identifying other proteins with which the protein interacts.  Animal models also provide an important tool; in particular, knockout mice provide a way to study the effects of different gene mutations.  In this approach, the normal mouse gene coding for the analogous function has been removed, and normal or mutated human genes are then inserted to assess their biological effects.  Epidemiological studies can provide important evidence for other factors, both genetic and nongenetic, that modify the effect of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> gene mutations.  New technical tools for study of gene function are now being developed; for example, microarray techniques that permit the assessment of gene variants or gene expression at multiple gene sites may allow the identification of other gene proteins that interact with or modify the effect of the BRCA1 and BRCA2 protein products.  
</P>
<a name="Section_605" /><P __id="_605">Taken together, current data suggest that the BRCA1 and BRCA2 protein products interact with each other and with RAD51 and other proteins known to be involved in DNA repair.  Loss of DNA repair function is assumed to lead to the accumulation of additional mutations and ultimately to carcinogenesis.  Several review articles are available in the literature on <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> gene function.<a href="#Reference2.14">14</a><a href="#Reference2.15">15</a></P>






</a>
<a name="Section_110"><Span class="Summary-SummarySection-Title-Level2">Mutations in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span></Span>
<a name="Section_111" /><P __id="_111">Nearly 2,000 distinct mutations and sequence variations in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> have
already been described.<a href="#Reference2.16">16</a>  The mutations that have been associated with
increased risk of cancer result in missing or nonfunctional proteins,
supporting the hypothesis that <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> are tumor suppressor genes. 
While a small number of these mutations have been found repeatedly in unrelated
families, most have not been reported in more than a few families.
</P>
<a name="Section_112" /><P __id="_112">Mutation screening methods vary in their sensitivity.  Methods widely used in
research laboratories, such as <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460217&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460217&amp;version=HealthProfessional&amp;language=English');  return(false);">single-stranded conformational polymorphism</a> (SSCP)
analysis and <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460136&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460136&amp;version=HealthProfessional&amp;language=English');  return(false);">conformation-sensitive gel electrophoresis</a> (CSGE), miss nearly a
third of the mutations that are detected by DNA sequencing.<a href="#Reference2.17">17</a>  In addition,
large genomic rearrangements are missed by most of the techniques, including
direct DNA sequencing.  Such
rearrangements are believed to be responsible for 10% to 15% of <Span Class="Protocol-GeneName">BRCA1</Span>
inactivating mutations.<a href="#Reference2.18">18</a><a href="#Reference2.19">19</a>
</P>
</a>
<a name="Section_113"><Span class="Summary-SummarySection-Title-Level2">Prevalence and Founder Effects</Span>
<a name="Section_114" /><P __id="_114">Approximately 1 in 800 individuals in the general population may carry a
pathogenic mutation in <Span Class="Protocol-GeneName">BRCA1</Span>.  The frequency of carriers in selected groups has
been measured.  Among cases identified from the Cancer Surveillance System of
Western Washington, the frequency of <Span Class="Protocol-GeneName">BRCA1</Span> mutations was highest in cases
diagnosed before age 30 years (23% carriers, 95% confidence interval (CI), 5.0-53.8),
and in those with more than 3 relatives with breast cancer (20%, 95% CI,
6%-44%).  A family history of ovarian cancer in a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460150&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460150&amp;version=HealthProfessional&amp;language=English');  return(false);">first-degree relative</a> was
also associated with an increased prevalence of <Span Class="Protocol-GeneName">BRCA1</Span> mutations (25%, 95% CI,
3.2%-65.1%).<a href="#Reference2.20">20</a>  In a second study, 263 women with familial breast cancer were
analyzed.<a href="#Reference2.21">21</a>  <Span Class="Protocol-GeneName">BRCA1</Span> mutations were found in 7% (95% CI, 0.3%-39%) of families
with site-specific breast cancer, 18% of families with bilateral breast cancer,
and 40% (95% CI, 1.7%-80.0%) of families with both breast and ovarian cancer. 
In a population-based series of incident cases of ovarian cancer in Canada, the
overall prevalence of <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations was 11.7%; among women with a
first-degree relative with breast or ovarian cancer, it was 19%.  Of note, 6.5%
of women with no affected first-degree relative carried a mutation, suggesting
a higher overall prevalence of mutations in women with a diagnosis of ovarian
cancer than in those with breast cancer.<a href="#Reference2.22">22</a>
</P>
<a name="Section_915" /><P __id="_915">In some cases the same mutation has been found in multiple apparently unrelated families. This observation is consistent with a  founder effect.  This occurs when a
contemporary population can be traced back to a small, isolated group of
founders.  Most notably, 2 specific <Span Class="Protocol-GeneName">BRCA1</Span> mutations (185delAG and 5382insC) and a <Span Class="Protocol-GeneName">BRCA2</Span>
mutation (6174delT) have been reported to be common in <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460127&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460127&amp;version=HealthProfessional&amp;language=English');  return(false);">Ashkenazi Jews</a> (those
tracing their roots to Central and Eastern Europe).  Carrier frequencies for
these mutations have been determined in the general Jewish population: 0.9% (95% CI, 0.7%-1.1%) for the 185delAG mutation, 0.3% (95% CI, 0.2%-0.4%) for the 5382insC mutation, and 1.3% (95% CI, 1.0%-1.5%) for the <Span Class="Protocol-GeneName">BRCA2</Span>
6174delT mutation.<a href="#Reference2.23">23</a><a href="#Reference2.24">24</a><a href="#Reference2.25">25</a><a href="#Reference2.26">26</a>  Altogether, the frequency of these 3 mutations
approximates 1 in 40 among Ashkenazi Jews; they account for 25% of early-onset
breast cancer, and up to 90% of families with multiple cases of both breast and
ovarian cancer in this population.<a href="#Reference2.27">27</a><a href="#Reference2.28">28</a>  Additional founder mutations have
been described in the Netherlands (<Span Class="Protocol-GeneName">BRCA1</Span> 2804delAA and several large deletion
mutations), Iceland (<Span Class="Protocol-GeneName">BRCA2</Span>, 995del5), and Sweden (<Span Class="Protocol-GeneName">BRCA1</Span>, 3171ins5).<a href="#Reference2.29">29</a><a href="#Reference2.30">30</a><a href="#Reference2.31">31</a><a href="#Reference2.32">32</a>  
</P>
<a name="Section_116" /><P __id="_116">The presence of these founder mutations has practical implications for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460195&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460195&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic
testing</a>.  Many laboratories offer directed testing specifically for 
ethnic-specific alleles.  This greatly simplifies the technical aspects of
the test but is not without pitfalls.    It is
estimated that 15% of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations that occur among
Ashkenazim are nonfounder mutations.<a href="#Reference2.33">33</a></P>
</a>
<a name="Section_117"><Span class="Summary-SummarySection-Title-Level2">Penetrance of Mutations</Span>
<a name="Section_118" /><P __id="_118">The proportion of individuals carrying a mutation who will manifest the
disease is referred to as <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339344&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339344&amp;version=HealthProfessional&amp;language=English');  return(false);">penetrance</a>.  For adult-onset diseases, penetrance is
usually dependent upon the individual carrier's age and sex.  For example, the
penetrance for breast cancer in female <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers is often quoted by age 50 years (generally premenopausal) and by age 70 years. Of the numerous methods for estimating penetrance, none are without potential biases, and determining an individual mutation carrier's risk of cancer involves some level of imprecision.</P>
<a name="Section_715" /><P __id="_715">Estimates of penetrance by age 70 years for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations show a large range, from 14% to 87% for breast cancer and 10% to 68% for ovarian cancer.<a href="#Reference2.7">7</a><a href="#Reference2.22">22</a><a href="#Reference2.25">25</a><a href="#Reference2.34">34</a><a href="#Reference2.35">35</a><a href="#Reference2.36">36</a><a href="#Reference2.37">37</a><a href="#Reference2.38">38</a><a href="#Reference2.39">39</a><a href="#Reference2.40">40</a><a href="#Reference2.41">41</a><a href="#Reference2.42">42</a><a href="#Reference2.43">43</a><a href="#Reference2.44">44</a><a href="#Reference2.45">45</a><a href="#Reference2.46">46</a><a href="#Reference2.47">47</a><a href="#Reference2.48">48</a><a href="#Reference2.49">49</a><a href="#Reference2.50">50</a>
 Initial penetrance estimates for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations were derived from multiple-case families from the Breast Cancer Linkage Consortium (BCLC), families studied to localize and clone the genes.<a href="#Reference2.7">7</a><a href="#Reference2.34">34</a><a href="#Reference2.35">35</a>
 For breast cancer, the estimates ranged from 50% to 73% by age 50 years and 65% to 87% by age 70 years for <Span Class="Protocol-GeneName">BRCA1</Span>, and 59% and 82% at ages 50 years and 70 years, respectively, for <Span Class="Protocol-GeneName">BRCA2</Span>.  For ovarian cancer, the estimates were as high as 29% by age 50 years and 63% by age 70 years.<a href="#Reference2.34">34</a><a href="#Reference2.35">35</a>
 For many patients currently seeking genetic testing for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span>, the family history will not be as strong as this study by the BCLC (e.g., more than 4 affected relatives in the same biologic lineage). Thus, the penetrance figures derived from the BCLC may not provide a high level of accuracy for individual patients seeking <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44961&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044961&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic counseling</a> and testing.</P><a name="Section_820" /><P __id="_820">There are now several lines of evidence indicating that primary fallopian tube cancer should be considered a part of the BRCA1/2 <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460203&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460203&amp;version=HealthProfessional&amp;language=English');  return(false);">phenotype</a>.  Epidemiologic evidence points to an increased risk of early-onset breast and/or ovarian cancer among first-degree relatives of women with fallopian tube cancers.<a href="#Reference2.51">51</a> Histopathologic examination of fallopian tubes removed prophylactically from women with a hereditary predisposition to ovarian cancer show dysplastic and hyperplastic lesions that are accompanied by changes in cell-cycle and apoptosis-related proteins, suggesting a premalignant phenotype.<a href="#Reference2.52">52</a><a href="#Reference2.53">53</a>  A retrospective review of 29 Ashkenazi Jewish patients with primary fallopian tube tumors identified <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460154&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460154&amp;version=HealthProfessional&amp;language=English');  return(false);">germline</a> <Span Class="Protocol-GeneName">BRCA</Span> mutations in 17%.<a href="#Reference2.54">54</a>  While the true incidence of fallopian tube tumors in <Span Class="Protocol-GeneName">BRCA</Span> carriers is not known, there is a growing consensus that prophylactic oophorectomy should be accompanied by prophylactic removal of the fallopian tubes.</P><a name="Section_716" /><P __id="_716">In addition to the estimates from multiple-case families and patients from high-risk genetics clinics,<a href="#Reference2.7">7</a><a href="#Reference2.34">34</a><a href="#Reference2.35">35</a><a href="#Reference2.37">37</a><a href="#Reference2.39">39</a><a href="#Reference2.43">43</a><a href="#Reference2.50">50</a><a href="#Reference2.55">55</a>
 at least 13 studies have estimated penetrance by studying the families of mutation carriers who were not specifically recruited and studied because of a positive family history.<a href="#Reference2.22">22</a><a href="#Reference2.25">25</a><a href="#Reference2.38">38</a><a href="#Reference2.40">40</a><a href="#Reference2.41">41</a><a href="#Reference2.42">42</a><a href="#Reference2.43">43</a><a href="#Reference2.44">44</a><a href="#Reference2.45">45</a><a href="#Reference2.46">46</a><a href="#Reference2.47">47</a><a href="#Reference2.48">48</a><a href="#Reference2.49">49</a>
 Often these studies have concentrated on founder populations in which testing of larger, more population-based subjects are possible owing to a reduced number of mutations that require testing,<a href="#Reference2.25">25</a><a href="#Reference2.36">36</a><a href="#Reference2.38">38</a><a href="#Reference2.41">41</a><a href="#Reference2.44">44</a><a href="#Reference2.45">45</a><a href="#Reference2.47">47</a> compared with complete sequencing of the 2 genes required in most populations.  The first study of a community-based series was  carried out in the Washington, D.C., area. Blood samples and family medical histories were collected from more than 5,000 Ashkenazi Jewish individuals.<a href="#Reference2.25">25</a> Study participants were tested for 3 founder mutations: 185delAG and 5382insC in <Span Class="Protocol-GeneName">BRCA1</Span>, and 6174delT in <Span Class="Protocol-GeneName">BRCA2</Span>. The prevalence of breast cancer in the relatives of carriers was compared with that reported by mutation-negative individuals. The risk of breast cancer in carriers of these mutations was estimated to be 56% (95% CI, 40%-73%) by age 70 years. Ovarian cancer risk was estimated to be 16% (95% CI, 6%-28%). These values were lower than most prior risk estimates. Men carrying <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations were at modestly increased risk of prostate cancer, reaching 16% by age 70 years. Subsequent studies have provided additional support for an approximately 2-fold increased risk of prostate cancer in <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.<a href="#Reference2.41">41</a><a href="#Reference2.56">56</a><a href="#Reference2.57">57</a>.</P><a name="Section_717" /><P __id="_717">Many subsequent studies, whether in founder or predominantly outbred populations, have estimated breast cancer risks by age 70 years of approximately 60% or lower and ovarian cancer risks of approximately 40% or lower, though often with large confidence limits because, even in studies of founder populations, the number of identified mutation carriers is relatively small.  Most studies have done molecular testing on the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460211&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460211&amp;version=HealthProfessional&amp;language=English');  return(false);">proband</a> only and have done no,<a href="#Reference2.22">22</a><a href="#Reference2.25">25</a><a href="#Reference2.36">36</a><a href="#Reference2.38">38</a><a href="#Reference2.41">41</a><a href="#Reference2.42">42</a><a href="#Reference2.43">43</a><a href="#Reference2.44">44</a><a href="#Reference2.45">45</a><a href="#Reference2.47">47</a><a href="#Reference2.48">48</a>
 or limited,<a href="#Reference2.40">40</a><a href="#Reference2.50">50</a> testing among relatives.  Instead, the mutation status of relatives is modeled on simple Mendelian principles that on average, one half of first-degree relatives of mutation carriers will themselves be carriers.  Such modeling may lead to imprecision in the penetrance estimates; by chance, more than or less than half the relatives of some families will be carriers.  In the New York Breast Cancer Study of 104 mutation-positive Ashkenazi Jews with breast cancer, penetrance estimates were based only on relatives whose mutation status was known.<a href="#Reference2.49">49</a> These estimates were 69% and 74% for breast cancer by age 70 years for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers, respectively, and 46% and 12% for ovarian cancer for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span>, respectively.</P><a name="Section_727" /><P __id="_727">The largest study to date to estimate penetrance involved a pooled analysis of 22 studies of over 8,000 breast and ovarian cancer cases unselected for family history.<a href="#Reference2.48">48</a> Subjects were from 12 different countries and had a broad spectrum of mutations. Using modified segregation analysis on the families of the nearly 500 cases found to carry a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation, the cumulative risk of breast cancer by age 70 years was 65% (95% CI, 44%-78%) for <Span Class="Protocol-GeneName">BRCA1</Span> and 45% (95% CI, 31%-56%) for <Span Class="Protocol-GeneName">BRCA2</Span>. The penetrances for ovarian cancer are somewhat higher for <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, especially for ovarian cancer and early-onset breast cancer. These estimates are average risks of cancer among mutation carriers, assuming there is at least one family member with breast cancer or ovarian cancer (since all probands had these cancers), the situation likely to be encountered in clinical genetics situations. A case series of 491 women with stage I or stage II breast cancer and a known or suspected deleterious <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation was reviewed for incidence of ovarian cancer.  The actuarial risk of developing ovarian cancer at 10 years following diagnosis of breast cancer was 12.7% for <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers and 6.8% for <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.  Eight of 83 cancer deaths (9.6%) in this series were because of ovarian cancer.  Systemic treatment for the primary breast cancer did not alter these findings.<a href="#Reference2.58">58</a></P><a name="Section_718" /><P __id="_718">The continuing uncertainty as to the exact penetrance for breast and ovarian cancer among BRCA1/2 mutation carriers may be due to several factors, including differences owing to study design, allelic <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339333&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339333&amp;version=HealthProfessional&amp;language=English');  return(false);">heterogeneity</a> (differing risks for different mutations within either of the genes), and to modifying genetic and/or environmental factors.<a href="#Reference2.48">48</a><a href="#Reference2.49">49</a><a href="#Reference2.59">59</a><a href="#Reference2.60">60</a>
<a href="#Reference2.61">61</a> While the average breast and ovarian cancer penetrances may not be as high as initially estimated, they are very high, both in relative and absolute terms, and additional studies will be required to further characterize potential modifying factors in order to arrive at more precise individual risk projections.  Precise penetrance estimates for less common cancers, such as pancreatic cancer, are lacking.</P><a name="Section_733" /><P __id="_733">The tables titled “<SummaryRef href="CDR0000062855#_731">Studies of Cancer Penetrance Among BRCA1 and BRCA2 Mutation Carriers: Cumulative Incidence of Breast Cancer</SummaryRef>” and “<SummaryRef href="CDR0000062855#_732">Studies of Cancer Penetrance Among BRCA1 and BRCA2 Mutation Carriers: Cumulative Incidence of Ovarian Cancer</SummaryRef>” review the incidence  of breast and ovarian cancer among <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.</P><a name="TableSection"><a name="Section_731"><table Rules="all" Frame="border" Border="1" valign="top" cellspacing="0" cellpadding="5" width="100%"><span class="Summary-Table-Caption"><b>Table 2. Studies of Cancer Penetrance Among <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> Mutation Carriers: Cumulative Incidence of Breast Cancer</b></span><div name="EnlargePlaceholder" align="right" /><COLGROUP><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /></COLGROUP><THEAD><tr class="Summary-Table-Head"><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b /> 
									</td><td colspan="6" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Cumulative Incidence of Breast Cancer to Given Age</b> 
									</td></tr></THEAD><TBODY><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b><Span Class="Protocol-GeneName">BRCA1</Span></b></td><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName"><b>BRCA2</b></Span></td><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName"><b>BRCA1/2</b></Span></td></tr><tr><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>Population</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Linkage analysis- maximization of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=415709&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000415709&amp;version=HealthProfessional&amp;language=English');  return(false);">logarithm of the odd (LOD) score</a></b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—214 breast-ovary families (BCLC) <a href="#Reference2.7">7</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">59%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">82%</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—<Span Class="Protocol-GeneName">BRCA1</Span>-linked families (BCLC) <a href="#Reference2.35">35</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">51%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">85%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—237 breast and breast-ovarian cancer families (BCLC) <a href="#Reference2.37">37</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">49%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">71%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">28%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">84%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Incidence of second cancers after breast cancer</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—33 <Span Class="Protocol-GeneName">BRCA1</Span>-linked families (BCLC) <a href="#Reference2.34">34</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">73%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">87%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">—BRCA1</Span>-linked families (BCLC) <a href="#Reference2.35">35</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">50%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">65%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Analysis of family members</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish ovarian cancer cases, 7 <Span Class="Protocol-GeneName">BRCA1</Span>, 3 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.36">36</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">30%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">50%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">16%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">23%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish breast-ovary families, 16 <Span Class="Protocol-GeneName">BRCA1</Span>, 9 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.36">36</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">37%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">64%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">18%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">49%#</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Kin cohort using family and cancer registries</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected Icelandic breast cancer patients, 56 female and 13 male <Span Class="Protocol-GeneName">BRCA2</Span> 995del5 <a href="#Reference2.38">38</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">17%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">37%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Second or contralateral cancer incidence; focus was on nonbreast and ovary outcomes</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—173 breast-ovarian cancer families either <Span Class="Protocol-GeneName">BRCA2</Span>-positive or <Span Class="Protocol-GeneName">BRCA2</Span>-linked (BCLC) <a href="#Reference2.39">39</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">37%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">52%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Modified segregation analysis - all available relatives tested (MENDEL)</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Australian population-based breast cancer age &lt;40 years, 9 <Span Class="Protocol-GeneName">BRCA1</Span>, 9 <Span Class="Protocol-GeneName">BRCA2 </Span><a href="#Reference2.40">40</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">10%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">40%</td></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Kin cohort</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Community-based Washington area Jews, 61 <Span Class="Protocol-GeneName">BRCA1</Span>, 59 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.25">25</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">38%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">59%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">26%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">51%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">33%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">56%</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish women with breast cancer, 34 <Span Class="Protocol-GeneName">BRCA1</Span>, 15 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.41">41</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">60%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">28%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish women with ovarian cancer, 44 <Span Class="Protocol-GeneName">BRCA1</Span>, 24 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.44">44</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">31%*</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">44%&amp;</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">6%*</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">37%&amp;</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian cancer, 39 <Span Class="Protocol-GeneName">BRCA1</Span>, 21 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.22">22</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">68%@</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">14%@</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Modified segregation analysis (MENDEL)</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Breast cancer cases age &lt;55 years, 8 <Span Class="Protocol-GeneName">BRCA1</Span>, 16 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.42">42</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">32%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">47%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">18%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">56%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">21%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">54%</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Families with 2+ cases ovarian cancer, 40 <Span Class="Protocol-GeneName">BRCA1</Span>, 11 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.43">43</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">39%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">72%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">19%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">71%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian cancer, 12 <Span Class="Protocol-GeneName">BRCA1</Span> <a href="#Reference2.43">43</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">34%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">50%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—164 <Span Class="Protocol-GeneName">BRCA2</Span>-positive families from BCLC <a href="#Reference2.46">46</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">41%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian or breast cancer from 22 studies, 289 <Span Class="Protocol-GeneName">BRCA1</Span>, 221 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.48">48</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">38%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">65%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">15%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">45%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Australian multiple-case families, 28 <Span Class="Protocol-GeneName">BRCA1</Span>, 23 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.50">50</a> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">48%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">74%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Relative risk times population rates</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish hospital-based ovarian cancer patients, 103 <Span Class="Protocol-GeneName">BRCA1</Span>, 44 <Span Class="Protocol-GeneName">BRCA2</Span> founder mutations <a href="#Reference2.45">45</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">18%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">59%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">6%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">38%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Direct Kaplan-Meier estimates restricted to relatives known to be mutation positive</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected Jewish breast cancer patients from NY, 67 <Span Class="Protocol-GeneName">BRCA1</Span>, 37 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.49">49</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">39%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">69%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">34%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">74%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr></TBODY></table><br /><table border="0" width="100%"><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i># - Outcome is breast OR ovarian cancer</i></td></tr><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>
* - Incidence to age 55
years</i></td></tr><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>&amp; - Incidence to age 75 years</i></td></tr><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>@ - Incidence to age 80 years</i></td></tr></table><Br /></a></a><a name="TableSection"><a name="Section_732"><table Rules="all" Frame="border" Border="1" valign="top" cellspacing="0" cellpadding="5" width="100%"><span class="Summary-Table-Caption"><b>Table 3. Studies of Cancer Penetrance 
Among <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> 
Mutation Carriers: Cumulative Incidence of Ovarian Cancer</b></span><div name="EnlargePlaceholder" align="right" /><COLGROUP><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /></COLGROUP><THEAD><tr class="Summary-Table-Head"><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b /> 
									</td><td colspan="6" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Cumulative Incidence of Ovarian Cancer to Given Age </b> 
									</td></tr></THEAD><TBODY><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b><Span Class="Protocol-GeneName">BRCA1</Span></b></td><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b><Span Class="Protocol-GeneName">BRCA2</Span></b></td><td rowspan="0" colspan="2" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b><Span Class="Protocol-GeneName">BRCA1/2</Span></b></td></tr><tr><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>Population</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>50 yr</b></td><td rowspan="0" colspan="0" align="Center" Valign="Top" class="Summary-SummarySection-Small"><b>70 yr</b></td></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Incidence of second cancers after breast cancer</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—33 <Span Class="Protocol-GeneName">BRCA1</Span>-linked families (BCLC) <a href="#Reference2.34">34</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">29%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">44%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">—BRCA1</Span>-linked families (BCLC)  <a href="#Reference2.35">35</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">29%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">44%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Linkage analysis - maximization of LOD score</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">—BRCA1</Span>-linked families (BCLC) <a href="#Reference2.35">35</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">23%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">63%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—237 breast and breast-ovarian cancer families (BCLC) <a href="#Reference2.37">37</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">0%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">27%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Kin cohort</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Community-based Washington area Jews, 61 <Span Class="Protocol-GeneName">BRCA1</Span>, 59 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.25">25</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">8%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">16%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">5%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">18%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">7%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">16%</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian cancer, 39 <Span Class="Protocol-GeneName">BRCA1</Span>, 21 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.22">22</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">36%@</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">10%@</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Second or contralateral cancer incidence; focus was on nonbreast and ovary outcomes</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—173 breast-ovarian cancer families either <Span Class="Protocol-GeneName">BRCA2</Span>-positive or <Span Class="Protocol-GeneName">BRCA2</Span>-linked (BCLC) <a href="#Reference2.39">39</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">3%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">16%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Modified segregation analysis (MENDEL)</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Breast cancer cases age &lt;55 years, 8 <Span Class="Protocol-GeneName">BRCA1</Span>, 16 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.42">42</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">11%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">36%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">3%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">10%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">4%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">16%</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Families with 2+ cases ovarian cancer, 40 <Span Class="Protocol-GeneName">BRCA1</Span>, 11 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.43">43</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">17%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">53%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">1%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">31%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian cancer, 12 <Span Class="Protocol-GeneName">BRCA1</Span> <a href="#Reference2.43">43</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">21%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">68%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—164 <Span Class="Protocol-GeneName">BRCA2</Span>-positive families from BCLC <a href="#Reference2.46">46</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">14%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian or breast cancer from 22 studies, 289 <Span Class="Protocol-GeneName">BRCA1</Span>, 221 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.48">48</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">13%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">39%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">1%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">11%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Relative risk times population rates</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Jewish women with ovarian cancer, 44 <Span Class="Protocol-GeneName">BRCA1</Span>, 24 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.44">44</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">&gt;40%&amp;</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">20%&amp;</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected cases ovarian or breast cancer from 22 studies, 289 <Span Class="Protocol-GeneName">BRCA1</Span>, 221 <Span Class="Protocol-GeneName">BRCA2 </Span><a href="#Reference2.47">47</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">11%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">37%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">3%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">21%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="7" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Direct Kaplan-Meier estimates restricted to relatives known to be mutation positive</b></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">—Unselected Jewish breast cancer patients from NY, 67 <Span Class="Protocol-GeneName">BRCA1</Span>, 37 <Span Class="Protocol-GeneName">BRCA2</Span> <a href="#Reference2.49">49</a></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">21%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">46%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">2%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">12%</td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr></TBODY></table><br /><table border="0" width="100%"><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>&amp; - Incidence to age 75 years</i></td></tr><tr><td colspan="7" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>@ - Incidence to age 80
 years</i></td></tr></table><Br /></a></a>





</a>

<a name="Section_79"><Span class="Summary-SummarySection-Title-Level2">Models for Prediction of the Likelihood of a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> Mutation</Span>


<a name="Section_646" /><P __id="_646">Several studies have assessed the frequency of <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations in women with breast or ovarian cancer. These studies have used populations derived from clinical referral centers.<a href="#Reference2.21">21</a><a href="#Reference2.62">62</a><a href="#Reference2.63">63</a><a href="#Reference2.64">64</a><a href="#Reference2.65">65</a><a href="#Reference2.66">66</a><a href="#Reference2.67">67</a> Personal characteristics associated with an increased likelihood of a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation include the following:</P><a name="Section_647" /><a name="ListSection" /><UL __id="_647" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Breast cancer diagnosed at an early age.</LI><LI class="Protocol-IL-Bullet">Bilateral breast cancer.</LI><LI class="Protocol-IL-Bullet">A history of both breast and ovarian cancer.</LI><LI class="Protocol-IL-Bullet">The presence of breast cancer in 1 or more male family members.<a href="#Reference2.21">21</a><a href="#Reference2.62">62</a><a href="#Reference2.63">63</a><a href="#Reference2.64">64</a><a href="#Reference2.67">67</a></LI></UL><a name="END_ListSection" /><a name="Section_648" /><P __id="_648">Family history characteristics associated with an increased likelihood of carrying a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation include the following: </P><a name="Section_649" /><a name="ListSection" /><UL __id="_649" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Multiple cases of breast cancer in the family.</LI><LI class="Protocol-IL-Bullet">Both breast and ovarian cancer in the family.</LI><LI class="Protocol-IL-Bullet">One or more family members with 2 primary cancers.</LI><LI class="Protocol-IL-Bullet">Ashkenazi Jewish background.<a href="#Reference2.21">21</a><a href="#Reference2.62">62</a><a href="#Reference2.63">63</a><a href="#Reference2.64">64</a></LI></UL><a name="END_ListSection" /><a name="Section_650" /><P __id="_650">The likelihood of having a <Span Class="Protocol-GeneName">BRCA</Span> mutation can vary from one individual to the next based on their country of origin, ethnicity, and family history of cancer. The models outlined in the table  titled Characteristics of Common Models for Estimating the Likelihood of a <Span Class="Protocol-GeneName">BRCA</Span> Mutation take these factors into account and assist in providing tailored <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460214&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460214&amp;version=HealthProfessional&amp;language=English');  return(false);">risk assessments</a>. Another model, the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), was developed in 2004 to assess both breast and ovarian cancer risks and the probabilities of carrying a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation.<a href="#Reference2.68">68</a> This model appears to perform well, particularly in the situation of a family history of breast cancer, compared to the Claus and BRCAPRO models, but because of its complexity, it is not readily applied in a clinical setting and is not included in the following table.</P>
<a name="TableSection"><a name="Section_678"><table Rules="all" Frame="border" Border="1" valign="top" cellspacing="0" cellpadding="5" width="100%"><span class="Summary-Table-Caption"><b>Table 4. Characteristics of Common Models for Estimating the Likelihood of a <Span Class="Protocol-GeneName">BRCA</Span> Mutation</b></span><div name="EnlargePlaceholder" align="right" /><COLGROUP><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /><COL Width="1*" /></COLGROUP><THEAD><tr class="Summary-Table-Head"><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b /> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Couch <a href="#Reference2.21">21</a></b> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Shattuck-Eidens <a href="#Reference2.62">62</a></b> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Frank <a href="#Reference2.64">64</a></b> 
									</td><td colspan="0" align="Center" Valign="Middle" class="Summary-SummarySection-Small"><b>Parmigiani <a href="#Reference2.67">67</a></b> 
									</td></tr></THEAD><TFOOT><tr><td colspan="5" Valign="Top" Align="Left" class="Summary-SummarySection-Small"><i>CSGE = conformation sensitive gel electrophoresis  </i></td></tr></TFOOT><TBODY><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Gene</b></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">BRCA1</Span></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">BRCA1</Span></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Study population</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">169 women with breast cancer and family history of breast cancer and/or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">798 women with either early-onset breast cancer or ovarian cancer, or with family history of breast or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">238 women with breast cancer diagnosed at age &lt;50 years or with ovarian cancer, with at least 1 first-degree or second-degree relative with breast cancer &lt;50 years or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Statistical model (BRCAPRO)  </td></tr><tr><td rowspan="6" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Proband characteristics</b>  </td><td rowspan="3" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband may or may not have breast or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband must be affected with breast cancer and/or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband must be affected with breast cancer &lt;50 years or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband may or may not have breast or ovarian cancer  </td></tr><tr><td rowspan="2" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account bilateral breast cancer and age of onset of proband  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account probands with bilateral breast cancer and those with both breast and ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Consideration of proband’s current age or age at diagnosis of breast or ovarian cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Special consideration for probands with breast cancer &lt;40 years  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account:  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Bilateral breast cancer and those with breast cancer, ovarian cancer, or breast and ovarian cancer at any age  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Male breast cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation status  </td></tr><tr><td rowspan="7" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Family history characteristics</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Family must have &gt;2 cases of breast cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">May or may not have affected relatives  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Must have first-degree relative with breast cancer &lt;50 years or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Includes all first-degree relatives and second-degree relatives with and without cancer </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account proband or relatives with breast and/or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account relatives with breast and/or ovarian cancer </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account additional relatives with breast cancer &lt;50 years or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account:</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Uses average age at diagnosis of breast cancers  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not take into account age of onset of cancer or bilateral breast cancer in relatives  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Relatives with male or female breast cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account Ashkenazi Jewish ancestry  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Takes into account Ashkenazi Jewish ancestry </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Female relatives with ovarian cancer or breast and ovarian cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Current age or age at death and age at diagnosis of breast cancer and ovarian cancer  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- Ashkenazi Jewish ancestry  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">- <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation status  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Provides risk estimate for  </b></td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Composite family probability  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband (who has breast or ovarian cancer)  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Proband (who has breast cancer &lt;50 years or ovarian cancer)  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Any affected or unaffected family member  </td></tr><tr><td rowspan="6" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Limitations</b> </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not estimate likelihood of <Span Class="Protocol-GeneName">BRCA2</Span> mutation  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not estimate likelihood of <Span Class="Protocol-GeneName">BRCA2</Span> mutation  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Not applicable to women diagnosed with breast cancer at ≥ 50 years  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Requires computer software and time-consuming data entry</td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Not applicable to families with site-specific ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Further calculation required for unaffected relatives  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Further calculation required for unaffected relatives  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Incorporates only first-degree relatives and second-degree relatives; may need to change proband to best capture risk </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Does not take into account bilaterality or male breast cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Underestimates risk with multiple affected members  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Combined data for Ashkenazi Jewish and non-Jewish families so it may overestimate risk for non-Jewish probands and underestimate risk for Jewish probands  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Has been validated in a high-risk genetic counseling clinic <a href="#Reference2.69">69</a></td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Some estimates are based on small sample size </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Validity in moderate family histories unknown </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Further calculation required for unaffected relatives  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Because testing used CSGE, may underestimate mutation likelihood  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /></tr><tr><td rowspan="4" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small"><b>Best application</b>  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Families with 1 or more cases of breast cancer, Ashkenazi Jewish families, and families with multiple affected members  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Families with small number of affected members  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Families with 2 first-degree relatives with breast cancer &lt;50 years or ovarian cancer  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Widely applicable  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Provides likelihood of either <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation  </td><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Only model to incorporate unaffected relatives, male breast cancer, bilateral breast cancer, and age at diagnosis for all affected individuals  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Provides likelihood of either <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation  </td></tr><tr><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small" /><td rowspan="0" colspan="0" align="Left" Valign="Top" class="Summary-SummarySection-Small">Program also provides Couch, Shattuck-Eidens and Frank risk estimates  </td></tr></TBODY></table><br /></a></a><a name="Section_652">

<Span class="Summary-SummarySection-Title-Level3">Population Estimates of the Likelihood of Having a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> Mutation</Span>


<a name="Section_653" /><P __id="_653">  Statistics regarding the percentage of women found to be <Span Class="Protocol-GeneName">BRCA</Span> mutation carriers among samples of women with a variety of personal cancer histories regardless of family history are provided below.  These data can help determine who might best benefit from a referral for cancer genetic counseling and consideration of genetic testing, but cannot replace a personalized risk assessment, which might indicate a higher or lower mutation likelihood based on family history characteristics. </P>
<a name="Section_729" /><P __id="_729">Among non-Ashkenazi Jewish individuals (likelihood of having any <Span Class="Protocol-GeneName">BRCA</Span> mutation):</P><a name="Section_730" /><a name="ListSection" /><UL __id="_730" class="Protocol-UL"><LI class="Protocol-IL-Bullet">General non-Ashkenazi Jewish population: 		1 in 500 (.002%).<a href="#Reference2.70">70</a></LI><LI class="Protocol-IL-Bullet">Women with breast cancer (all ages): 1 in 50 (2%).<a href="#Reference2.71">71</a></LI><LI class="Protocol-IL-Bullet">Women with breast cancer (younger than 40 years): 1 in 11 (9%).<a href="#Reference2.72">72</a></LI><LI class="Protocol-IL-Bullet">Men with breast cancer (regardless of age): 1 in 20 (5%).<a href="#Reference2.73">73</a></LI><LI class="Protocol-IL-Bullet">Women with ovarian cancer (all ages): 1 in 10 (10%).<a href="#Reference2.22">22</a><a href="#Reference2.74">74</a></LI></UL><a name="END_ListSection" /><a name="Section_658" /><P __id="_658">Among Ashkenazi Jewish individuals (likelihood of having one of 3 founder mutations):</P><a name="Section_654" /><a name="ListSection" /><UL __id="_654" class="Protocol-UL"><LI class="Protocol-IL-Bullet">General Ashkenazi Jewish population: 1 in 40 (2.5%).<a href="#Reference2.25">25</a></LI><LI class="Protocol-IL-Bullet">Women with breast cancer (all ages): 1 in 10 (10%).<a href="#Reference2.49">49</a></LI><LI class="Protocol-IL-Bullet">Women with breast cancer (younger than 40 years): 1 in 3 (30%-35%).<a href="#Reference2.49">49</a><a href="#Reference2.75">75</a><a href="#Reference2.76">76</a></LI><LI class="Protocol-IL-Bullet">Men with breast cancer (regardless of age): 1 in 5 (19%).<a href="#Reference2.77">77</a></LI><LI class="Protocol-IL-Bullet">Women with ovarian cancer or primary peritoneal cancer (all ages): 1 in 3 (36%-41%).<a href="#Reference2.44">44</a><a href="#Reference2.54">54</a><a href="#Reference2.78">78</a></LI></UL><a name="END_ListSection" /><a name="Section_657" /><P __id="_657">Genetic testing for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> has been available to the public since 1996.  As more individuals have undergone testing, risk assessment models have improved.  This in turn gives providers better data with which to estimate an individual patient’s risk of carrying a mutation.  There remains an art to risk assessment in practitioners’ selection of the best model to fit their individual patient’s circumstances and consideration of factors that might limit the ability to provide an accurate risk assessment (i.e., small family size or paucity of women).  </P></a>
</a><a name="Section_125"><Span class="Summary-SummarySection-Title-Level2">Role of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> in Sporadic Cancer</Span>
<a name="Section_126" /><P __id="_126">Given that germline mutations in <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> lead to a very high probability
of developing breast and/or ovarian cancer, it was a natural assumption that
these genes would also be involved in the development of the more common
nonhereditary forms of the disease.  To date, only weak connections have been
made between these genes and sporadic breast and ovarian cancer.  Studies of tumor tissue from sporadic breast cancers have detected no somatic
<Span Class="Protocol-GeneName">BRCA1</Span> mutations  and a very low frequency of <Span Class="Protocol-GeneName">BRCA2</Span> mutations.<a href="#Reference2.79">79</a><a href="#Reference2.80">80</a><a href="#Reference2.81">81</a><a href="#Reference2.82">82</a><a href="#Reference2.83">83</a>  In ovarian cancer tumor
tissue, however, <Span Class="Protocol-GeneName">BRCA1</Span> mutations appear to occur with some frequency.  In an unselected series of 103 ovarian
cancers, 7 disease-causing mutations in <Span Class="Protocol-GeneName">BRCA1</Span> were found that were not present
in normal tissue of these patients.<a href="#Reference2.84">84</a>  Another series of 221 ovarian cancers analyzed for mutations in <Span Class="Protocol-GeneName">BRCA1</Span> identified 15 somatic mutations and 18 tumors with evidence of <Span Class="Protocol-GeneName">BRCA1</Span> dysfunction due to hypermethylation.<a href="#Reference2.85">85</a></P>
<a name="Section_127" /><P __id="_127">Since few somatic <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations are seen in
sporadic breast tumors, other mechanisms for the inactivation of these tumor
suppressor genes have been investigated.  In particular, decreased expression
of wild-type <Span Class="Protocol-GeneName">BRCA1</Span> may occur on an epigenetic basis, i.e., as a result of
DNA methylation or other physiological change that results in loss of gene
expression, an event that in turn leads to cancer.  In support of this hypothesis, artificially
decreasing expression of <Span Class="Protocol-GeneName">BRCA1</Span> using antisense oligonucleotides resulted in
accelerated growth of mammary epithelial cells in culture.<a href="#Reference2.86">86</a>  Compared with
normal breast epithelium, many breast cancers have low levels of the <Span Class="Protocol-GeneName">BRCA1</Span>
mRNA, which may result from hypermethylation of the gene promoter.<a href="#Reference2.86">86</a><a href="#Reference2.87">87</a><a href="#Reference2.88">88</a><a href="#Reference2.89">89</a><a href="#Reference2.90">90</a> 
Similar findings have not been reported for <Span Class="Protocol-GeneName">BRCA2</Span>, though the BRCA2 <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460162&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460162&amp;version=HealthProfessional&amp;language=English');  return(false);">locus</a> on
chromosome 13q is the target of frequent <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=464169&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000464169&amp;version=HealthProfessional&amp;language=English');  return(false);">loss of heterozygosity (LOH)</a> in breast
cancer.<a href="#Reference2.91">91</a><a href="#Reference2.92">92</a>
</P>
<a name="Section_615" /><P __id="_615">Taken together, current pathologic, cytogenetic, and gene expression data suggest not only that inactivation of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> plays a role in sporadic cancer, but also that there are biologic differences between <Span Class="Protocol-GeneName">BRCA1</Span>-related, <Span Class="Protocol-GeneName">BRCA2</Span>-related, and sporadic breast cancers.  A clear understanding of these differences (and similarities) has not yet been reached.<a href="#Reference2.93">93</a><a href="#Reference2.94">94</a><a href="#Reference2.95">95</a><a href="#Reference2.96">96</a><a href="#Reference2.97">97</a></P>
</a>
<a name="Section_129"><Span class="Summary-SummarySection-Title-Level2">Molecular Correlations</Span>
<a name="Section_130" /><P __id="_130">Mutations in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> confer a highly increased susceptibility to breast
and ovarian cancer, but these mutations do not lead to cancer by themselves. 
The current consensus is that these are gatekeeper genes that, when removed,
allow other genetic defects to accumulate.  The nature of these other molecular
events may define the pathway through which <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> function.
</P>
<a name="Section_131" /><P __id="_131">A number of studies have looked at steroid hormone receptor levels in tumors
containing <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations.  In most of these studies, <Span Class="Protocol-GeneName">BRCA1</Span> cancers
were shown to be more often estrogen receptor negative than nonhereditary
cancers.<a href="#Reference2.98">98</a><a href="#Reference2.99">99</a><a href="#Reference2.100">100</a><a href="#Reference2.101">101</a><a href="#Reference2.102">102</a>  Some discrepancies exist in these studies that may be
attributable to the relatively small sample sizes and the geographically or
ethnically defined populations that may all carry the same mutation.  This
raises the issue of whether specific founder mutations in <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> such
as the Ashkenazi or Icelandic mutations have specifically associated
phenotypes.  
</P>
<a name="Section_132" /><P __id="_132">One such genotype-phenotype correlation that appears significant is with
families carrying <Span Class="Protocol-GeneName">BRCA2</Span> mutations in a specific region of the gene.  From 25
families with <Span Class="Protocol-GeneName">BRCA2</Span> mutations, an ovarian cancer cluster region was
identified in exon 11 bordered by nucleotide 3,035 and 6,629.<a href="#Reference2.9">9</a><a href="#Reference2.37">37</a>  This is
the region of the gene containing the BRC repeats, which have been shown to
specifically interact with <Span Class="Protocol-GeneName">RAD51</Span>.  A study of 164 families with <Span Class="Protocol-GeneName">BRCA2</Span> mutations
collected by the Breast Cancer Linkage Consortium confirmed the initial
finding.  Mutations within the ovarian cancer cluster region were associated
with an increased risk of ovarian cancer and a decreased risk of breast cancer
in comparison to families with mutations on either side of this region.<a href="#Reference2.46">46</a>
In addition, a study of 356 families with protein-truncating <Span Class="Protocol-GeneName">BRCA1</Span> mutations collected by the Breast Cancer Linkage Consortium reported breast cancer risk to be lower with mutations in the central region (nucleotides 2,401-4,190) compared with surrounding regions. Ovarian cancer risk was significantly reduced with mutations 3’ to nucleotide 4,191.<a href="#Reference2.103">103</a>  These observations have generally been confirmed in subsequent studies;<a href="#Reference2.48">48</a><a href="#Reference2.50">50</a><a href="#Reference2.104">104</a> however, none of the studies has had sufficient numbers of mutation-positive individuals to make definitive conclusions, and the findings are probably not sufficiently established to use in individual risk assessment and management. </P><a name="Section_133" /><P __id="_133">Additional evidence exists that this region of <Span Class="Protocol-GeneName">BRCA2</Span> contains a specific
functional domain.  Of the 5 different <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339342&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339342&amp;version=HealthProfessional&amp;language=English');  return(false);">homozygous</a> <Span Class="Protocol-GeneName">BRCA2</Span> knockout mice
constructed by independent laboratories, 3 lead to embryonic lethality during
the first 10 days of gestation.<a href="#Reference2.105">105</a><a href="#Reference2.106">106</a><a href="#Reference2.107">107</a>  The other 2 knockouts yield viable
full-term mice that can survive to adulthood.<a href="#Reference2.108">108</a><a href="#Reference2.109">109</a>  The dramatic difference
in phenotype correlates with the position of the <Span Class="Protocol-GeneName">BRCA2</Span> mutation.  The mice that
die in utero contain a truncation in the <Span Class="Protocol-GeneName">BRCA2</Span> gene before a series of repeated
sequences in the large exon 11, while in those mice that can come to term, some
copies of these repeats are retained.  The repeats themselves have been shown
to be the site of interaction of the Rad51 protein, suggesting that Rad51
binding is critical in determining the function of <Span Class="Protocol-GeneName">BRCA2</Span> both during
development and neoplasia.<a href="#Reference2.110">110</a> 
</P>
<a name="Section_134" /><P __id="_134">Genetic changes associated with <Span Class="Protocol-GeneName">BRCA1</Span>- and <Span Class="Protocol-GeneName">BRCA2</Span>-related cancers are just
beginning to be examined.  Mutations in <Span Class="Protocol-GeneName">TP53</Span> seem to be much more frequent in
<Span Class="Protocol-GeneName">BRCA1</Span> breast cancers (20/26) and somewhat more frequent in <Span Class="Protocol-GeneName">BRCA2</Span>-associated
breast cancers (10/22) than in grade-matched sporadic cancers (7/20).<a href="#Reference2.111">111</a>  <Span Class="Protocol-GeneName">BRCA</Span>
mutation-associated cancers contain <Span Class="Protocol-GeneName">TP53</Span> mutations not typically found in
sporadic breast cancer, and 12 individual hereditary breast cancers were shown
to contain more than a single <Span Class="Protocol-GeneName">TP53</Span> mutation.  This raised the issue that
mutations of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> may confer a mutator phenotype allowing the
general accumulation of a high rate of genetic abnormalities.  Analysis of the
coding sequence from the I-ran and Pancho oncogenes and the a-globin gene
revealed no increase in mutations in <Span Class="Protocol-GeneName">BRCA</Span> mutation-associated breast cancers. 
In addition, no evidence was seen of the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=285938&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000285938&amp;version=HealthProfessional&amp;language=English');  return(false);">microsatellite</a> instability
characteristic of HNPCC associated cancers.  Therefore, <Span Class="Protocol-GeneName">TP53</Span> inactivation (or
perhaps gain of function mutations) may be specifically selected for during
<Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> tumor progression.
</P>
<a name="Section_135" /><P __id="_135">A genome-wide screening for chromosomal gains or losses was performed on <Span Class="Protocol-GeneName">BRCA1</Span>
and <Span Class="Protocol-GeneName">BRCA2</Span> breast cancers to determine the presence of other associated genetic
hot-spots.<a href="#Reference2.94">94</a>  On the whole, <Span Class="Protocol-GeneName">BRCA</Span>-associated cancers had more regions that
were amplified or deleted compared with controls (not stage matched and grade matched),
suggesting a generalized increase in large-scale genomic instability. 
Specifically, chromosomes 5q, 4q, and 4p had very frequent LOH in <Span Class="Protocol-GeneName">BRCA1</Span> tumors,
while <Span Class="Protocol-GeneName">BRCA2</Span> tumors were characterized by losses at 13q (near the BRCA2 locus
itself) and 6q and chromosomal gains at 17q (outside of the HER2/neu locus) and
20q.  LOH of both chromosomes 13 and 17 have been found simultaneously in a
series of sporadic ovarian cancers, suggesting a synergistic mechanism.<a href="#Reference2.112">112</a> In addition, the oncogene <Span Class="Protocol-GeneName">MYC</Span> on chromosome 8q24 was found to  be amplified in 48% of 60 <Span Class="Protocol-GeneName">BRCA1</Span>-related breast cancers versus 14% of non-<Span Class="Protocol-GeneName">BRCA1</Span> tumors.<a href="#Reference2.113">113</a></P>
</a>
<a name="Section_136"><Span class="Summary-SummarySection-Title-Level2">Pathology/Prognosis of Breast Cancer</Span><br /><br />

<a name="Section_759">

<Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">BRCA1</Span></Span><br /><br />



<a name="Section_771"><Span class="Summary-SummarySection-Title-Level4">Pathology</Span><a name="Section_772" /><P __id="_772">The identification of a histologic pattern characterizing hereditary breast
cancer has been elusive, though historically, medullary, tubular, and lobular
histologies have been associated with familial breast
cancer.<a href="#Reference2.114">114</a>  Other studies have noted an excess of medullary histology in multicase
families.<a href="#Reference2.115">115</a><a href="#Reference2.116">116</a>  Since the identification of the <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> genes, several studies have evaluated the distinct pathologic patterns seen in known hereditary breast cancers. Medullary histology was significantly more common (19% vs. 0%)
in a series of <Span Class="Protocol-GeneName">BRCA1</Span>-associated breast cancer compared with sporadic cases in a
study from France,<a href="#Reference2.117">117</a> in carriers from the Breast Cancer Linkage
Consortium,<a href="#Reference2.118">118</a>, in a Swedish population-based study of breast cancer cases from high-risk families,<a href="#Reference2.119">119</a> and among women with early-onset breast cancer in a
population-based study,<a href="#Reference2.120">120</a> suggesting that medullary histology itself may be
an indication for <Span Class="Protocol-GeneName">BRCA1</Span> testing.
</P><a name="Section_773" /><P __id="_773"> The Breast Cancer Linkage Consortium reported a relative lack of an <i>in situ</i> component in <Span Class="Protocol-GeneName">BRCA1-</Span>associated breast cancers.<a href="#Reference2.118">118</a>  Data from the Mayo Clinic cohort of women undergoing  mastectomy, however, found a significantly lower prevalence of hyperplastic lesions in <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations, but no difference in the prevalence of <i>in situ</i> lesions.<a href="#Reference2.121">121</a> A population-based case-control study of ductal carcinoma <i>in situ</i> patients also found the prevalence of <Span Class="Protocol-GeneName">BRCA</Span> mutations to be similar in these women, as previously reported in studies of invasive breast cancer patients.<a href="#Reference2.122">122</a> Therefore, it appears that ductal carcinoma <i>in situ</i> is a component of the hereditary breast ovarian cancer syndrome.</P></a><a name="Section_774"><Span class="Summary-SummarySection-Title-Level4">Prognosis</Span><a name="Section_775" /><P __id="_775">The phenotypic expression of <Span Class="Protocol-GeneName">BRCA1</Span>-related breast cancer indicates distinctive prognostic features.  A large study of 1,555 women with invasive breast cancer in 10 North American centers failed to find the expected correlation of tumor size with lymph node status among carriers of a deleterious <Span Class="Protocol-GeneName">BRCA1</Span> mutation, suggesting that these tumors are characterized by an accelerated growth rate.<a href="#Reference2.123">123</a>  Investigators from the Mayo Clinic reached similar conclusions based on the risk-reducing mastectomy cohort, in whom both <i>in situ</i> and invasive lesions from <Span Class="Protocol-GeneName">BRCA1/2</Span> carriers had higher-grade tumors and higher proliferations indices.<a href="#Reference2.121">121</a>  A Norwegian study reported that breast cancers occurring in <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers were more likely to be invasive, high grade, and estrogen receptor negative.<a href="#Reference2.124">124</a>  A case-control study among women of Jewish descent also found that <Span Class="Protocol-GeneName">BRCA1</Span>-associated tumors were significantly more likely to be grade III and estrogen receptor negative.<a href="#Reference2.125">125</a>  Analysis of tumors from the North American study indicates that the estrogen receptor negative status of the <Span Class="Protocol-GeneName">BRCA1</Span> tumors is an intrinsic feature and not simply a correlate of younger age or higher grade.<a href="#Reference2.126">126</a> The Breast Cancer Linkage Consortium compared the histopathologic features of breast cancer in women with <Span Class="Protocol-GeneName">BRCA1</Span> mutations to a control group and found an excess of high-grade tumors, high mitotic rates, high proliferative fractions, and increased aneuploidy.<a href="#Reference2.118">118</a>  They also found an increased frequency of high-intensity immunostaining for p53 in tumors from <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers.<a href="#Reference2.127">127</a>  A population-based study confirmed the excess of high-grade tumors with high mitotic rates in <Span Class="Protocol-GeneName">BRCA1</Span> carriers, but did not find a relative absence of <i>in situ</i> cancers in this group.<a href="#Reference2.120">120</a> In a separate study of tumors from women with 1 of the 3 Ashkenazi founder mutations, immunohistochemical analysis demonstrated a relatively low rate of HER2/neu positivity and no differences in p53, epidermal growth factor receptor, cathepsin D, bcl-2, or cyclin D staining compared to a control group.<a href="#Reference2.99">99</a></P><a name="Section_776" /><P __id="_776">The recent development of gene-expression technology has created the potential to increase the specificity of the classification of breast cancer at the molecular level.  Global gene expression profiles of tumors with <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations and sporadic tumors differed significantly from each other in 1 small series.<a href="#Reference2.128">128</a>  Using comparative genomic hybridization (CGH),  investigators from the Netherlands were able to develop a profile of distinct somatic genetic alterations, which can identify <Span Class="Protocol-GeneName">BRCA1</Span>-associated tumors with an accuracy of 84%.<a href="#Reference2.129">129</a> Another study using tissue microarray technology to compare <Span Class="Protocol-GeneName">BRCA1</Span>, <Span Class="Protocol-GeneName">BRCA2</Span>, and sporadic tumors found that <Span Class="Protocol-GeneName">BRCA1</Span> tumors were more likely to be BCL2-negative and to express high levels of P-cadherin.<a href="#Reference2.102">102</a></P><a name="Section_777" /><P __id="_777">One potentially unifying hypothesis is that at least a subset of <Span Class="Protocol-GeneName">BRCA1</Span> tumors may be derived from the basal epithelial layer of cells of the normal mammary gland, which account for 3% to 15% of unselected invasive ductal cancers.  These tumors characteristically exhibit higher-grade features, areas of necrosis,  and frequent <Span Class="Protocol-GeneName">TP53</Span> mutations.<a href="#Reference2.130">130</a> They are typically estrogen receptor negative, are HER2-negative, and they stain positive for cytokeratin 5/6 or 17.<a href="#Reference2.131">131</a><a href="#Reference2.132">132</a> A study of 76 estrogen receptor negative breast cancers found that those occurring in <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers were significantly more likely to have a basal epithelial phenotype as determined by cytokeratin 5/6 expression.<a href="#Reference2.130">130</a> Among a set of breast tumors studied by gene expression array to 
determine molecular phenotype, all tumors with <Span Class="Protocol-GeneName">BRCA1</Span> alterations fell within the basal tumor subtype.<a href="#Reference2.133">133</a>  If, in fact, the basal epithelial cells of the breast represent the breast stem cells, a regulatory role for wildtype <Span Class="Protocol-GeneName">BRCA1</Span>, as has been suggested,<a href="#Reference2.134">134</a> it may explain the aggressive phenotype of <Span Class="Protocol-GeneName">BRCA1</Span>-associated breast cancer when <Span Class="Protocol-GeneName">BRCA1</Span> function is damaged.  Further studies are needed to fully appreciate the significance of this subtype of breast cancer within the hereditary <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339343&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339343&amp;version=HealthProfessional&amp;language=English');  return(false);">syndromes</a>.</P><a name="Section_778" /><P __id="_778">In accordance with the poor prognostic features noted histologically for <Span Class="Protocol-GeneName">BRCA1</Span>-related breast cancer, 2 European studies reported survival rates that were similar to or worse than sporadic cases, with a significantly increased risk of contralateral breast cancer.<a href="#Reference2.101">101</a><a href="#Reference2.135">135</a><a href="#Reference2.136">136</a> A case series report found higher rates of both ipsilateral and contralateral breast cancers among <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers than among mutation-negative cases.<a href="#Reference2.137">137</a>  Higher rates of ipsilateral and contralateral breast cancers were also seen in the cohort of Ashkenazi women with founder mutations.<a href="#Reference2.138">138</a>  That study failed, however, to show a significantly different event-free or overall survival at 5 years compared with nonmutation carriers.  A retrospective cohort study of 496 Ashkenazi breast cancer patients from 2 centers compared the relative survival among the 56 <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers followed for a median 116 months.  <Span Class="Protocol-GeneName">BRCA1</Span> mutations were independently associated with worse disease-specific survival; there was no effect for <Span Class="Protocol-GeneName">BRCA2</Span>.  The poorer prognosis associated with <Span Class="Protocol-GeneName">BRCA1</Span> was not observed in women who received chemotherapy.<a href="#Reference2.139">139</a></P><a name="Section_779" /><P __id="_779">In summary, there is a growing consensus that <Span Class="Protocol-GeneName">BRCA1</Span>-related breast cancer presents with clinical, histopathologic, and molecular features, suggesting a more aggressive phenotype. Most clinical outcome studies are consistent with there being a somewhat worse prognosis, especially among women who do not receive chemotherapy. There is no consensus about whether these differences should  alter the approach to treating women with <Span Class="Protocol-GeneName">BRCA1</Span>-related breast tumors.</P></a></a>
<a name="Section_766">

<Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">BRCA2</Span></Span><br /><br />



<a name="Section_780"><Span class="Summary-SummarySection-Title-Level4">Pathology</Span><a name="Section_781" /><P __id="_781">The phenotype for <Span Class="Protocol-GeneName">BRCA2</Span>-related tumors appears to be more heterogeneous and is less well-characterized than that of <Span Class="Protocol-GeneName">BRCA1</Span>.  A report from Iceland, where a <Span Class="Protocol-GeneName">BRCA2</Span> founder mutation (999del5) accounts for nearly all hereditary breast cancer, found less tubule formation, more nuclear pleomorphism, and higher mitotic rates in <Span Class="Protocol-GeneName">BRCA2</Span>-related tumors compared with sporadic controls.<a href="#Reference2.140">140</a> A large case series from North America and Europe described a greater proportion of <Span Class="Protocol-GeneName">BRCA2</Span> associated tumors with continuous pushing margins, fewer tubules and lower mitotic counts.<a href="#Reference2.141">141</a>  Other reports suggest that <Span Class="Protocol-GeneName">BRCA2</Span> related tumors include an excess of lobular and tubulolobular histology.<a href="#Reference2.120">120</a><a href="#Reference2.142">142</a></P></a><a name="Section_782">

<Span class="Summary-SummarySection-Title-Level4">Prognosis</Span>


<a name="Section_783" /><P __id="_783">Studies of the prognosis of <Span Class="Protocol-GeneName">BRCA2</Span> associated breast cancer have not shown substantial differences in comparison with sporadic breast cancer.<a href="#Reference2.143">143</a></P>
</a>
</a>







</a>
<a name="Section_408">

<Span class="Summary-SummarySection-Title-Level2">Pathology/Prognosis of Ovarian Cancer</Span><br /><br />




<a name="Section_784"><Span class="Summary-SummarySection-Title-Level3">Pathology</Span><a name="Section_141" /><P __id="_141">Ovarian cancer arising in women with <Span Class="Protocol-GeneName">BRCA1</Span> mutations is more likely to be invasive serous adenocarcinoma, and less likely to be mucinous or borderline.<a href="#Reference2.144">144</a> Approximately 60% of sporadic ovarian cancers have serous histology, but a
survey of all published data shows that 94% of <Span Class="Protocol-GeneName">BRCA1</Span> related ovarian cancers
have this type of histology.<a href="#Reference2.84">84</a>   Serous carcinoma was also found to be the predominant histologic subtype of intraperitoneal carcinoma among <Span Class="Protocol-GeneName">BRCA1/2</Span> carriers in a Dutch case-control study.<a href="#Reference2.145">145</a> Both primary ovarian carcinomas and primary peritoneal carcinomas have a higher incidence of somatic <Span Class="Protocol-GeneName">TP53</Span> mutations and exhibit relatively aggressive features, including higher grade and p53 overexpression.<a href="#Reference2.144">144</a><a href="#Reference2.146">146</a> The histopathologic profile of <Span Class="Protocol-GeneName">BRCA2</Span> related ovarian cancer has not been well defined.  The finding of differential expression of genes in <Span Class="Protocol-GeneName">BRCA1</Span>, <Span Class="Protocol-GeneName">BRCA2</Span>, and sporadic ovarian cancer, using DNA microarray technology suggests distinct molecular pathways of carcinogenesis, which may ultimately distinguish them histologically.<a href="#Reference2.147">147</a></P></a><a name="Section_785">

<Span class="Summary-SummarySection-Title-Level3">Prognosis</Span>


<a name="Section_786" /><P __id="_786">Despite generally poor prognostic factors, several studies have found an improved survival among ovarian cancer patients with <Span Class="Protocol-GeneName">BRCA</Span> mutations, which may be explained by an increased response to platinum-based chemotherapy.<a href="#Reference2.125">125</a><a href="#Reference2.148">148</a><a href="#Reference2.149">149</a> One study found that survival of 43 <Span Class="Protocol-GeneName">BRCA1</Span> carriers with advanced ovarian cancer was significantly better than that of matched sporadic cases.<a href="#Reference2.148">148</a> Median survival was 77 months in the <Span Class="Protocol-GeneName">BRCA1</Span> carriers, versus 29 months in noncarriers.  A nationwide, population-based case-control study in Israel found 3-year survival rates to be significantly better for ovarian cancer patients with <Span Class="Protocol-GeneName">BRCA</Span> founder mutations, compared with  controls.<a href="#Reference2.149">149</a> In a retrospective, hospital-based study (n = 71), <Span Class="Protocol-GeneName">BRCA</Span> Ashkenazi heterozygotes had a better response to platinum-based chemotherapy, as measured by response to primary therapy, disease-free survival, and overall survival, compared with sporadic cases.<a href="#Reference2.150">150</a></P>
<a name="Section_787" /><P __id="_787">A similar study in Japanese patients also found a survival advantage in
stage III <Span Class="Protocol-GeneName">BRCA1</Span>- associated ovarian cancers treated with cisplatin regimens compared with
nonhereditary cancers treated in a similar manner.<a href="#Reference2.151">151</a>  In a study of 103 ovarian
cancers unselected for family history, the cancers in the 11 <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers had prognostic features consistent with better survival, including a
high rate of negative second-look surgeries after the primary chemotherapy and
more well-differentiated pathologic features.<a href="#Reference2.84">84</a>    In contrast, a population-based
study from Sweden noted an initial survival advantage in <Span Class="Protocol-GeneName">BRCA1</Span>-associated
cases, but this advantage did not persist after 3 or 4 years.  Similarly, a case-control study from the Netherlands found an improvement in short-term (up to 5 years) survival among women with familial ovarian cancer compared to sporadic controls, but no difference in longer-term survival.<a href="#Reference2.152">152</a> Finally, a case-control study at the University of Iowa failed to find any survival advantage for women with <Span Class="Protocol-GeneName">BRCA1</Span> inactivation, whether by germline mutation, somatic mutation, or <Span Class="Protocol-GeneName">BRCA1</Span> promoter silencing.<a href="#Reference2.135">135</a><a href="#Reference2.153">153</a> In this study, however, cases (women with <Span Class="Protocol-GeneName">BRCA1</Span> inactivation) were matched to controls on several variables, including tumor grade and p53 status, thus possibly minimizing any differences between the 2 groups.</P><a name="Section_788" /><P __id="_788">Further large studies with appropriate control populations will be required to determine whether there is a survival advantage in either <Span Class="Protocol-GeneName">BRCA1</Span>- or <Span Class="Protocol-GeneName">BRCA2</Span>-related ovarian cancers.</P></a>
</a><a name="Section_144"><Span class="Summary-SummarySection-Title-Level2">Li-Fraumeni Syndrome</Span>
<a name="Section_145" /><P __id="_145">Breast cancer is also a component of the rare Li-Fraumeni syndrome (LFS), in
which germline mutations of the <Span Class="Protocol-GeneName">TP53</Span> gene on chromosome 17p have been
documented.<a href="#Reference2.154">154</a>  This syndrome is characterized by premenopausal breast cancer
in combination with childhood sarcoma, brain tumors, leukemia, and
adrenocortical carcinoma.<a href="#Reference2.155">155</a><a href="#Reference2.156">156</a>  Tumors in LFS families tend to occur in
childhood and early adulthood, and often present as multiple primaries in the
same individual.  Evidence supports a genotype-phenotype correlation, with an association of the location of the mutation, the kind of cancer that develops, and the age of onset.<a href="#Reference2.157">157</a> Brain and adrenal gland tumors were associated with specific sites of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460164&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460164&amp;version=HealthProfessional&amp;language=English');  return(false);">missense mutations</a>. Age at onset of breast cancer was 34.6 years in families with a <Span Class="Protocol-GeneName">TP53</Span> mutation compared with 42.5 years in those families without a mutation. A germline mutation in the <Span Class="Protocol-GeneName">TP53</Span> gene has been identified in
more than 50% of families exhibiting this syndrome, and inheritance is 
autosomal dominant, with a penetrance of at least 50% by age 50 years.  
</P>
<a name="Section_146" /><P __id="_146">Located on chromosome 17p, <Span Class="Protocol-GeneName">TP53</Span> encodes a 53kd nuclear phosphoprotein that binds
DNA sequences and functions as a negative regulator of cell growth and
proliferation in the setting of DNA damage.  In response to DNA damage, p53
protein arrests cells in the G1 phase of the cell cycle, allowing DNA repair
mechanisms to proceed before DNA synthesis.  The p53 protein is also an
active component of programmed cell death.<a href="#Reference2.158">158</a>  Inactivation of the <Span Class="Protocol-GeneName">TP53</Span> gene
or disruption of the protein product is thought to allow the persistence of
damaged DNA and the possible development of malignant cells.<a href="#Reference2.156">156</a>  Evidence
also exists that patients treated for a <Span Class="Protocol-GeneName">TP53</Span>-related tumor with chemotherapy or
radiation therapy may be at risk of a treatment-related second malignancy.  
</P>
<a name="Section_719" /><P __id="_719">Mutations in <Span Class="Protocol-GeneName">TP53</Span> are thought to account for fewer than 1% of breast cancer cases.<a href="#Reference2.159">159</a> 
 
Because many of the cancers associated with germline <Span Class="Protocol-GeneName">TP53 </Span>mutations do not lend
themselves to early detection, predictive testing of LFS family members has so
far been limited and  primarily confined to the research setting.   
</P>
</a>
<a name="Section_756">




<Span class="Summary-SummarySection-Title-Level2"><Span Class="Protocol-GeneName">CHEK2</Span></Span>


<a name="Section_757" /><P __id="_757"><Span Class="Protocol-GeneName">CHEK2</Span>, a gene involved in the DNA damage repair response pathway, was initially evaluated as a potential cause of LFS.<a href="#Reference2.160">160</a>   While it does not appear to be a common cause of LFS,<a href="#Reference2.161">161</a> based on numerous studies, a single mutation, 1100delC, appears to be a rare, low-penetrance susceptibility allele.<a href="#Reference2.162">162</a><a href="#Reference2.163">163</a><a href="#Reference2.164">164</a><a href="#Reference2.165">165</a><a href="#Reference2.166">166</a><a href="#Reference2.167">167</a>  The deletion was present in 1.2% of the European controls, 4.2% of the European BRCA1/2-negative familial breast cancer cases, and 1.4% of unselected female breast cancer cases.<a href="#Reference2.162">162</a> In both Europe and the United States (where the mutation appears to be slightly less common), additional studies have detected the mutation in 4% to 11% of familial cases of breast cancer and overall have found an approximately 1.5-fold to 2-fold increased risk of female breast cancer.<a href="#Reference2.168">168</a><a href="#Reference2.169">169</a><a href="#Reference2.170">170</a><a href="#Reference2.171">171</a> Because of its low frequency, however, no single study has had sufficient power to detect a statistically significant risk among unselected breast cancer cases. A multicenter combined analysis/reanalysis of nearly 20,000 subjects from 10 case-control studies, however, has verified a significant, 2.3-fold excess of breast cancer among mutation carriers.<a href="#Reference2.172">172</a>  At least one study has also suggested that the mutation may be associated with both breast and colorectal cancer.<a href="#Reference2.169">169</a> Although the initial report suggested that male mutation carriers were at a significantly increased risk of breast cancer,<a href="#Reference2.167">167</a> several follow-up studies have failed to confirm the association.<a href="#Reference2.173">173</a><a href="#Reference2.174">174</a><a href="#Reference2.175">175</a><a href="#Reference2.176">176</a> Additional, larger studies will be required to more precisely define the absolute risk of female breast and other cancers in individuals who carry germline <Span Class="Protocol-GeneName">CHEK2</Span> variants. </P>
</a>
<a name="Section_148"><Span class="Summary-SummarySection-Title-Level2">Cowden’s Syndrome</Span>
<a name="Section_149" /><P __id="_149">One of the more than 50 cancer-related genodermatoses, Cowden’s syndrome is
characterized by an excess of breast cancer, gastrointestinal malignancies, and
thyroid disease, both benign and malignant.<a href="#Reference2.175">175</a>  Lifetime estimates for breast
cancer among women with Cowden’s syndrome range from 25% to 50%.  As in
other forms of hereditary breast cancer, onset is often at young ages and may
be bilateral.<a href="#Reference2.176">176</a>  Skin manifestations include multiple trichilemmomas, oral
fibromas and papillomas, and acral, palmar, and plantar keratoses.  History or
observation of the characteristic skin features raises a suspicion of Cowden’s
syndrome.  Germline mutations in <Span Class="Protocol-GeneName">PTEN</Span>, a protein tyrosine phosphatase with
homology to tensin, located on chromosome 10q23, are responsible for this
syndrome.  Loss of heterozygosity at the <Span Class="Protocol-GeneName">PTEN</Span> locus observed in a high
proportion of related cancers suggests that <Span Class="Protocol-GeneName">PTEN</Span> functions as a tumor
suppressor gene.  Its defined enzymatic function indicates a role in
maintenance of the control of cell proliferation.<a href="#Reference2.177">177</a>  Disruption of <Span Class="Protocol-GeneName">PTEN</Span>
appears to occur late in tumorigenesis and may act as a regulatory molecule of
cytoskeletal function.  Although <Span Class="Protocol-GeneName">PTEN</Span> accounts for a small fraction of hereditary
breast cancer, the characterization of PTEN function will provide valuable
insights into the signal pathway and the maintenance of normal cell
physiology.<a href="#Reference2.178">178</a>
</P>
</a>
<a name="Section_150"><Span class="Summary-SummarySection-Title-Level2">Ataxia Telangiectasia</Span>
<a name="Section_151" /><P __id="_151">Ataxia telangiectasia (AT) is an <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339339&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339339&amp;version=HealthProfessional&amp;language=English');  return(false);">autosomal recessive</a> disorder characterized by
neurologic deterioration, telangiectasias, immunodeficiency states, and
hypersensitivity to ionizing radiation.  It is estimated that 1%
of the general population may be heterozygote carriers of the <Span Class="Protocol-GeneName">ATM</Span> gene, which
has been localized to chromosome 11q22-23.<a href="#Reference2.179">179</a>  More than 200 mutations in the gene have been
identified to date, most of which are truncating
mutations.<a href="#Reference2.180">180</a>  ATM proteins have been shown to play a role in cell cycle
control.<a href="#Reference2.181">181</a>  In vitro, AT cells are sensitive to ionizing radiation and
radiomimetic drugs, and lack cell cycle regulatory properties after exposure to
radiation.<a href="#Reference2.182">182</a>  
</P>
<a name="Section_152" /><P __id="_152">It is well known that individuals homozygous for <Span Class="Protocol-GeneName">ATM</Span> are at increased risk of
malignancies, especially hematologic.  A number of epidemiologic studies have
also suggested a statistically increased risk of breast cancer among female
heterozygote carriers, with an estimated relative risk of 3.9 to 6.4.<a href="#Reference2.183">183</a><a href="#Reference2.184">184</a><a href="#Reference2.185">185</a> 
Studies searching for an excess of <Span Class="Protocol-GeneName">ATM</Span> mutations among breast cancer patients
have provided conflicting results.<a href="#Reference2.186">186</a><a href="#Reference2.187">187</a><a href="#Reference2.188">188</a><a href="#Reference2.189">189</a><a href="#Reference2.190">190</a><a href="#Reference2.191">191</a><a href="#Reference2.192">192</a><a href="#Reference2.193">193</a><a href="#Reference2.194">194</a>  If an association
between the heterozygous carrier status and breast cancer is established, it
could account for a significant proportion of hereditary breast cancer, given
the high heterozygote carrier rate in the population, and could pose a
potential risk related to screening-related radiation exposure in these
individuals.
</P>
</a>
<a name="Section_153"><Span class="Summary-SummarySection-Title-Level2">Peutz-Jeghers Syndrome</Span>
<a name="Section_154" /><P __id="_154">Peutz-Jeghers syndrome (PJS) is an early-onset autosomal dominant disorder
characterized by melanocytic macules on the lips, perioral, and buccal regions,
and multiple gastrointestinal polyps, both hamartomatous and
adenomatous.<a href="#Reference2.195">195</a><a href="#Reference2.196">196</a><a href="#Reference2.197">197</a>   Mutations in the <Span Class="Protocol-GeneName">STK11</Span> gene at chromosome 19p13.3, which
appears to function as a tumor suppressor gene,<a href="#Reference2.198">198</a> have been identified as
one cause of PJS.<a href="#Reference2.199">199</a><a href="#Reference2.200">200</a> Germline mutations in <Span Class="Protocol-GeneName">STK11</Span>, also known as <Span Class="Protocol-GeneName">LKB1</Span>, have been reported and appear to be responsible for about 50% of  the cases of PJS.<a href="#Reference2.199">199</a><a href="#Reference2.200">200</a><a href="#Reference2.201">201</a><a href="#Reference2.202">202</a><a href="#Reference2.203">203</a><a href="#Reference2.204">204</a>  A meta-analysis performed on available reports from
the literature concluded that patients with this syndrome have a very high risk
of developing breast, gastrointestinal, and other malignancies.<a href="#Reference2.205">205</a>  Of 210 patients with
PJS in this overview, it was estimated that the risk of developing noncutaneous
cancer between the ages of 15 years and 64 years is 93%.  The highest cumulative risk in these
patients was for breast (54%), colon (39%), pancreatic (36%), stomach (29%),
and ovarian (21%) cancer.  The risk estimates for breast and ovarian cancer are
similar to those observed in women carrying <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations.<a href="#Reference2.205">205</a>  
Multiple case reports have suggested most ovarian cancer cases associated with this syndrome are sex cord stromal tumors, which have a variable behavior, ranging from benign
to highly malignant.<a href="#Reference2.206">206</a><a href="#Reference2.207">207</a><a href="#Reference2.208">208</a><a href="#Reference2.209">209</a></P>
<a name="Section_155" /><P __id="_155">The identification and location of breast cancer genes permit further
investigation of the precise role they play in cancer progression, and will
allow us to determine the percentage of total breast cancer caused by the
inheritance of mutant genes.  This in turn will ultimately enrich our
understanding of all breast cancer, sporadic as well as hereditary, and will
facilitate the identification of high-risk individuals.
</P>

</a>        
       <a name="ReferenceSection"><p><Span Class="Summary-ReferenceSection">
							References
						</Span><ol><li><a name="Reference2.1" />Narod SA, Feunteun J, Lynch HT, et al.: Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 338 (8759): 82-3, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1676470&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.2" />Phipps RF, Perry PM: Familial breast cancer. Postgrad Med J 64 (757): 847-9, 1988. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3076666&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.3" />Sellers TA, Potter JD, Rich SS, et al.: Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 86 (24): 1860-5, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7990161&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.4" />Newman B, Austin MA, Lee M, et al.: Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proceedings of the National Academy of Sciences  85(9): 3044-3048, 1988 
			<A /><br /><br /></li><li><a name="Reference2.5" />Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48 (2): 232-42, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1990835&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.6" />Hall JM, Lee MK, Newman B, et al.: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (4988): 1684-9, 1990. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2270482&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.7" />Easton DF, Bishop DT, Ford D, et al.: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52 (4): 678-701, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8460634&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.8" />Wooster R, Neuhausen SL, Mangion J, et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (5181): 2088-90, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8091231&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.9" />Gayther SA, Mangion J, Russell P, et al.: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15 (1): 103-5, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988179&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.10" />Tonin P, Weber B, Offit K, et al.: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2 (11): 1179-83, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8898735&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.11" />Smith SA, Easton DF, Evans DG, et al.: Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2 (2): 128-31, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1303261&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.12" />Collins N, McManus R, Wooster R, et al.: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10 (8): 1673-5, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7731724&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.13" />Holt JT, Thompson ME, Szabo C, et al.: Growth retardation and tumour inhibition by BRCA1. Nat Genet 12 (3): 298-302, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8589721&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.14" />Jasin M: Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21 (58): 8981-93, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12483514&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.15" />Liu Y, West SC: Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 4 (1): 9-13, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879553&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.16" />An Open Access On-Line Breast Cancer Mutation Data Base. Bethesda, Md: National Human Genome Research Institute, 2002. <a Class="Protocol-ExternalRef" href="http://research.nhgri.nih.gov/bic/?CFID=313172&amp;CFTOKEN=38988484">Available online.</a> Last accessed November 15, 2005. 
			<A /><br /><br /></li><li><a name="Reference2.17" />Eng C, Brody LC, Wagner TM, et al.: Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 38 (12): 824-33, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11748305&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.18" />Unger MA, Nathanson KL, Calzone K, et al.: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67 (4): 841-50, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10978226&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.19" />Bunyan DJ, Eccles DM, Sillibourne J, et al.: Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 91 (6): 1155-9, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15475941&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.20" />Malone KE, Daling JR, Thompson JD, et al.: BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279 (12): 922-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544766&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.21" />Couch FJ, DeShano ML, Blackwood MA, et al.: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336 (20): 1409-15, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9145677&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.22" />Risch HA, McLaughlin JR, Cole DE, et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (3): 700-10, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11179017&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.23" />Struewing JP, Abeliovich D, Peretz T, et al.: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11 (2): 198-200, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7550349&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.24" />Oddoux C, Struewing JP, Clayton CM, et al.: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14 (2): 188-90, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8841192&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.25" />Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (20): 1401-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9145676&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.26" />Roa BB, Boyd AA, Volcik K, et al.: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (2): 185-7, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8841191&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.27" />Ellisen LW, Haber DA: Hereditary breast cancer. Annu Rev Med 49: 425-36, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9509273&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.28" />Brody LC, Biesecker BB: Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 77 (3): 208-26, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9653432&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.29" />Peelen T, van Vliet M, Petrij-Bosch A, et al.: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60 (5): 1041-9, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9150151&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.30" />Thorlacius S, Olafsdottir G, Tryggvadottir L, et al.: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13 (1): 117-9, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8673089&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.31" />Arason A, Jonasdottir A, Barkardottir RB, et al.: A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 35 (6): 446-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9643283&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.32" />Einbeigi Z, Bergman A, Kindblom LG, et al.: A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer 37 (15): 1904-9, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11576847&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.33" />Frank TS, Deffenbaugh AM, Reid JE, et al.: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20 (6): 1480-90, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11896095&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.34" />Ford D, Easton DF, Bishop DT, et al.: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 (8899): 692-5, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7907678&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.35" />Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56 (1): 265-71, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7825587&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.36" />Levy-Lahad E, Catane R, Eisenberg S, et al.: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60 (5): 1059-67, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9150153&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.37" />Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (3): 676-89, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9497246&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.38" />Thorlacius S, Struewing JP, Hartge P, et al.: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352 (9137): 1337-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9802270&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.39" />Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91 (15): 1310-6, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10433620&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.40" />Hopper JL, Southey MC, Dite GS, et al.: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8 (9): 741-7, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10498392&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.41" />Warner E, Foulkes W, Goodwin P, et al.: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91 (14): 1241-7, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10413426&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.42" />Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 83 (10): 1301-8, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11044354&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.43" />Antoniou AC, Gayther SA, Stratton JF, et al.: Risk models for familial ovarian and breast cancer. Genet Epidemiol 18 (2): 173-90, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10642429&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.44" />Moslehi R, Chu W, Karlan B, et al.: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66 (4): 1259-72, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10739756&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.45" />Satagopan JM, Offit K, Foulkes W, et al.: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 10 (5): 467-73, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11352856&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.46" />Thompson D, Easton D; Breast Cancer Linkage Consortium.: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2): 410-9, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11170890&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.47" />Satagopan JM, Boyd J, Kauff ND, et al.: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (12): 3776-81, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12473589&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.48" />Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (5): 1117-30, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12677558&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.49" />King MC, Marks JH, Mandell JB, et al.: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (5645): 643-6, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14576434&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.50" />Scott CL, Jenkins MA, Southey MC, et al.: Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 112 (5-6): 542-51, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12601471&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.51" />Aziz S, Kuperstein G, Rosen B, et al.: A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80 (3): 341-5, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11263928&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.52" />Piek JM, van Diest PJ, Zweemer RP, et al.: Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195 (4): 451-6, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11745677&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.53" />Carcangiu ML, Radice P, Manoukian S, et al.: Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 23 (1): 35-40, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14668548&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.54" />Levine DA, Argenta PA, Yee CJ, et al.: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 (22): 4222-7, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14615451&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.55" />Thompson D, Szabo CI, Mangion J, et al.: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 99 (2): 827-31, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11792833&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.56" />Edwards SM, Kote-Jarai Z, Meitz J, et al.: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72 (1): 1-12, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12474142&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.57" />Giusti RM, Rutter JL, Duray PH, et al.: A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40 (10): 787-92, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14569130&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.58" />Metcalfe KA, Lynch HT, Ghadirian P, et al.: The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96 (1): 222-6, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15589605&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.59" />Wang WW, Spurdle AB, Kolachana P, et al.: A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 10 (9): 955-60, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11535547&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.60" />Levy-Lahad E, Lahad A, Eisenberg S, et al.: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A 98 (6): 3232-6, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11248061&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.61" />Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2 (2): 113-23, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12635174&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.62" />Shattuck-Eidens D, Oliphant A, McClure M, et al.: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (15): 1242-50, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333265&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.63" />Spiegelman D, Colditz GA, Hunter D, et al.: Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 86 (8): 600-7, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145275&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.64" />Frank TS, Manley SA, Olopade OI, et al.: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16 (7): 2417-25, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9667259&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.65" />Chang-Claude J, Dong J, Schmidt S, et al.: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet 35 (2): 116-21, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9507390&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.66" />Couch FJ, Hartmann LC: BRCA1 testing--advances and retreats. JAMA 279 (12): 955-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544772&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.67" />Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 (1): 145-58, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9443863&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.68" />Antoniou AC, Pharoah PP, Smith P, et al.: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91 (8): 1580-90, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15381934&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.69" />Berry DA, Iversen ES Jr, Gudbjartsson DF, et al.: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20 (11): 2701-12, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12039933&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.70" />Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60 (5): 1013-20, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9150148&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.71" />Papelard H, de Bock GH, van Eijk R, et al.: Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83 (6): 719-24, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10952774&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.72" />Loman N, Johannsson O, Kristoffersson U, et al.: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93 (16): 1215-23, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11504767&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.73" />Basham VM, Lipscombe JM, Ward JM, et al.: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4 (1): R2, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879560&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.74" />Rubin SC, Blackwood MA, Bandera C, et al.: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178 (4): 670-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9579428&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.75" />Gershoni-Baruch R, Dagan E, Fried G, et al.: Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer 36 (8): 983-6, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10885601&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.76" />Hodgson SV, Heap E, Cameron J, et al.: Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet 36 (5): 369-73, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10353781&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.77" />Struewing JP, Coriaty ZM, Ron E, et al.: Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 65 (6): 1800-2, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10577940&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.78" />Hirsh-Yechezkel G, Chetrit A, Lubin F, et al.: Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 89 (3): 494-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12798717&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.79" />Futreal PA, Liu Q, Shattuck-Eidens D, et al.: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (5182): 120-2, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7939630&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.80" />Lancaster JM, Wooster R, Mangion J, et al.: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13 (2): 238-40, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8640235&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.81" />Weber BH, Brohm M, Stec I, et al.: A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 59 (4): 962-4, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8808615&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.82" />Miki Y, Katagiri T, Kasumi F, et al.: Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13 (2): 245-7, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8640237&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.83" />Teng DH, Bogden R, Mitchell J, et al.: Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13 (2): 241-4, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8640236&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.84" />Berchuck A, Heron KA, Carney ME, et al.: Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4 (10): 2433-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9796975&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.85" />Geisler JP, Hatterman-Zogg MA, Rathe JA, et al.: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94 (1): 61-7, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11773283&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.86" />Thompson ME, Jensen RA, Obermiller PS, et al.: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9 (4): 444-50, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7795653&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.87" />Sourvinos G, Spandidos DA: Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 245 (1): 75-80, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9535786&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.88" />Ozçelik H, To MD, Couture J, et al.: Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer 77 (1): 1-6, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9639385&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.89" />Dobrovic A, Simpfendorfer D: Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57 (16): 3347-50, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9269993&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.90" />Mancini DN, Rodenhiser DI, Ainsworth PJ, et al.: CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16 (9): 1161-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9528858&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.91" />Cleton-Jansen AM, Collins N, Lakhani SR, et al.: Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 72 (5): 1241-4, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7577475&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.92" />Hamann U, Herbold C, Costa S, et al.: Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res 56 (9): 1988-90, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8616837&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.93" />van 't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (6871): 530-6, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11823860&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.94" />Kallioniemi OP, Kallioniemi A, Sudar D, et al.: Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol 4 (1): 41-6, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8448377&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.95" />Kallioniemi OP: Linking chromosomal clues. Nat Genet 15 (1): 5-6, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988157&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.96" />Tirkkonen M, Johannsson O, Agnarsson BA, et al.: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57 (7): 1222-7, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9102202&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.97" />Tirkkonen M, Kainu T, Loman N, et al.: Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 24 (1): 56-61, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9892109&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.98" />Karp SE, Tonin PN, Bégin LR, et al.: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80 (3): 435-41, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9241077&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.99" />Robson M, Rajan P, Rosen PP, et al.: BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 58 (9): 1839-42, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9581822&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.100" />Loman N, Johannsson O, Bendahl PO, et al.: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 (2): 310-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9669814&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.101" />Verhoog LC, Brekelmans CT, Seynaeve C, et al.: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351 (9099): 316-21, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9652611&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.102" />Palacios J, Honrado E, Osorio A, et al.: Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9 (10 Pt 1): 3606-14, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14506147&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.103" />Thompson D, Easton D; Breast Cancer Linkage Consortium.: Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11 (4): 329-36, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11927492&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.104" />Lubinski J, Phelan CM, Ghadirian P, et al.: Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 3 (1): 1-10, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15131399&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.105" />Sharan SK, Morimatsu M, Albrecht U, et al.: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 (6627): 804-10, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9126738&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.106" />Ludwig T, Chapman DL, Papaioannou VE, et al.: Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11 (10): 1226-41, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9171368&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.107" />Suzuki A, de la Pompa JL, Hakem R, et al.: Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11 (10): 1242-52, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9171369&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.108" />Connor F, Bertwistle D, Mee PJ, et al.: Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17 (4): 423-30, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9398843&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.109" />Patel KJ, Yu VP, Lee H, et al.: Involvement of Brca2 in DNA repair. Mol Cell 1 (3): 347-57, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9660919&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.110" />Chen PL, Chen CF, Chen Y, et al.: The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 95 (9): 5287-92, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9560268&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.111" />Crook T, Brooks LA, Crossland S, et al.: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17 (13): 1681-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9796697&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.112" />Gras E, Cortes J, Diez O, et al.: Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92 (4): 787-95, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11550149&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.113" />Grushko TA, Dignam JJ, Das S, et al.: MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 (2): 499-507, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14760071&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.114" />Malone KE, Daling JR, Weiss NS, et al.: Family history and survival of young women with invasive breast carcinoma. Cancer 78 (7): 1417-25, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8839546&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.115" />Claus EB, Risch N, Thompson WD, et al.: Relationship between breast histopathology and family history of breast cancer. Cancer 71 (1): 147-53, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8380113&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.116" />Rosen PP, Lesser ML, Senie RT, et al.: Epidemiology of breast carcinoma III: relationship of family history to tumor type. Cancer 50 (1): 171-9, 1982. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6282433&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.117" />Eisinger F, Jacquemier J, Charpin C, et al.: Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58 (8): 1588-92, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9563465&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.118" />Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349 (9064): 1505-10, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9167459&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.119" />Lorenzo Bermejo J, Hemminki K: A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations. Ann Oncol 16 (2): 322-9, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15668291&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.120" />Armes JE, Egan AJ, Southey MC, et al.: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83 (11): 2335-45, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9840533&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.121" />Adem C, Reynolds C, Soderberg CL, et al.: Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97 (1): 1-11, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12491499&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.122" />Claus EB, Petruzella S, Matloff E, et al.: Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293 (8): 964-9, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15728167&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.123" />Foulkes WD, Metcalfe K, Hanna W, et al.: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98 (8): 1569-77, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14534871&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.124" />Møller P, Borg A, Heimdal K, et al.: The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer 37 (8): 1027-32, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11334729&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.125" />Robson M, Gilewski T, Haas B, et al.: BRCA-associated breast cancer in young women. J Clin Oncol 16 (5): 1642-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9586873&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.126" />Foulkes WD, Metcalfe K, Sun P, et al.: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10 (6): 2029-34, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15041722&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.127" />Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (9): 2310-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11981002&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.128" />Hedenfalk I, Duggan D, Chen Y, et al.: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (8): 539-48, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11207349&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.129" />Wessels LF, van Welsem T, Hart AA, et al.: Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62 (23): 7110-7, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12460933&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.130" />Foulkes WD, Stefansson IM, Chappuis PO, et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (19): 1482-5, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14519755&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.131" />Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (16): 5367-74, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15328174&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.132" />Palacios J, Honrado E, Osorio A, et al.: Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90 (1): 5-14, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15770521&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.133" />Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (14): 8418-23, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12829800&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.134" />Foulkes WD: BRCA1 functions as a breast stem cell regulator. J Med Genet 41 (1): 1-5, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14729816&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.135" />Jóhannsson OT, Ranstam J, Borg A, et al.: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16 (2): 397-404, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9469321&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.136" />Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al.: Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18 (24): 4053-9, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11118466&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.137" />Haffty BG, Harrold E, Khan AJ, et al.: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359 (9316): 1471-7, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11988246&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.138" />Robson M, Levin D, Federici M, et al.: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91 (24): 2112-7, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601383&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.139" />Robson ME, Chappuis PO, Satagopan J, et al.: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6 (1): R8-R17, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14680495&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.140" />Agnarsson BA, Jonasson JG, Björnsdottir IB, et al.: Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47 (2): 121-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9497100&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.141" />Lakhani SR, Jacquemier J, Sloane JP, et al.: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (15): 1138-45, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9701363&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.142" />Marcus JN, Watson P, Page DL, et al.: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77 (4): 697-709, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8616762&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.143" />Verhoog LC, Berns EM, Brekelmans CT, et al.: Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18 (21 Suppl): 119S-24S, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11060339&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.144" />Lakhani SR, Manek S, Penault-Llorca F, et al.: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10 (7): 2473-81, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15073127&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.145" />Piek JM, Torrenga B, Hermsen B, et al.: Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer 2 (2): 73-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14574155&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.146" />Schorge JO, Muto MG, Lee SJ, et al.: BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 60 (5): 1361-4, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10728699&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.147" />Jazaeri AA, Yee CJ, Sotiriou C, et al.: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94 (13): 990-1000, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096084&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.148" />Rubin SC, Benjamin I, Behbakht K, et al.: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335 (19): 1413-6, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8875917&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.149" />Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al.: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20 (2): 463-6, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11786575&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.150" />Cass I, Baldwin RL, Varkey T, et al.: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (9): 2187-95, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12712470&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.151" />Aida H, Takakuwa K, Nagata H, et al.: Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4 (1): 235-40, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9516977&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.152" />Zweemer RP, Verheijen RH, Coebergh JW, et al.: Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 98 (2): 219-23, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11574135&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.153" />Buller RE, Shahin MS, Geisler JP, et al.: Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8 (5): 1196-202, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12006538&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.154" />Garber JE, Goldstein AM, Kantor AF, et al.: Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51 (22): 6094-7, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933872&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.155" />Bottomley RH, Condit PT: Cancer families. Cancer Bull  20: 22-24, 1968 
			<A /><br /><br /></li><li><a name="Reference2.156" />Malkin D: The Li-Fraumeni syndrome. Cancer: Principles and Practice of Oncology Updates  7(7): 1-14, 1993 
			<A /><br /><br /></li><li><a name="Reference2.157" />Olivier M, Goldgar DE, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63 (20): 6643-50, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14583457&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.158" />Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (18): 1318-27, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8413413&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.159" />Sidransky D, Tokino T, Helzlsouer K, et al.: Inherited p53 gene mutations in breast cancer. Cancer Res 52 (10): 2984-6, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1581912&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.160" />Bell DW, Varley JM, Szydlo TE, et al.: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286 (5449): 2528-31, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10617473&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.161" />Sodha N, Houlston RS, Bullock S, et al.: Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 20 (6): 460-2, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12442270&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.162" />Meijers-Heijboer H, van den Ouweland A, Klijn J, et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31 (1): 55-9, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11967536&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.163" />Kuschel B, Auranen A, Gregory CS, et al.: Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 12 (8): 809-12, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12917215&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.164" />Sodha N, Bullock S, Taylor R, et al.: CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 87 (12): 1445-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12454775&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.165" />Ingvarsson S, Sigbjornsdottir BI, Huiping C, et al.: Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4 (3): R4, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12052256&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.166" />Vahteristo P, Bartkova J, Eerola H, et al.: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71 (2): 432-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12094328&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.167" />Meijers-Heijboer H, Wijnen J, Vasen H, et al.: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72 (5): 1308-14, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12690581&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.168" />Offit K, Pierce H, Kirchhoff T, et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4 (1): 1, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12529183&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.169" />Oldenburg RA, Kroeze-Jansema K, Kraan J, et al.: The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 63 (23): 8153-7, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14678969&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.170" />Neuhausen S, Dunning A, Steele L, et al.: Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108 (3): 477-8, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14648718&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.171" />Ohayon T, Gal I, Baruch RG, et al.: CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108 (3): 479-80, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14648719&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.172" />CHEK2 Breast Cancer Case-Control Consortium.: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74 (6): 1175-82, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15122511&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.173" />Osorio A, Rodríguez-López R, Díez O, et al.: The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 108 (1): 54-6, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14618615&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.174" />Syrjäkoski K, Kuukasjärvi T, Auvinen A, et al.: CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108 (3): 475-6, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14648717&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.175" />Tsou HC, Teng DH, Ping XL, et al.: The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 61 (5): 1036-43, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9345101&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.176" />Olopade OI, Weber BL: Breast cancer genetics: toward molecular characterization of individuals at increased risk for breast cancer: part I. Cancer: Principles and Practice of Oncology Updates  12(10): 1-12, 1998 
			<A /><br /><br /></li><li><a name="Reference2.177" />Lynch ED, Ostermeyer EA, Lee MK, et al.: Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61 (6): 1254-60, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9399897&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.178" />Myers MP, Tonks NK: PTEN: sometimes taking it off can be better than putting it on. Am J Hum Genet 61 (6): 1234-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9399917&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.179" />Savitsky K, Bar-Shira A, Gilad S, et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (5218): 1749-53, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7792600&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.180" />Telatar M, Teraoka S, Wang Z, et al.: Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 62 (1): 86-97, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9443866&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.181" />Uhrhammer N, Bay JO, Bignon YJ: Seventh International Workshop on Ataxia-Telangiectasia. Cancer Res 58 (15): 3480-5, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9699683&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.182" />Gilad S, Chessa L, Khosravi R, et al.: Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet 62 (3): 551-61, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9497252&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.183" />Swift M, Reitnauer PJ, Morrell D, et al.: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316 (21): 1289-94, 1987. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3574400&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.184" />Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 66 (6 Suppl): S177-82, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7836845&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.185" />Olsen JH, Hahnemann JM, Børresen-Dale AL, et al.: Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 93 (2): 121-7, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11208881&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.186" />FitzGerald MG, Bean JM, Hegde SR, et al.: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15 (3): 307-10, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9054948&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.187" />Chen J, Birkholtz GG, Lindblom P, et al.: The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 58 (7): 1376-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9537233&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.188" />Bay JO, Grancho M, Pernin D, et al.: No evidence for constitutional ATM mutation in breast/gastric cancer families. Int J Oncol 12 (6): 1385-90, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9592204&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.189" />Laake K, Vu P, Andersen TI, et al.: Screening breast cancer patients for Norwegian ATM mutations. Br J Cancer 83 (12): 1650-3, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11104561&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.190" />Dörk T, Bendix R, Bremer M, et al.: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 61 (20): 7608-15, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11606401&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.191" />Teraoka SN, Malone KE, Doody DR, et al.: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 92 (3): 479-87, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11505391&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.192" />Chenevix-Trench G, Spurdle AB, Gatei M, et al.: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94 (3): 205-15, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11830610&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.193" />Thorstenson YR, Roxas A, Kroiss R, et al.: Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63 (12): 3325-33, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12810666&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.194" />Cavaciuti E, Laugé A, Janin N, et al.: Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer 42 (1): 1-9, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15390180&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.195" />Peutz JL: On a very remarkable case of familial polyposis of the mucous membrane of the intestinal tract and nasopharynx accompanied by peculiar pigmentations of the skin and mucous membrane. Ned Tijdschr Geneeskd  10: 134-146, 1921 
			<A /><br /><br /></li><li><a name="Reference2.196" />Jeghers H, McKusick VA, Katz KH: Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits: a syndrome of diagnostic significance. N Engl J Med  241(25): 993-1005, 1949 
			<A /><br /><br /></li><li><a name="Reference2.197" />Spigelman AD, Murday V, Phillips RK: Cancer and the Peutz-Jeghers syndrome. Gut 30 (11): 1588-90, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2599445&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.198" />Gruber SB, Entius MM, Petersen GM, et al.: Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 58 (23): 5267-70, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9850045&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.199" />Hemminki A, Markie D, Tomlinson I, et al.: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391 (6663): 184-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9428765&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.200" />Jenne DE, Reimann H, Nezu J, et al.: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18 (1): 38-43, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9425897&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.201" />Ylikorkala A, Avizienyte E, Tomlinson IP, et al.: Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet 8 (1): 45-51, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887330&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.202" />Yoon KA, Ku JL, Choi HS, et al.: Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients. Br J Cancer 82 (8): 1403-6, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10780518&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.203" />Westerman AM, Entius MM, Boor PP, et al.: Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families. Hum Mutat 13 (6): 476-81, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408777&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.204" />Lim W, Hearle N, Shah B, et al.: Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 89 (2): 308-13, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12865922&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.205" />Giardiello FM, Brensinger JD, Tersmette AC, et al.: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119 (6): 1447-53, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11113065&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.206" />Humphries AL Jr, Shepherd MH, Peters HJ: Peutz-Jeghers syndrome with colonic adenocarcinoma and ovarian tumor. JAMA  197(4): 138-140, 1966 
			<A /><br /><br /></li><li><a name="Reference2.207" />Christian CD, McLoughlin TG, Cathcart ER, et al.: Peutz-Jeghers syndrome associated with functioning ovarian tumor. JAMA  190(10):157-160, 1964 
			<A /><br /><br /></li><li><a name="Reference2.208" />Solh HM, Azoury RS, Najjar SS: Peutz-Jeghers syndrome associated with precocious puberty. J Pediatr 103 (4): 593-5, 1983. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6620020&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference2.209" />Scully RE: Sex cord tumor with annular tubules a distinctive ovarian tumor of the Peutz-Jeghers syndrome. Cancer 25 (5): 1107-21, 1970. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5429475&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li></ol></p></a></a><a name="Section_156">
        <Span class="Summary-SummarySection-Title-Level1">Genetic Polymorphisms and Breast Cancer Risk</Span><br /><br />

<a name="Section_157"><Span class="Summary-SummarySection-Title-Level2">Background</Span>
<a name="Section_158" /><P __id="_158">The search for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46129&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046129&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic markers</a> for breast cancer <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=256553&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000256553&amp;version=HealthProfessional&amp;language=English');  return(false);">susceptibility</a> has led to an
increasing number of epidemiologic studies of relatively common genetic markers
referred to as genetic <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44805&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044805&amp;version=HealthProfessional&amp;language=English');  return(false);">polymorphisms</a>.<a href="#Reference3.1">1</a>  These polymorphically expressed <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=HealthProfessional&amp;language=English');  return(false);">genes</a>
code for enzymes that may have a role in the metabolism of estrogens or
detoxification of drugs and environmental carcinogens.  Although the clinical
significance and causality of associations with breast cancer
is unclear, genetic polymorphisms may account for why some women are more
sensitive than others to environmental carcinogens such as replacement
estrogens or cigarette smoke. 
</P>
</a>
<a name="Section_159"><Span class="Summary-SummarySection-Title-Level2">Summary of Evidence</Span>
<a name="Section_160" /><P __id="_160">Evidence of associations between genetic polymorphisms and breast cancer risk
in women has been obtained from case-control or cohort (nested case-control)
analytic studies, usually with just a single center or research group (level of
evidence: 3).  The endpoint in these studies has sometimes been prevalent
breast cancer rather than the more satisfactory endpoint of incident breast
cancer.  In several studies of genetic polymorphisms and breast cancer,
convenience samples of cases and controls have been used.  Some
studies have been population based, however, with incident cases of breast cancer and
with adequate control of confounding factors.  Results have largely
been inconsistent, and none of the markers has had clinical applications. 
</P>
</a>
<a name="Section_161"><Span class="Summary-SummarySection-Title-Level2">Significance</Span><br /><br />
<a name="Section_349">

<Span class="Summary-SummarySection-Title-Level3">Cytochrome p450 Enzymes</Span>


<a name="Section_163" /><P __id="_163">Cytochrome p450 enzymes are members of a multiple gene superfamily that play
an important role in steroidogenesis and detoxification of xenobiotics such as
polycyclic aromatic hydrocarbons, benzo(a)pyrene, arylamines, and heterocyclic
amines.<a href="#Reference3.2">2</a>  The p450 cytochromes provide a line of defense against exposure to
environmental chemicals.  However, carcinogens may be activated by p450
metabolism.  Cytochrome p450 enzymes are expressed primarily in the liver and
in other tissues.
</P><a name="Section_164" /><P __id="_164">Molecular epidemiology studies of cancer of the breast (as well as lung,
bladder, colon, and other sites) have examined associations with p450
cytochrome genotypes such as <Span Class="Protocol-GeneName">CYP1A1</Span>, <Span Class="Protocol-GeneName">CYP2D6</Span>, and <Span Class="Protocol-GeneName">CYP17</Span>.  Earlier studies,
carried out before the availability of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=45671&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045671&amp;version=HealthProfessional&amp;language=English');  return(false);">DNA</a> tests for <Span Class="Protocol-GeneName">CYP1A1</Span> and <Span Class="Protocol-GeneName">CYP2D6</Span>,
examined the activity of the corresponding polymorphically expressed enzyme. 
</P><a name="Section_165" /><P __id="_165">The <Span Class="Protocol-GeneName">CYP1A1</Span> gene, located on <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46470&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046470&amp;version=HealthProfessional&amp;language=English');  return(false);">chromosome</a> 15q, codes for aryl hydrocarbon
hydroxylase (AHH).  AHH, which catabolizes polycyclic aromatic hydrocarbons and
arylamines, has been found in breast tumor tissue.  AHH is strongly inducible,
i.e., greater enzymatic activity is seen with greater exposure to substrates. 
AHH catalyzes the mono-oxygenation of polycyclic aromatic hydrocarbons to
phenolic products and epoxides that may be carcinogenic.  AHH is also involved
in the conversion of estrogen to hydroxylated conjugated estrogens such as
2-hydroxyestradiol.
</P><a name="Section_166" /><P __id="_166">Three polymorphisms of this <Span Class="Protocol-GeneName">p450</Span> gene that code for AHH have been identified so
far: an MspI RFLP of the 3’ end of the gene (MspI); an adenine-to-guanine
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46063&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=HealthProfessional&amp;language=English');  return(false);">mutation</a> in <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460146&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460146&amp;version=HealthProfessional&amp;language=English');  return(false);">exon</a> 7 of this gene, which causes an isoleucine-to-valine
substitution (Ile-Val); and a polymorphism of the <Span Class="Protocol-GeneName">CYP1A1</Span> gene identified among
African Americans (AA).  The frequencies of the MspI and Ile-Val polymorphisms
vary considerably by race; the frequencies are higher among Japanese and
Hawaiian populations as compared with Caucasians and African Americans.
</P><a name="Section_167" /><P __id="_167">The <Span Class="Protocol-GeneName">CYP2D6</Span> gene is located on chromosome 22q and codes for debrisoquine
hydroxylase, which metabolizes a variety of drugs and other
xenobiotics.  Like other polymorphically expressed p450 enzymes, debrisoquine
hydroxylase may
activate procarcinogens or, conversely, detoxify carcinogens.  A number of
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339337&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339337&amp;version=HealthProfessional&amp;language=English');  return(false);">alleles</a> have been characterized at the CYP2D6 <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460162&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460162&amp;version=HealthProfessional&amp;language=English');  return(false);">locus</a>.  The poor metabolizer
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460203&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460203&amp;version=HealthProfessional&amp;language=English');  return(false);">phenotype</a> (<Span Class="Protocol-GeneName">CYP2D6</Span> mutant/mutant genotype), which is rare in Asians, occurs in
about 5% to 10% of Caucasians and in 2% of African Americans.
</P><a name="Section_168" /><P __id="_168">Relatively few molecular epidemiology studies of the <Span Class="Protocol-GeneName">CYP2D6</Span> genotype and breast
cancer risk have been reported.  Based upon genotype assays in breast cancer
cases and controls, negative results have been reported in Great Britain <a href="#Reference3.3">3</a><a href="#Reference3.4">4</a>
and in the United States.<a href="#Reference3.5">5</a>
</P>
</a>
<a name="Section_351">

<Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">N-acetyl transferase 1</Span> and <Span Class="Protocol-GeneName">N-acetyl transferase 2</Span></Span>


<a name="Section_170" /><P __id="_170">The <Span Class="Protocol-GeneName">N-acetyl transferase-1 (NAT1)</Span>  and <Span Class="Protocol-GeneName">N-acetyl transferase-2 (NAT2)</Span> genes are
located on chromosome 8q.  Both are polymorphically expressed in a variety of
tissues.  <Span Class="Protocol-GeneName">NAT2</Span> detoxifies or, conversely, activates aromatic amines such as 4-aminobiphenyl found in
tobacco smoke.<a href="#Reference3.5">5</a>  Both phenotypic assays and genotypic
assays for <Span Class="Protocol-GeneName">NAT2</Span> can be used to classify individuals as rapid or slow
acetylators.  Genetic variants of the <Span Class="Protocol-GeneName">NAT2</Span> gene have been <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460134&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460134&amp;version=HealthProfessional&amp;language=English');  return(false);">cloned</a>, and 6 alleles
at this locus have been identified; the F1 allele confers the fast acetylator
phenotype.  The distribution of <Span Class="Protocol-GeneName">NAT1</Span> and <Span Class="Protocol-GeneName">NAT2</Span> alleles differs widely between
racial and ethnic groups.  Studies of the <Span Class="Protocol-GeneName">NAT2</Span> genotype and breast cancer
susceptibility have reported inconsistent results.<a href="#Reference3.6">6</a><a href="#Reference3.7">7</a><a href="#Reference3.8">8</a><a href="#Reference3.9">9</a>
</P>
</a>
<a name="Section_352">

<Span class="Summary-SummarySection-Title-Level3"><Span Class="Protocol-GeneName">Glutathione S-transferase</Span></Span>


<a name="Section_172" /><P __id="_172">The <Span Class="Protocol-GeneName">glutathione S-transferase-M1(GSTM1)</Span> gene is located on chromosome 1, and the
gene for <Span Class="Protocol-GeneName">glutathione S-transferase-T1 (GSTT1)</Span> is located on chromosome 11q.  A
<Span Class="Protocol-GeneName">glutathione S-transferase-P1 (GSTP1)</Span> gene has also been identified.  The
glutathione S-transferase genes may play a role in susceptibility to cancer. 
Glutathione S-transferases detoxify a variety of carcinogens and cytotoxic
drugs (for example, benzo(a)pyrene, monohalomethanes such as methyl chloride,
ethylene oxide, pesticides, and solvents used in industry) by catalyzing the
conjugation of a glutathione moiety to the substrate.  Individuals who are
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339342&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339342&amp;version=HealthProfessional&amp;language=English');  return(false);">homozygous</a> <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460132&amp;version=HealthProfessional&amp;language=English');  return(false);">carriers</a> of deletions in the <Span Class="Protocol-GeneName">GSTM1</Span>, <Span Class="Protocol-GeneName">GSTT1</Span>, or <Span Class="Protocol-GeneName">GSTP1</Span> genes may have a
higher risk of cancer of the breast and other sites because of their impaired
ability to metabolize and eliminate carcinogens.<a href="#Reference3.10">10</a><a href="#Reference3.11">11</a><a href="#Reference3.12">12</a>
</P>
<a name="Section_173" /><P __id="_173"><Span Class="Protocol-GeneName">GSTM1</Span> is polymorphically expressed, and 3 alleles at the GSTM1 locus have been
identified: <Span Class="Protocol-GeneName">GSTM1-0</Span> (homozygous deletion genotype), <Span Class="Protocol-GeneName">GSTM1a</Span>, and <Span Class="Protocol-GeneName">GSTM1b</Span>.  The
null allele (<Span Class="Protocol-GeneName">GSTM1-0</Span>) is present in about 38% to 67% of Caucasians and 22% to
35% of African Americans.   <Span Class="Protocol-GeneName">GSTM</Span> is not expressed in breast tissue at high
levels.  Two functionally different genotypes at the GSTT1 locus have been
described: <Span Class="Protocol-GeneName">GSTT1-0</Span> (homozygous deletion genotype) and <Span Class="Protocol-GeneName">GSTT1-1</Span> (genotypes with 1
or 2 undeleted alleles).<a href="#Reference3.9">9</a>  A polymorphism of the <Span Class="Protocol-GeneName">GSTP1</Span> gene, <Span Class="Protocol-GeneName">A313G</Span> (changing
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460135&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460135&amp;version=HealthProfessional&amp;language=English');  return(false);">codon</a> 105 from Ile to Val), has been identified.
</P><a name="Section_174" /><P __id="_174">Glutathione S-transferase genotypes have also been examined in relation to age
at breast cancer diagnosis in women with a positive family history.  One study
examined 185 breast cancer cases ascertained through hereditary breast cancer
clinics in the United States and found no association between <Span Class="Protocol-GeneName">GSTM1</Span> genotypes
and breast cancer <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339344&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339344&amp;version=HealthProfessional&amp;language=English');  return(false);">penetrance</a>.  However, the <Span Class="Protocol-GeneName">GSTT1-0</Span> allele was associated with
accelerated age at first breast cancer diagnosis as compared to the <Span Class="Protocol-GeneName">GSTT1-1</Span>
allele.  Approximately 40% of the subjects were diagnosed before age 40
years.<a href="#Reference3.9">9</a> 
</P></a>

</a>


        
       <a name="ReferenceSection"><p><Span Class="Summary-ReferenceSection">
							References
						</Span><ol><li><a name="Reference3.1" />Nathanson KL, Weber BL: "Other" breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 10 (7): 715-20, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11257104&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.2" />Strong LC, Amos CI: Inherited susceptibility. In: Schottenfeld D, Fraumeni JF Jr, eds.: Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press, 1996, pp 559-583 
			<A /><br /><br /></li><li><a name="Reference3.3" />Wolf CR, Smith CA, Gough AC, et al.: Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13 (6): 1035-8, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1600608&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.4" />Smith CA, Moss JE, Gough AC, et al.: Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect 98: 107-12, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1486838&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.5" />Buchert ET, Woosley RL, Swain SM, et al.: Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics 3 (6): 322-7, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8148873&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.6" />Ambrosone CB, Freudenheim JL, Graham S, et al.: Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276 (18): 1494-501, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8903261&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.7" />Agúndez JA, Ladero JM, Olivera M, et al.: Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 52 (1): 7-11, 1995 Jan-Feb. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7800347&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.8" />Millikan RC, Pittman GS, Newman B, et al.: Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7 (5): 371-8, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9610785&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.9" />Morabia A, Bernstein M, Heritier S, et al.: NAT2-smoking interaction with respect to breast cancer in menopausal women. Am J Epidemiol  147: A179, S45, 1998 
			<A /><br /><br /></li><li><a name="Reference3.10" />Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6 (9): 733-43, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9298582&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.11" />Maugard CM, Charrier J, Pitard A, et al.: Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer 91 (3): 334-9, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11169956&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference3.12" />Mitrunen K, Jourenkova N, Kataja V, et al.: Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 10 (3): 229-36, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11303592&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li></ol></p></a></a><a name="Section_575">
        <Span class="Summary-SummarySection-Title-Level1">Interventions</Span>
<a name="Section_176" /><P __id="_176">Few data exist on the outcomes of interventions to reduce risk in people with a
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=256553&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000256553&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic susceptibility</a> to breast or ovarian cancer.  As a result,
recommendations for management are primarily based on expert opinion.  In
addition, as outlined in other sections of this summary, uncertainty is often
considerable regarding the level of cancer risk associated with a positive
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=302456&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000302456&amp;version=HealthProfessional&amp;language=English');  return(false);">family history</a> or genetic test.  In this setting, personal preferences are
likely to be an important factor in patients’ decisions about risk reduction
strategies.</P>


<a name="Section_177"><Span class="Summary-SummarySection-Title-Level2">Breast Cancer</Span><br /><br />
<a name="Section_355">

<Span class="Summary-SummarySection-Title-Level3">Screening</Span>


<a name="Section_179" /><P __id="_179">Refer to the PDQ summary on <SummaryRef href="CDR0000062751">Screening for Breast Cancer</SummaryRef> for information
on <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460216&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460216&amp;version=HealthProfessional&amp;language=English');  return(false);">screening</a> in the general population, and to the PDQ summary <SummaryRef href="CDR0000062838">Cancer
Genetics Overview</SummaryRef> for information on levels of evidence related to
screening and prevention.
</P>
<a name="Section_356">

<Span class="Summary-SummarySection-Title-Level4">Breast Self-Examination</Span>


<a name="Section_181" /><P __id="_181">In the general population, evidence for the value of breast self-examination (BSE) is limited. 
Preliminary results have been reported from a randomized study of BSE being
conducted in Shanghai, China.<a href="#Reference4.1">1</a>  At 5 years, no reduction in breast cancer
mortality was seen in the BSE group compared with the control group of women, nor
was a substantive stage shift seen in breast cancers that were diagnosed. 
(Refer to the PDQ summary on <SummaryRef href="CDR0000062751">Screening for Breast Cancer</SummaryRef> for more information.)
</P><a name="Section_182" /><P __id="_182">Little direct prospective evidence exists regarding BSE among female <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460132&amp;version=HealthProfessional&amp;language=English');  return(false);">carriers</a>
of a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> high-risk <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46063&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=HealthProfessional&amp;language=English');  return(false);">mutation</a>, male carriers of a <Span Class="Protocol-GeneName">BRCA2</Span> mutation, or
women at inherited risk of breast cancer.  In the Canadian National Breast
Screening Study, women with <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460150&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460150&amp;version=HealthProfessional&amp;language=English');  return(false);">first-degree relatives</a> with breast cancer had
statistically significantly higher BSE competency scores than those without a
family history.  In a study of 251 high-risk women at a referral center, 5 breast cancers were detected by self-examination less than a year after a previous screen (as compared with 1 cancer detected by clinician exam and 11 cancers detected as a result of mammography).  Women in the cohort were instructed in self-examination, but it is not stated whether the interval cancers were detected as a result of planned self-examination or incidental discovery of breast masses.<a href="#Reference4.2">2</a> In another series of <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers,  4 of 9 incident cancers were diagnosed as palpable masses after a reportedly normal mammogram, further suggesting the potential value of self-examination.<a href="#Reference4.3">3</a> A task force convened by the Cancer Genetics Studies
Consortium has recommended “monthly self-examination beginning early in adult
life (e.g., by age 18-21) to establish a regular habit and allow familiarity
with the normal characteristics of breast tissue.  Education and instruction in
self-examination are recommended.”<a href="#Reference4.4">4</a> 
</P><a name="Section_183" /><P __id="_183">Level of evidence: 5
</P>
</a>
<a name="Section_378">

<Span class="Summary-SummarySection-Title-Level4">Clinical Breast Examination</Span>


<a name="Section_185" /><P __id="_185">Few prospective data exist regarding clinical breast examination (CBE) among female carriers of a <Span Class="Protocol-GeneName">BRCA1</Span> or
<Span Class="Protocol-GeneName">BRCA2</Span> high-risk mutation, male carriers of a <Span Class="Protocol-GeneName">BRCA2</Span> mutation, or women at
inherited risk of breast cancer.
</P><a name="Section_186" /><P __id="_186">The Cancer Genetics Studies Consortium task force concluded, “as with
self-examination, the contribution of clinical examination may be particularly
important for women at inherited risk of early breast cancer.”  They
recommended that female carriers of a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> high-risk mutation undergo
annual or semiannual clinical examinations beginning at age 25 to 35 years.<a href="#Reference4.4">4</a>
</P><a name="Section_187" /><P __id="_187">Level of evidence: 5
</P>
</a>
<a name="Section_380">

<Span class="Summary-SummarySection-Title-Level4">Mammography</Span>


<a name="Section_189" /><P __id="_189">In the general population, strong evidence suggests that regular mammography
screening of women aged 50 to 59 years leads to a 25% to 30% reduction in
breast cancer mortality.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062751">Screening for Breast
Cancer</SummaryRef> for more information.)  For women who begin mammographic screening at
age 40 to 49 years, a 17% reduction in breast cancer mortality is seen, which
occurs 15 years after the start of screening.<a href="#Reference4.5">5</a>  Observational data from a
cohort study of more than 28,000 women suggest that the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=322883&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000322883&amp;version=HealthProfessional&amp;language=English');  return(false);">sensitivity</a> of
mammography is lower for young women.  In this study, the sensitivity was
lowest for younger women (aged 30-49 years) who had a first-degree relative
with breast cancer.  For these women, mammography detected 69% of breast
cancers diagnosed within 13 months of the first screening mammography.  By
contrast, sensitivity for women younger than 50 years without a family history
was 88% (<i>P</i> = .08).  For women aged 50 years and older, sensitivity was 93% at 13 months
and did not vary by family history.<a href="#Reference4.6">6</a>  Preliminary data suggest that
mammography sensitivity is lower in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> carriers than in 
noncarriers.<a href="#Reference4.3">3</a>  Subsequent observational studies have found that the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460206&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460206&amp;version=HealthProfessional&amp;language=English');  return(false);">positive predictive value</a> (PPV) of mammography increases with age and is highest among older
women and among women with a family history of breast cancer.<a href="#Reference4.7">7</a> Higher PPVs may be due to increased breast cancer incidence, higher
sensitivity, and/or higher specificity.<a href="#Reference4.8">8</a>
One study found an association between the presence of pushing margins, a histopathologic description of a pattern of invasion, and false-negative mammograms in 28 women, 26 of whom had a <Span Class="Protocol-GeneName">BRCA1</Span> mutation and 2 of whom had a <Span Class="Protocol-GeneName">BRCA2</Span> mutation.  Pushing margins, characteristic of medullary histology, is associated with an absence of fibrotic reaction.<a href="#Reference4.9">9</a></P><a name="Section_190" /><P __id="_190">The randomized Canadian National Breast Screening Study-2 (NBSS2) compared
annual CBE plus mammography to CBE alone in women aged 50 to 59 years from the
general population.  Both groups were given instruction in BSE.<a href="#Reference4.10">10</a>  Although
mammography detected smaller primary invasive tumors and more invasive as well
as ductal carcinomas <i>in situ</i> (DCIS) than CBE, the breast cancer mortality rates
in the CBE-plus-mammography group and the CBE- alone group were nearly
identical, and compared favorably with other breast cancer screening trials. 
After a mean follow-up of 13 years (range 11.3-16.0 years), the cumulative
breast cancer mortality ratio was 1.02 (95% confidence interval (CI) = 0.78 to
1.33).  One possible explanation of this finding was the careful training and
supervision of the health professionals performing CBE.
</P><a name="Section_191" /><P __id="_191">In a prospective study of 251 individuals with <Span Class="Protocol-GeneName">BRCA</Span> mutations who received uniform recommendations regarding screening and risk-reducing, or prophylactic,  surgery, annual mammography detected breast cancer in 6 women at a mean of 20.2 months after receipt of BRCA results.<a href="#Reference4.2">2</a>  The Cancer Genetics
Studies Consortium task force has recommended for female carriers of a <Span Class="Protocol-GeneName">BRCA1</Span> or
<Span Class="Protocol-GeneName">BRCA2</Span> high-risk mutation, “annual mammography, beginning at age 25 to 35 years. 
Mammograms should be done at a consistent location when possible, with prior
films available for comparison.”<a href="#Reference4.4">4</a>  Data from prospective studies on the
relative benefits and risks of screening with an ionizing radiation tool versus
CBE or other nonionizing radiation tools would be useful, given accumulating
evidence that the <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> gene products are involved in repair of DNA
damage from radiation.<a href="#Reference4.11">11</a><a href="#Reference4.12">12</a><a href="#Reference4.13">13</a>
</P><a name="Section_192" /><P __id="_192">Level of evidence:  5
</P>
<a name="Section_857" /><P __id="_857">The limited sensitivity of mammography and an interest in methods of screening that do not involve ionizing radiation has led to evaluation of other screening techniques, including magnetic resonance imaging (MRI), breast ultrasound, breast ductal lavage, and digital mammography. </P></a>
<a name="Section_858"><Span class="Summary-SummarySection-Title-Level4">Magnetic Resonance Imaging</Span><a name="Section_905" /><P __id="_905">Because of the relative insensitivity of mammography in women at hereditary risk for breast cancer, a number of screening modalities have been proposed and investigated in high-risk women, including <Span Class="Protocol-GeneName">BRCA</Span> mutation carriers. Several studies have described the experience with breast MRI screening in women at risk for breast cancer, including descriptions of relatively large multi-institutional trials. Several considerations must be kept in mind when reviewing these reports:</P><a name="Section_906" /><a name="ListSection" /><UL __id="_906" class="Protocol-UL"><LI class="Protocol-IL-Bullet">The studies are variable in terms of the underlying population being studied, equipment and signal processing protocols, the manner of reporting results, and the manner in which sensitivity and specificity are calculated.</LI><LI class="Protocol-IL-Bullet">The different screening tests (MRI and mammogram with or without ultrasound) are performed nearly simultaneously in these studies, and the screening modalities are compared to each other. Therefore, sensitivity is defined somewhat differently in these studies than in the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) of follow-up and outcome reporting.</LI><LI class="Protocol-IL-Bullet">The number of screening rounds is limited, and the distinction between prevalent (first round) and incident cancer detection rates is often unclear.</LI></UL><a name="END_ListSection" /><a name="Section_907" /><P __id="_907">Despite these caveats, the reported studies consistently demonstrate that breast MRI is more sensitive than either mammography or ultrasound for the detection of hereditary breast cancer.<a href="#Reference4.14">14</a><a href="#Reference4.15">15</a><a href="#Reference4.16">16</a><a href="#Reference4.17">17</a><a href="#Reference4.18">18</a> Most cancers in these programs were screen detected with only 6% of cancers presenting in the interval between screenings. The sensitivity of MRI (as defined by the study methodology) ranged from 71% to 100%. Of the combined studies, 82% of the cancers were identified by MRI compared to 40% by mammography.

</P><a name="Section_909" /><P __id="_909">Concerns have been raised about the reduced specificity of MRI compared to other screening modalities. In one study, after the initial MRI screen, 16.5% of the patients were recalled for further evaluation, and 7.6% of subjects were recommended to undergo a short-interval follow-up examination at 6 months.<a href="#Reference4.18">18</a> These rates declined significantly during later screening rounds, with fewer than 10% of the subjects recalled for more detailed MRI and fewer than 3% recommended to have short interval follow-up. In a second study, Magnetic Resonance Imaging for Breast Screening (MARIBS), the recall rate for additional evaluation was 10.7% per year.<a href="#Reference4.17">17</a> The benign biopsy rates in the first study were 11% at first round, 6.6% at second round, and 4.7% at third round.<a href="#Reference4.18">18</a> In the MARIBS study, the aggregate surgical biopsy rate was 9 per 1,000 screening episodes, though this may underestimate the burden because follow-up ultrasounds, core-needle biopsies, and fine-needle aspirations have not been included in the numerator of the MARIBS calculation.<a href="#Reference4.17">17</a> The PPV of MRI has been calculated differently in the various series and fluctuates somewhat, depending on whether all abnormal examinations or only the examinations that result in a biopsy are counted in the denominator. Generally, the PPV of a recommendation for tissue sampling (as opposed to further investigation) is in the range of 50% in most series.


</P><a name="Section_933" /><P __id="_933">These trials appear to establish that MRI is superior to mammography in the detection of hereditary breast cancer, and that women participating in these trials including annual MRI screening were less likely to have a cancer not detected by screening. However, mammography clearly identifies some cancers that are not identified by MRI. Most of these mammographically detected cancers in women with a negative MRI appear to be ductal carcinomas <i>in situ</i>, presumably presenting as microcalcifications without significant ductal enhancement. While MRI does appear to be more sensitive than mammogram, it is unknown whether MRI screening results in a survival benefit or even in downstaging compared to mammography alone. One screening study demonstrated that patients were more likely to be diagnosed with small tumors and node-negative disease than women in 2 nonrandomized control groups.<a href="#Reference4.15">15</a> However, a randomized study of screening with or without MRI using tumor stage or mortality as an endpoint has not been performed. Despite the apparent sensitivity of MRI screening, some women in MRI-based programs will nevertheless develop life-threatening breast cancer.</P></a><a name="Section_860">

<Span class="Summary-SummarySection-Title-Level4">Ultrasound</Span>


<a name="Section_861" /><P __id="_861">Several studies have reported instances of breast cancer detected by ultrasound  that were missed by mammography, as discussed in one review.<a href="#Reference4.19">19</a> In a pilot study of ultrasound as an adjunct to mammography in 149 women with moderately increased risk based on family history, 1 cancer was detected, based on ultrasound findings.  Nine other biopsies of benign lesions were performed. One was based on abnormalities on both mammography and ultrasound, and the remaining 8 were based on abnormalities on ultrasound alone.<a href="#Reference4.19">19</a> Uncertainties about ultrasound include the effect of screening on mortality, the rate and outcome of <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460147&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460147&amp;version=HealthProfessional&amp;language=English');  return(false);">false-positive results</a>, and access to experienced breast ultrasonographers.</P>
</a>
<a name="Section_862">

<Span class="Summary-SummarySection-Title-Level4">Breast Ductal Lavage</Span>


<a name="Section_863" /><P __id="_863">All ductal and lobular breast cancers originate in the epithelial cells that line the breast milk ducts.   Breast ductal lavage (BDL) involves the insertion of a catheter into the milk ducts under local anesthesia through breast duct openings on the surface of the nipple, followed by a saline infusion to wash out cells for cytological examination.  The technique is a feasible method for collecting adequate samples of cells for examination, and cytological atypia can be detected.<a href="#Reference4.20">20</a>   The finding of atypia on BDL may provide risk information beyond that provided by the Gail risk model.<a href="#Reference4.21">21</a>  A study involving 426 high-risk women reported on the diagnosis of 2 cases of DCIS following BDL.<a href="#Reference4.20">20</a> The risk implications of atypia found on BDL, as compared with atypia found on breast biopsy, are not known; neither is the sensitivity or specificity of BDL as a predictor of early breast cancer known. There are no current data that BDL is an effective screening strategy.</P>
</a>
<a name="Section_864">

<Span class="Summary-SummarySection-Title-Level4">Digital Mammography</Span>


<a name="Section_865" /><P __id="_865">Digital mammography refers to the use of a digital detector to detect and record x-ray images.  This technology improves contrast resolution,<a href="#Reference4.22">22</a> and has been proposed as a potential strategy for improving the sensitivity of mammography.  A screening study comparing digital with routine mammography in 6,736 examinations of women aged 40 years and older found no difference in cancer detection rates;<a href="#Reference4.23">23</a> however, digital mammography resulted in fewer recalls.</P>
</a>
</a>



<a name="Section_360"><Span class="Summary-SummarySection-Title-Level3">Prevention</Span>


<a name="Section_194" /><P __id="_194">Refer to the PDQ summary on <SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef> for information
on prevention in the general population, and to the PDQ summary <SummaryRef href="CDR0000062838">Cancer
Genetics Overview</SummaryRef> for information on levels of evidence related to screening
and prevention.
</P>
<a name="Section_361">

<Span class="Summary-SummarySection-Title-Level4">Reproductive Factors</Span><br /><br />



<a name="Section_371">

<Span class="Summary-SummarySection-Title-Level4">Pregnancy and Lactation</Span>


<a name="Section_197" /><P __id="_197">In the general population, breast cancer risk increases with early menarche and
late menopause, and is reduced at early first full-term pregnancy.  (Refer to the
PDQ summary on <SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef> for more information.)  In the
Nurses’ Health Study, these were risk factors among women who did not have a
mother or sister with breast cancer.<a href="#Reference4.24">24</a>  Among women with a family history of
breast cancer, pregnancy at any age appeared to be associated with an increase
in risk of breast cancer, persisting to age 70 years. 
</P><a name="Section_198" /><P __id="_198">One study evaluated risk modifiers among 333 female carriers of a <Span Class="Protocol-GeneName">BRCA1</Span> 
high-risk mutation.  In women with known mutations of the <Span Class="Protocol-GeneName">BRCA1</Span> gene, early age
at first live birth and parity of 3 or more have been associated with a lowered
risk of breast cancer.<a href="#Reference4.25">25</a><a href="#Reference4.26">26</a>  A relative risk (RR)  of 0.85 was estimated for each
additional birth, up to 5 or more. As noted in the <SummaryRef href="CDR0000062855#_395">Ovarian Cancer Prevention</SummaryRef>
section of this summary, however, increasing parity appeared to be associated
with an increased risk of ovarian cancer.  In a case-control study from New
Zealand, investigators noted no difference in the impact of parity upon the
risk of breast cancer between women with a family history of breast cancer and
those without a family history.<a href="#Reference4.27">27</a>
</P><a name="Section_199" /><P __id="_199">Level of evidence: 3
</P>
<a name="Section_758" /><P __id="_758">In the general population, breastfeeding has been associated with a slight reduction in breast cancer risk in a few studies, including a large collaborative reanalysis of multiple epidemiologic studies,<a href="#Reference4.28">28</a> and at least one study suggests that it may be protective in <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers.  In a multicenter breast cancer case-control study of 685 <Span Class="Protocol-GeneName">BRCA1</Span> and  280 <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers with breast cancer and 965 mutation carriers without breast cancer drawn from multiple-case families, among <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, breastfeeding for 1 year or more was associated with approximately a 45% reduced risk of breast cancer.<a href="#Reference4.29">29</a>  No such reduced risk was observed among <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers. The difference in risk between <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> is unknown.  This study needs to be replicated.</P></a>
</a>
<a name="Section_381">

<Span class="Summary-SummarySection-Title-Level4">Oral Contraceptives</Span>


<a name="Section_201" /><P __id="_201">Among the general population, oral contraceptives may produce a slight,
short-term increase in breast cancer risk.  (Refer to the PDQ summary on
<SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef> for more information.)  In a meta-analysis of data
from 54 studies, family history of breast cancer was not associated with any
variation in risk associated with oral contraceptive use.<a href="#Reference4.30">30</a>  In a study of 50
Jewish women younger than 40 years with breast cancer, those with a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span>
high-risk mutation had a higher likelihood of long-term oral contraceptive use
(&gt;48 months) before their first pregnancy.<a href="#Reference4.31">31</a>  The authors concluded that oral
contraceptive use might increase the risk of breast cancer among carriers of a
<Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation more than in noncarriers.  In a case-control study of more than 1,300 pairs of women, each case was matched to a woman with a mutation in the same gene, born within 2 years of the case, and in the same country, who had not developed cancer. Oral contraceptive use was associated with a statistically significant 20% (CI, 2%-40%) increase in risk of breast cancer among <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, particularly if use:</P><a name="Section_698" /><a name="ListSection" /><UL __id="_698" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Began before 1975, a period when estrogen doses were relatively high (38% increase, CI 11%-72%).</LI><LI class="Protocol-IL-Bullet">Began before age 30 years (29% increase, CI, 9%-52%).</LI><LI class="Protocol-IL-Bullet">Lasted for 5 or more years (33% increase, CI, 11%-60%).<a href="#Reference4.32">32</a></LI></UL><a name="END_ListSection" /><a name="Section_694" /><P __id="_694">There was no increased risk associated with use among <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers.</P><a name="Section_677" /><P __id="_677">One study examined
proliferation of normal breast epithelium among women undergoing reduction
mammoplasty.<a href="#Reference4.33">33</a>  The study found a substantially higher cellular proliferation
rate among women who used oral contraceptives before their first full-term
pregnancy.  In addition, among women currently on oral contraceptives, women
with a family history of breast cancer had much higher cellular proliferation
rates than those women without a family history.  These findings are consistent
with increased breast cancer risk among women with a family history of breast
cancer who use oral contraceptives.   

</P><a name="Section_202" /><P __id="_202">In considering contraceptive options and preventive actions, the potential
impact of oral contraceptive use upon the risk of both breast and ovarian
cancer, as well as other health-related effects of oral contraceptives, needs to
be considered.
</P><a name="Section_203" /><P __id="_203">Levels of evidence for oral contraceptive studies: 3B, 3
</P>
</a>
<a name="Section_382">

<Span class="Summary-SummarySection-Title-Level4">Ovarian Ablation</Span>


<a name="Section_205" /><P __id="_205">In the general population, removal of both ovaries has been associated with a
reduction in breast cancer risk of up to 75%, depending on parity, weight, and
age at time of artificial menopause.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062779">Prevention
of Breast Cancer</SummaryRef> for more information.)  In a study of 680 women, and who were at various levels of familial risk, from the Mayo Clinic who had bilateral oophorectomy before age 60, the likelihood of breast cancers developing was reduced for all risk groups.<a href="#Reference4.34">34</a> Ovarian ablation, however, is
associated with important side effects such as hot flashes, impaired sleep
habits, vaginal dryness, dyspareunia, and increased risk of osteoporosis and
heart disease.  A variety of strategies may be necessary to counteract the
adverse effects of ovarian ablation. 
</P><a name="Section_206" /><P __id="_206">In support of early small studies,<a href="#Reference4.35">35</a><a href="#Reference4.36">36</a> a retrospective study of 551 women with disease-associated <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations found a significant reduction in risk of breast cancer (hazard ratio (HR) 0.47, 95% CI, 0.29-0.77) as well as ovarian cancer (HR 0.04, 95% CI, 0.01-0.16) after bilateral oophorectomy.<a href="#Reference4.37">37</a> A prospective single-institution study of 170 women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations showed a similar trend.  With oophorectomy, the HR was 0.15 (95% CI, 0.02-1.31) for ovarian, fallopian tube, or primary peritoneal cancer, and 0.32 (95% CI, 0.08-1.2) for breast cancer; the HR for either cancer was 0.25 (95% CI, 0.08-0.74).<a href="#Reference4.38">38</a>
</P><a name="Section_207" /><P __id="_207">Levels of evidence: 3, 4
</P>
</a>
<a name="Section_383">

<Span class="Summary-SummarySection-Title-Level4">Hormone Replacement Therapy</Span>


<a name="Section_695" /><P __id="_695">Both observational and randomized clinical trial data suggest an increased risk of breast cancer associated with hormone replacement therapy (HRT) in the general population.<a href="#Reference4.39">39</a><a href="#Reference4.40">40</a><a href="#Reference4.41">41</a><a href="#Reference4.42">42</a> The Women’s Health Initiative (WHI) is a randomized controlled trial of approximately 160,000 postmenopausal women investigating the risks and benefits of strategies that may reduce the incidence of heart disease, breast and colorectal cancer, and fractures, including dietary interventions and 2 trials of hormone therapy. The estrogen-plus-progestin arm  of the study, which randomized more than 16,000 women to receive combined hormone therapy or placebo, was halted early because health risks exceeded  benefits.<a href="#Reference4.41">41</a><a href="#Reference4.42">42</a>  One of the adverse outcomes prompting closure was a significant increase in both total (245 vs. 185 cases) and invasive (199 vs. 150) breast cancers (RR =1.24; 95% CI, 1.02-1.50, <i>P</i> &lt;.001) in women randomized to receive estrogen and progestin.<a href="#Reference4.42">42</a> HRT-related breast cancers had adverse prognostic characteristics (more advanced stages and larger tumors) compared with cancers occurring in the placebo group, and HRT was also associated with a substantial increase in abnormal mammograms.<a href="#Reference4.42">42</a></P><a name="Section_209" /><P __id="_209"> Breast
cancer risk associated with postmenopausal HRT has been variably reported to be
increased <a href="#Reference4.43">43</a><a href="#Reference4.44">44</a><a href="#Reference4.45">45</a> or unaffected by a family history of breast cancer;<a href="#Reference4.25">25</a><a href="#Reference4.46">46</a><a href="#Reference4.47">47</a>
risk did not vary by family history in the meta-analysis.<a href="#Reference4.30">30</a>  The WHI study has not reported analyses stratified on breast cancer family history, and subjects have not been systematically tested for <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations.<a href="#Reference4.42">42</a> Short-term use
of hormones for treatment of menopausal symptoms appears to confer little or no
breast cancer risk in the general population.<a href="#Reference4.48">48</a>
</P><a name="Section_210" /><P __id="_210">No data exist on the effect of HRT on breast cancer risk among carriers of a
<Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> high-risk mutation.
</P><a name="Section_211" /><P __id="_211">Level of evidence: 4B
</P>
</a>
<a name="Section_385">

<Span class="Summary-SummarySection-Title-Level4">Tamoxifen</Span>


<a name="Section_213" /><P __id="_213">Tamoxifen (a synthetic antiestrogen) increases breast-cell growth inhibitory
factors and concomitantly reduces breast-cell growth stimulatory factors.  The National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (NSABP-P1), a
 prospective randomized double-blind trial, compared  tamoxifen (20 mg/day)
to placebo for 5 years. Tamoxifen was shown to reduce the risk of invasive
breast cancer by 49%. The protective effect was largely confined to estrogen receptor–positive breast cancer, which was reduced by 69%.  The incidence of estrogen receptor–negative cancer  was not reduced with statistical significance.<a href="#Reference4.49">49</a>  Similar reductions were noted in the risk of
preinvasive breast cancer.  Reductions in breast cancer risk were noted among
women with a family history of breast cancer and those without a family
history.  These benefits were associated with an increased incidence among
women older than 50 years of endometrial cancers and thrombotic events.  Interim data
from 2 European tamoxifen prevention trials did not show a reduction in breast
cancer risk with tamoxifen after a median follow-up of 48 months <a href="#Reference4.50">50</a> or 70
months,<a href="#Reference4.51">51</a>respectively.  In 1 trial, however, reduction in breast cancer risk
was seen among a subgroup who also used HRT.<a href="#Reference4.50">50</a>  These trials varied
considerably in study design and populations.  (Refer to the PDQ summary on
<SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef> for more information.)
</P><a name="Section_405" /><P __id="_405">A substudy of the NSABP-P1 trial evaluated the effectiveness of tamoxifen in preventing breast cancer in <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers older than 35 years. <Span Class="Protocol-GeneName">BRCA2</Span>-positive women benefited from tamoxifen to the same extent as <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation–negative participants; however, tamoxifen use among healthy women with <Span Class="Protocol-GeneName">BRCA1</Span> mutations did not appear to reduce breast cancer incidence. These data must be viewed with caution in view of the small number of mutation carriers in the sample (8 <Span Class="Protocol-GeneName">BRCA1</Span> carriers and 11 <Span Class="Protocol-GeneName">BRCA2</Span> carriers).<a href="#Reference4.52">52</a></P><a name="Section_215" /><P __id="_215">Level of evidence: 1
</P>
</a>
<a name="Section_386">

<Span class="Summary-SummarySection-Title-Level4">Risk-Reducing Mastectomy</Span>


<a name="Section_217" /><P __id="_217">In the general population, both subcutaneous mastectomy and simple (total)
mastectomy have been used for prophylaxis.  Only 90% to 95% of breast tissue is
removed with subcutaneous mastectomy.<a href="#Reference4.53">53</a>  In a total or simple mastectomy, 
removal of the nipple-areolar complex increases the proportion of breast tissue
removed compared with subcutaneous mastectomy.  However, some breast tissue is
usually left behind with both procedures.  The risk of breast cancer following
either of these procedures has not been well established.
</P><a name="Section_684" /><P __id="_684">The effectiveness of risk-reducing mastectomy  in women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations has been evaluated in several studies. In one retrospective cohort study of 214 women considered to be at hereditary risk by virtue of a family history suggesting an <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339338&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339338&amp;version=HealthProfessional&amp;language=English');  return(false);">autosomal dominant </a>predisposition, 3 women were diagnosed with breast cancer after bilateral risk-reducing mastectomy, with a median follow-up of 14 years.<a href="#Reference4.54">54</a> As 37.4 cancers were expected, the calculated risk reduction was 92.0% (95% CI, 76.6-98.3). In a follow-up subset analysis, 176 of the 214 high-risk women in this cohort study underwent <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460195&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460195&amp;version=HealthProfessional&amp;language=English');  return(false);">mutation analysis</a> of <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span>. Mutations were found in 26 women (18 deleterious, 8 variants of uncertain significance). None of those women had developed breast cancer after a median follow-up of 13.4 years.<a href="#Reference4.55">55</a> Two of the 3 women diagnosed with breast cancer after risk-reducing mastectomy were tested, and neither carried a mutation. The calculated risk reduction among mutation carriers was 89.5% to 100% (95% CI, 41.4%-100%), depending on the assumptions made about the expected numbers of cancers among mutation carriers and the status of the untested woman who developed cancer despite mastectomy. The result of this retrospective cohort study has been supported by a prospective analysis of 76 mutation carriers undergoing risk-reducing mastectomy and followed prospectively for a mean of 2.9 years. No breast cancers were observed in these women, whereas 8 were identified in women undergoing regular surveillance (HR for breast cancer after risk-reducing mastectomy = 0 [95% CI, 0-0.36]).<a href="#Reference4.56">56</a> </P><a name="Section_728" /><P __id="_728">The Prevention and Observation of Surgical End Points (PROSE) study group estimated the degree of breast cancer risk reduction after risk-reducing mastectomy in <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers. The rate of breast cancer in 105 mutation carriers who underwent bilateral risk-reducing mastectomy was compared with that in 378 mutation carriers who did not choose surgery. Bilateral mastectomy reduced the risk of breast cancer after a mean follow-up of 6.4 years by approximately 90%.<a href="#Reference4.57">57</a></P><a name="Section_685" /><P __id="_685">Studies describing histopathologic findings in risk-reducing mastectomy specimens from women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations have been somewhat inconsistent. In 2 series, proliferative lesions associated with an increased risk of breast cancer (lobular carcinoma <i>in situ</i>, atypical lobular hyperplasia, atypical ductal hyperplasia, DCIS) were noted in 43% to 46% of women with mutations undergoing either unilateral or bilateral risk-reducing mastectomy.<a href="#Reference4.58">58</a><a href="#Reference4.59">59</a>
 In these series, 13% to 15% of patients were found to have previously unsuspected DCIS in the prophylactically removed breast. Among 47 cases of prophylactic-plus-bilateral or -contralateral mastectomies performed in known <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers from Australia, 3 (6%) cancers were detected at surgery.<a href="#Reference4.60">60</a></P><a name="Section_686" /><P __id="_686">These findings were not replicated in a third retrospective cohort study. In this study, proliferative fibrocystic changes were noted in 0 of 11 bilateral mastectomies from patients with deleterious mutations and in only 2 of 7 contralateral unilateral risk-reducing mastectomies in affected mutation carriers.<a href="#Reference4.61">61</a></P><a name="Section_220" /><P __id="_220">Although data are sparse, the evidence to date indicates that while a
substantial proportion of women with a strong family history of breast cancer
are interested in discussing risk-reducing mastectomy as a treatment option, uptake varies according to culture, geography, healthcare
system, insurance coverage, provider attitudes, and other social factors.  For
example, in 1 setting where the providers made 1 to 2 field trips to family
gatherings for family information sessions and individual counseling, only 3%
of unaffected carriers obtained risk-reducing mastectomy within 1 year of
follow-up.<a href="#Reference4.62">62</a>  Among women at increased risk of breast cancer due to family
history, fewer than 10% opted for mastectomy.<a href="#Reference4.63">63</a>  Selection of this option was
related to breast cancer–related worry as opposed to objective risk parameters
(e.g., number of relatives with breast cancer).  In addition, self-perceived
risk has been closely linked to interest in risk-reducing mastectomy.<a href="#Reference4.63">63</a></P><a name="Section_631" /><P __id="_631">Assuming risk reduction in the range of 90%, a theoretical model suggests that for a group of 30-year-old women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations, risk-reducing mastectomy would result in an average increased life expectancy of 2.9 to 5.3 years.<a href="#Reference4.64">64</a> While these data are useful for public policy decisions, they cannot be individualized for clinical care as they include assumptions that cannot be fully tested. Another study of at-risk women showed a 70% time-tradeoff value, indicating that the women were willing to sacrifice 30% of life expectancy in order to avoid risk-reducing mastectomy.<a href="#Reference4.65">65</a> A cost-effectiveness analysis study estimated that risk-reducing surgery (mastectomy and oophorectomy) is cost-effective compared with surveillance with regard to years of life saved, but not for improved quality of life.<a href="#Reference4.66">66</a></P><a name="Section_375" /><P __id="_375">In contrast, in a Dutch study of highly motivated women being followed every 6 months at a high-risk center, more than half (51%) of unaffected carriers opted for risk-reducing mastectomy. Almost 90% of the risk-reducing mastectomy surgeries were performed within 1 year of DNA testing. In this study, those most likely to have risk-reducing mastectomy were women younger than 55 years and with children.<a href="#Reference4.67">67</a> 

 
</P><a name="Section_577" /><P __id="_577">Individual psychological factors have an important role in decision-making about risk-reducing mastectomy by unaffected women.  Research is emerging about psychosocial outcomes of risk-reducing mastectomy.  (Refer to the <SummaryRef href="CDR0000062855#_313">Psychological Aspects of Medical Interventions</SummaryRef> section of this summary.)</P><a name="Section_376" /><P __id="_376">Level of evidence: 3B</P>
</a>
<a name="Section_388">

<Span class="Summary-SummarySection-Title-Level4">Other Factors</Span>


<a name="Section_224" /><P __id="_224">No data exist regarding the impact of abortion, diet, or alcohol on the risk of breast cancer among women at inherited risk of breast cancer. 
(Refer to the PDQ summary on <SummaryRef href="CDR0000062779">Prevention of Breast Cancer</SummaryRef> for information
relevant to the general population.)
In a retrospective analysis of 104 <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation–positive families, physical exercise as a teenager was associated with a delayed onset of breast cancer.<a href="#Reference4.68">68</a></P>
</a>
</a>







</a>










<a name="Section_389">

<Span class="Summary-SummarySection-Title-Level2">Ovarian Cancer</Span><br /><br />



<a name="Section_390">

<Span class="Summary-SummarySection-Title-Level3">Screening</Span>


<a name="Section_227" /><P __id="_227">Refer to the PDQ summary on <SummaryRef href="CDR0000062760">Screening for Ovarian Cancer</SummaryRef> for information
on screening in the general population, and to the PDQ summary <SummaryRef href="CDR0000062838">Cancer
Genetics Overview</SummaryRef> for information on levels of evidence related to screening
and prevention.
</P>
<a name="Section_392">

<Span class="Summary-SummarySection-Title-Level4">Clinical Examination</Span>


<a name="Section_229" /><P __id="_229">In the general population, clinical examination of the ovaries has neither the
specificity nor the sensitivity to reliably identify early ovarian cancer.  No data
exist regarding the benefit of clinical examination of the ovaries (bimanual
pelvic examination) in women at inherited risk of ovarian cancer.
</P><a name="Section_230" /><P __id="_230">Level of evidence: none
</P>
</a>
<a name="Section_393">

<Span class="Summary-SummarySection-Title-Level4">Serum CA 125</Span>


<a name="Section_232" /><P __id="_232">Limited data are available on the potential benefit of screening with serum CA
125 in women at inherited risk of ovarian cancer.  When 180 women considered at
high risk of ovarian cancer based on family history were screened for ovarian
cancer by gynecologic examination, transvaginal ultrasound (TVUS), and serum CA
125, 1 granulosa cell tumor, 3 tumors of low malignant potential, and 5
epithelial ovarian tumors (1 stage II and 4 stage III) were detected.  CA 125
levels were elevated in 1 of the tumors of low malignant potential and 3 of the
4 stage III ovarian carcinomas.<a href="#Reference4.69">69</a>
</P><a name="Section_850" /><P __id="_850">A 10-year observational study of 2,500 asymptomatic women with a family history of ovarian cancer who underwent transvaginal ultrasound screening and retrospective analysis of serum CA 125 levels is described in more detail in the <SummaryRef href="CDR0000062855#_394">Pelvic Ultrasound</SummaryRef> section of this summary.<a href="#Reference4.70">70</a></P><a name="Section_234" /><P __id="_234">Another study found elevated CA 125 levels in 68 of 597 (11.4%) women screened for
ovarian cancer.  Most of these women had a first-degree or second-degree
relative with ovarian cancer, though 51 had a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44868&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044868&amp;version=HealthProfessional&amp;language=English');  return(false);">pedigree</a> consistent with
inherited susceptibility to breast or ovarian cancer, and 7 had a pedigree
consistent with HNPCC.  Among the premenopausal patients, the elevations in CA
125 were associated with ultrasonographic evidence of endometriosis,
adenomyosis, or leiomyomas.  Among the 8 postmenopausal patients, all had
normal ovarian architecture on ultrasound.<a href="#Reference4.71">71</a><a href="#Reference4.72">72</a>  No data are available to
address the effectiveness of ovarian cancer screening in preventing deaths from
ovarian cancer.
</P><a name="Section_235" /><P __id="_235">In 1994, the National Institutes of Health (NIH) Consensus Statement on Ovarian
Cancer recommended against routine screening of the general population for
ovarian cancer with serum CA 125.  The NIH Consensus Statement did, however,
recommend that women at inherited risk of ovarian cancer undergo annual or
semiannual screening for ovarian cancer with TVUS and serum CA 125.<a href="#Reference4.73">73</a>  The
Cancer Genetics Studies Consortium task force recommended that female carriers
of a <Span Class="Protocol-GeneName">BRCA1</Span> high-risk mutation undergo annual or semiannual screening using TVUS
and serum CA 125 levels, beginning at age 25 to 35 years.<a href="#Reference4.4">4</a>
</P><a name="Section_236" /><P __id="_236">A phase II trial evaluating annual TVUS and serial CA 125 levels in 3,000
high-risk women registered in the United Kingdom Familial Ovarian Cancer
Registry is under way.  In the United States, the National Cancer
Institute (NCI) is conducting a large controlled clinical trial in which 74,000
women are randomized to regular medical care or research-based screening for
lung, colorectal, and ovarian cancer.  The ovarian cancer screening consists of
yearly serum CA 125 and TVUS.<a href="#Reference4.74">74</a>
</P><a name="Section_237" /><P __id="_237">Level of evidence: 5
</P>
</a>
<a name="Section_394">

<Span class="Summary-SummarySection-Title-Level4">Pelvic Ultrasound</Span>


<a name="Section_239" /><P __id="_239">In the general population, TVUS appears to be superior to transabdominal
ultrasound in preoperative diagnosis of adnexal masses.  Either technique has
lower specificity in premenopausal women than in postmenopausal women due to
the cyclic menstrual changes in premenopausal ovaries that can cause
difficulty in interpretation.  A screening trial of TVUS in 1,300
postmenopausal, asymptomatic women detected abnormalities in 2.5%.  More than
90% of the lesions found were benign.  Women with a family history of ovarian
cancer were more likely to be found with an ovarian malignancy (RR = 4.0).  No such association was noted for those with a family history of breast
cancer or colon cancer.<a href="#Reference4.75">75</a>
</P><a name="Section_240" /><P __id="_240">One study reported on the use of transvaginal color Doppler ultrasonography in
the evaluation of 126 women with adnexal masses who subsequently underwent
surgery.  Twenty epithelial ovarian cancers were detected, as well as 2
dysgerminomas, 2 ovarian tumors of low malignant potential, 1 immature
teratoma, and 1 Sertoli-Leydig cell tumor.  It was concluded that color Doppler
ultrasonography was able to increase the positive and <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460198&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460198&amp;version=HealthProfessional&amp;language=English');  return(false);">negative predictive
value</a> due to increased sensitivity and specificity of ultrasound
evaluation.<a href="#Reference4.76">76</a>
</P><a name="Section_241" /><P __id="_241">Another study reported that the addition of color Doppler ultrasonography was
able to increase the PPV of ultrasound imaging from 25%
to 60% among women with a personal history of breast cancer undergoing
screening for ovarian cancer.<a href="#Reference4.77">77</a>  As noted, however, clinical studies of color
Doppler imaging have shown that normal physiologic changes in the premenopausal
ovary near the time of ovulation have low impedance flow characteristics
similar to those seen in malignancy.<a href="#Reference4.71">71</a>
</P><a name="Section_851" /><P __id="_851">Data are limited regarding the potential benefit of pelvic ultrasound in
screening women at inherited risk of ovarian cancer.  A 10-year observational study in the United Kingdom of 2,500 asymptomatic women with at least one relative with ovarian cancer has evaluated TVUS and reported sensitivity and specificity with 10 years of follow-up and retrospective analysis of serum CA 125 levels.<a href="#Reference4.70">70</a>  Most women were screened once only, unless the initial scan was positive or the family history was especially strong.  There were 11 screening-detected cancers, 1 false-negative stage III cancer (occurring within 12 months of ultrasound screening), and 93 false-positive tests, for a test sensitivity of 92% and a specificity of 97.8%.  Among the 11 screening-detected cancers, 4 were stage Ia invasive, 4  borderline stage Ia, 1  invasive stage Ic, and 2 stage II/III serous carcinomas.  Sixty-five percent of the subjects were premenopausal, and 9 of the 12 cancers occurred in this group.  TVUS was quite sensitive in this high-risk group, but there were still a large number of women screened (n = 227) and false positives (n = 9) for each cancer were detected.  The retrospective analysis of serum CA 125 levels in this study also allowed its evaluation as a potential first-stage screen to reduce both the number of ultrasound tests required and false positives.<a href="#Reference4.70">70</a>  If only women with CA 125 levels of 20 or higher underwent ultrasound screening, an additional 4 cancers would have been missed (sensitivity of 58%), but only 22% of the subjects would have undergone ultrasound screening, reducing the number of false positives to 21.  Ultrasound screening only of those with CA 125 levels of 35 would have resulted in a sensitivity of  33% (7 additional cancers missed).</P><a name="Section_242" /><P __id="_242">Another study used
gynecologic examination, TVUS, and CA 125 to screen 180 women at high risk of
ovarian cancer with or without breast cancer.  (Refer to the <SummaryRef href="CDR0000062855#_393">Serum CA 125</SummaryRef>
section in this summary.)  Abnormal ultrasounds were noted in all 5 women with
invasive epithelial ovarian carcinomas.  Of these, however, 1 had stage II
disease and 4 had stage III disease.<a href="#Reference4.69">69</a>
</P><a name="Section_243" /><P __id="_243">One study screened 597 women at risk of ovarian cancer with serum CA 125, TVUS,
and color Doppler (described in the <SummaryRef href="CDR0000062855#_393">Serum CA 125</SummaryRef> section).  No epithelial
ovarian cancers were found.  One case of an ovarian tumor of low malignant
potential, however, was identified.<a href="#Reference4.71">71</a><a href="#Reference4.72">72</a>
</P><a name="Section_244" /><P __id="_244">Another study reported screening 386 women with first- or second-degree
relatives with ovarian cancer.  The study used TVUS, color flow Doppler, and
serum CA 125.  Initial ultrasound was abnormal in 89 of 381 women (23%). 
Ovarian masses persisted in 15 patients; all of these were benign at surgery. 
CA 125 levels were higher than 35 U/mL in 42 of 386 women (11%).  Two patients who
underwent surgery for rising CA 125 levels had normal ovaries.<a href="#Reference4.78">78</a>
</P><a name="Section_245" /><P __id="_245">The NIH Consensus Statement on Ovarian Cancer recommended against routine
screening of the general population with TVUS and serum CA 125.  The NIH
Consensus Statement did, however, recommend that women at inherited risk of
ovarian cancer undergo TVUS and serum CA 125 every 6 to 12 months, commencing
at age 35 years.<a href="#Reference4.73">73</a>  The Cancer Genetics Studies Consortium task force has
recommended that female carriers of a <Span Class="Protocol-GeneName">BRCA1</Span> high-risk mutation undergo annual
or semiannual screening using TVUS and serum CA 125 levels, beginning at age 25
to 35 years.<a href="#Reference4.4">4</a>
</P><a name="Section_246" /><P __id="_246">In the United States, NCI is conducting a large controlled clinical trial
in which 74,000 women are randomized to regular medical care or research-based
screening for lung, colorectal, and ovarian cancer.  The ovarian cancer
screening consists of yearly serum CA 125 and TVUS.<a href="#Reference4.74">74</a> NCI's Clinical Genetics Branch, the Gynecologic Oncology Group, and the Cancer Genetics Network are collaborating on a prospective study (GOG-0199) <a href="#Reference4.79">79</a> of women at increased genetic risk of ovarian cancer in which risk-reducing surgery and a novel CA 125-based screening strategy are being evaluated.<a href="#Reference4.80">80</a>
</P><a name="Section_247" /><P __id="_247">Level of evidence: 5
</P>
</a>
</a>

<a name="Section_395">

<Span class="Summary-SummarySection-Title-Level3">Prevention</Span>


<a name="Section_249" /><P __id="_249">Refer to the PDQ summary on <SummaryRef href="CDR0000062771">Prevention of Ovarian Cancer</SummaryRef> for information
on prevention in the general population, and to the PDQ summary <SummaryRef href="CDR0000062838">Cancer
Genetics Overview</SummaryRef> for information on levels of evidence related to screening
and prevention.
</P>
<a name="Section_396">

<Span class="Summary-SummarySection-Title-Level4">Reproductive Factors</Span>


<a name="Section_251" /><P __id="_251">It has been suggested that incessant ovulation, with repetitive trauma and
repair to the ovarian epithelium, increases the risk of ovarian cancer.  In
epidemiologic studies in the general population, physiologic states that
prevent ovulation have been associated with decreased risk of ovarian cancer. 
It has also been suggested that chronic overstimulation of the ovaries by
luteinizing hormone (LH) plays a role in ovarian cancer pathogenesis.<a href="#Reference4.81">81</a> 
Most of these data derive from studies in the general population, but some
information suggests the same is true in women at high risk due to genetic
predisposition.
</P>
<a name="Section_398">

<Span class="Summary-SummarySection-Title-Level4">Pregnancy</Span>


<a name="Section_253" /><P __id="_253">Among the general population, parity decreases the risk of ovarian cancer by
45% compared with nulliparous women.  Subsequent pregnancies after the first
appear to decrease ovarian cancer risk by 15%.<a href="#Reference4.82">82</a>  Data are limited regarding
the impact of fertility on the risk of ovarian cancer in women at high risk
due to genetic predisposition.
</P><a name="Section_254" /><P __id="_254">One study analyzed the reproductive histories of 333 women with a <Span Class="Protocol-GeneName">BRCA</Span>1
high-risk mutation.  Among these women, the risk of ovarian cancer increased
with increasing parity.  Each birth was associated with an additional 40%
increase in risk up to 5 births.  Late birth, however, appeared to convey a
protective effect.  Each 5-year interval in age at last birth was associated
with a risk reduction of 18%.  Women who had all their children after age 
30 years, or who were nulliparous, formed a low-risk group for ovarian cancer
(RR = 0.30).<a href="#Reference4.27">27</a>
</P><a name="Section_578" /><P __id="_578">A prospective population-based study of postmenopausal women found that nulliparity slightly increased the risk of developing ovarian cancer in women without a family history of breast or ovarian cancer (RR = 1.4, 95% CI 0.9-2.4).  This group showed that this risk was further increased in nulliparous women with a family history compared with parous women with a similar family history (RR = 2.7, 95% CI, 1.1-6.6).<a href="#Reference4.83">83</a></P><a name="Section_255" /><P __id="_255">A case-control study was conducted involving 170 women with primary ovarian
carcinomas or ovarian tumors of low malignant potential and 170
population-based controls.  Late age at last childbirth was protective against
development of ovarian cancer among women with a family history of breast or
ovarian cancer, but not those without such a family history.<a href="#Reference4.84">84</a>
</P><a name="Section_256" /><P __id="_256">In a study conducted using the Utah Population Database, a genealogy of about 1
million individuals linked to cancer incidence data, parity was not related to
the development of ovarian cancer in women with a strong family history of
ovarian, uterine, breast, or pancreatic cancer.<a href="#Reference4.85">85</a>
</P><a name="Section_257" /><P __id="_257">Level of evidence: 3
</P>
</a>

<a name="Section_399">

<Span class="Summary-SummarySection-Title-Level4">Lactation, Hormone Replacement Therapy, and Tubal Ligation</Span>


<a name="Section_259" /><P __id="_259">No data exist regarding the impact of lactation or HRT
on the risk of ovarian cancer in women at inherited risk of ovarian cancer, though consistent, prolonged exposure to unopposed estrogen HRT may increase the risk of ovarian cancer in the general population.<a href="#Reference4.86">86</a>  A
case-control study among women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations demonstrates a
significant reduction in risk of ovarian cancer (odds ratio (OR) =  0.39) for women who have
had a tubal ligation.  This protective effect was confined to those women with
mutations in <Span Class="Protocol-GeneName">BRCA1</Span> and persists after controlling for oral contraceptive pill
use, parity, history of breast cancer, and ethnicity.<a href="#Reference4.87">87</a>  A case-control study of ovarian cancer in Israel found a 40% to 50% reduced risk of ovarian cancer among women undergoing gynecologic surgeries (tubal ligation, hysterectomy, unilateral oophorectomy, ovarian cystectomy, excluding bilateral oophorectomy).<a href="#Reference4.88">88</a> The mechanism of protection is uncertain. Proposed mechanisms of action include decreased blood flow to the ovary, resulting in interruption of ovulation and/or ovarian hormone production; occlusion of the fallopian tube, thus blocking a pathway for potential carcinogens; or a reduction in the concentration of uterine growth factors that reach the ovary.<a href="#Reference4.89">89</a> (Refer to the PDQ
summary on <SummaryRef href="CDR0000062771">Prevention of Ovarian Cancer</SummaryRef> for information relevant to the general
population.)
</P>
</a>
<a name="Section_400">

<Span class="Summary-SummarySection-Title-Level4">Oral Contraceptives</Span>


<a name="Section_852" /><P __id="_852">Oral contraceptives have been shown to have a protective effect against ovarian cancer in the general population.  Whether oral contraceptives are protective for ovarian cancer among <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers is less clear. Several studies conducted in high-risk, multiple-case family clinic settings showed a protective effect,<a href="#Reference4.39">39</a><a href="#Reference4.87">87</a><a href="#Reference4.90">90</a> as did a small population-based study,<a href="#Reference4.91">91</a> while a large population-based study from Israel failed to demonstrate a protective effect.<a href="#Reference4.92">92</a></P><a name="Section_262" /><P __id="_262">A case-control study drawn from multiple-case families from high-risk clinics was performed evaluating oral contraceptive use among 207
women with a <Span Class="Protocol-GeneName">BRCA1</Span> high-risk mutation and ovarian cancer, and as controls, 161
of their sisters who had not been diagnosed with ovarian cancer.  Oral contraceptive use was associated with a reduced risk of ovarian cancer, and the magnitude of the association appeared to exist between oral contraceptive use and decreased risk
of ovarian cancer.  The association increased with duration of use.  Women who
took oral contraceptives for more than 6 years had a 60% reduction in risk. 
This reduction was similar for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> high-risk mutation carriers.<a href="#Reference4.39">39</a> 
A large,
population-based case-control study of ovarian cancer among 244 Jewish women in
Israel found the risk of ovarian cancer among <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers
decreased with each birth, but not with use of oral
contraceptives (OR = 1.07 for 5 or more years of use), though they were protective, as expected, among noncarriers (OR = 0.53 for 5 or more years of use).<a href="#Reference4.92">92</a> A small population-based case-control study of 36 <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers from the San Francisco Bay Area, however, observed a similar, protective effect in both mutation carriers and noncarriers (OR = approximately 0.5).<a href="#Reference4.91">91</a>  Finally, a multicenter study of subjects drawn from numerous registries observed a protective effect of oral contraceptives among the 147 <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers with ovarian cancer compared with the 304 matched mutation carriers without cancer (OR = 0.62 for 6 or more years of use).<a href="#Reference4.90">90</a>
</P><a name="Section_263" /><P __id="_263">As noted under oral contraceptives in the Breast Cancer Prevention section of
this summary, there are conflicting data regarding their effect on breast cancer risk, with some retrospective case-control studies suggesting that oral
contraceptive use increases the risk of breast cancer in women at
inherited risk of breast cancer,<a href="#Reference4.31">31</a><a href="#Reference4.93">93</a> including <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers,<a href="#Reference4.32">32</a> while a population-based study found a reduced risk among <Span Class="Protocol-GeneName">BRCA1</Span>-mutation carriers.<a href="#Reference4.94">94</a>
</P><a name="Section_264" /><P __id="_264">Level of evidence: 3
</P>
</a>
</a>
<a name="Section_401">

<Span class="Summary-SummarySection-Title-Level4">Risk-Reducing Oophorectomy</Span>


<a name="Section_266" /><P __id="_266">Numerous studies have found that women at inherited risk of breast and ovarian cancer have a decreased risk of ovarian cancer following risk-reducing oophorectomy.  A retrospective study of 551 women with disease-associated <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations found a significant reduction in risk of breast cancer (HR = 0.47; 95% CI, 0.29-0.77) and ovarian cancer (HR = 0.04; 95% CI, 0.01-0.16) after bilateral oophorectomy.<a href="#Reference4.37">37</a> A prospective single-institution study of 170 women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations showed a similar trend.<a href="#Reference4.38">38</a> With oophorectomy, the HR was 0.15 (95% CI, 0.02-1.31) for ovarian, fallopian tube, or primary peritoneal cancer, and 0.32 (95% CI, 0.08-1.2) for breast cancer; the HR for either cancer was 0.25 (95% CI, 0.08-0.74).  In a case-control study in Israel, bilateral oophorectomy was associated with reduced ovarian/peritoneal cancer risks (OR = 0.12; 95% CI, 0.06-0.24).<a href="#Reference4.88">88</a>
</P><a name="Section_794" /><P __id="_794">Studies on the degree of risk reduction afforded by risk-reducing oophorectomy have begun to clarify the spectrum of occult cancers discovered at the time of surgery.  Primary fallopian tube cancers, primary peritoneal cancers, and occult ovarian cancers have all been reported.  Several case series have reported a prevalence of malignant findings among mutation carriers undergoing risk-reducing oophorectomy to be in the range of 2.3% to 33%, with a median age of the affected women in the range of 42 to 48 years.<a href="#Reference4.95">95</a><a href="#Reference4.96">96</a><a href="#Reference4.97">97</a><a href="#Reference4.98">98</a> The wide variation in prevalence is likely due to differences in surgical technique and pathologic handling of the tissues.  In addition to occult cancers, premalignant lesions have also been described in fallopian tube tissue removed for prophylaxis.  In 1 series of 12 women with <Span Class="Protocol-GeneName">BRCA1</Span> mutations undergoing risk-reducing surgery, 11 had hyperplastic or dysplastic lesions identified in the tubal epithelium.  In several of the cases the lesions were multifocal.<a href="#Reference4.99">99</a> These surgical findings in prophylactic specimens are consistent with the identification of germline <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutations in women affected with both tubal and primary peritoneal cancers.<a href="#Reference4.100">100</a><a href="#Reference4.101">101</a><a href="#Reference4.102">102</a><a href="#Reference4.103">103</a><a href="#Reference4.104">104</a><a href="#Reference4.105">105</a></P><a name="Section_795" /><P __id="_795">These findings support the inclusion of fallopian tube cancers, which account for &lt;1% of all gynecologic cancers in the general population, as a component of hereditary ovarian cancer, and underscore the need for the routine collection of peritoneal washings and careful pathologic evaluation of all tissue obtained at the time of prophylactic surgery.  They also raise questions about the optimal surgical approach to provide maximal cancer risk reduction.  Some surgeons have recommended  hysterectomy in addition to bilateral salpingo-oophorectomy to remove the remnant of fallopian tube tissue embedded in the uterus, but there is no consensus  on this issue.  There is also the suggestion that uterine serous papillary carcinoma may be a <Span Class="Protocol-GeneName">BRCA1</Span>-related cancer,<a href="#Reference4.106">106</a> which might support a role for risk-reducing hysterectomy, but further studies are needed to establish this association.</P><a name="Section_899" /><P __id="_899">The
peritoneum, however, appears to remain at risk for the development of a
Mullerian-type adenocarcinoma, even after oophorectomy.<a href="#Reference4.107">107</a><a href="#Reference4.108">108</a><a href="#Reference4.109">109</a><a href="#Reference4.110">110</a><a href="#Reference4.111">111</a>  Of the 324
women from the Gilda Radner Familial Ovarian Cancer Registry who underwent
risk-reducing oophorectomy, 6 (1.8%) subsequently developed primary peritoneal
carcinoma.  No period of follow-up was specified.<a href="#Reference4.112">112</a> Among 238 individuals in the Creighton Registry with <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations who underwent risk-reducing oophorectomy, 5 subsequently developed intra-abdominal carcinomatosis (2.1%). Of note, all 5 of these women had  <Span Class="Protocol-GeneName">BRCA1</Span> mutations.<a href="#Reference4.113">113</a></P><a name="Section_821" /><P __id="_821">Levels of evidence: 3, 5
</P>
<a name="Section_853" /><P __id="_853">The risks of HRT for women who have mutations and undergo risk-reducing oophorectomy are uncertain. For women who are premenopausal at the time of surgery, the symptoms of surgical menopause (e.g., hot flashes, mood swings, weight gain, and genitourinary complaints) can cause a significant impairment in their quality of life. To reduce the impact of these symptoms, providers have often prescribed a time-limited course of systemic HRT after surgery.  There are no clinical studies addressing the safety of this practice and there are theoretical concerns that HRT may reduce the degree of breast cancer risk-reduction experienced by women undergoing premature menopause.   </P><a name="Section_866" /><P __id="_866">A Markov decision-analytic model suggests that HRT until age 50 is not likely to have a major negative impact on life expectancy in unaffected women undergoing oophorectomy.<a href="#Reference4.114">114</a> As decision-analytic models are very sensitive to the accuracy of the underlying assumptions, it seems prudent, in the absence of clinical data, to limit the dose and duration of systemic HRT to the minimum required to preserve quality of life and to discontinue it at the earliest opportunity, before age 50. There are insufficient data to determine whether systemic estrogen-only replacement (in women who have undergone hysterectomy) is safer than combined HRT in women with <Span Class="Protocol-GeneName">BRCA</Span> mutations, and similar considerations should hold for both forms of treatment. Women with predominantly genitourinary symptoms, however, may benefit from local estrogen therapy, which, in theory, should not be associated with an increased risk of breast cancer since systemic absorption is minimal. Recent reports from the Women’s Health Initiative cast doubt on the efficacy of HRT in managing genitourinary symptoms in postmenopausal women.<a href="#Reference4.115">115</a>  Women who have undergone risk-reducing mastectomy and are at limited risk for breast cancer may be better candidates for long-term systemic HRT with either estrogen-only or combined HRT, but even in this group complete safety cannot be assured. There are no data that address the risks and benefits of HRT in women with mutations who have a personal history of breast cancer.</P><a name="Section_854" /><P __id="_854">The risk-to-benefit ratio of HRT for postmenopausal women in the general population appears to be unfavorable, and several studies demonstrated an increase in the risk of breast cancer among such women.<a href="#Reference4.41">41</a> There are no studies specifically addressing the safety of systemic HRT in mutation carriers who are postmenopausal at the time of oophorectomy, and who have breast tissue at risk. Local estrogen treatment for women with genitourinary symptoms may still be considered. Unaffected women who have undergone bilateral mastectomy for risk reduction may be better candidates for HRT.</P></a>
</a>
</a>

       <a name="ReferenceSection"><p><Span Class="Summary-ReferenceSection">
							References
						</Span><ol><li><a name="Reference4.1" />Thomas DB, Gao DL, Self SG, et al.: Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 89 (5): 355-65, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060957&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.2" />Scheuer L, Kauff N, Robson M, et al.: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (5): 1260-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11870168&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.3" />Brekelmans CT, Seynaeve C, Bartels CC, et al.: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19 (4): 924-30, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11181654&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.4" />Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277 (12): 997-1003, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9091675&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.5" />Shapiro S: Periodic screening for breast cancer: the Health Insurance Plan project and its sequelae, 1963-1986. Baltimore, Md: Johns Hopkins University Press, 1988 
			<A /><br /><br /></li><li><a name="Reference4.6" />Kerlikowske K, Grady D, Barclay J, et al.: Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276 (1): 33-8, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667536&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.7" />Kerlikowske K, Carney PA, Geller B, et al.: Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133 (11): 855-63, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11103055&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.8" />Kerlikowske K, Grady D, Barclay J, et al.: Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 (20): 2444-50, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8230621&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.9" />Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al.: A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (1): 91-5, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12353239&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.10" />Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.11" />Sharan SK, Morimatsu M, Albrecht U, et al.: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 (6627): 804-10, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9126738&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.12" />Gowen LC, Avrutskaya AV, Latour AM, et al.: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281 (5379): 1009-12, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9703501&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.13" />Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90 (13): 978-85, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9665145&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.14" />Kuhl CK, Schrading S, Leutner CC, et al.: Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First midterm results of a multi-modality clinical screening trial . [Abstract] Proceedings of the American Society of Clinical Oncology  22: A-4,      2, 2003 <a Class="Protocol-ExternalRef" href="http://www.asco.org/ac/1,1003,_12-002643-00_18-0023-00_19-00101944,00.asp">Also available online.</a> Last accessed November 18, 2005. 
			<A /><br /><br /></li><li><a name="Reference4.15" />Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (5): 427-37, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15282350&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.16" />Lehman CD, Blume JD, Weatherall P, et al.: Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103 (9): 1898-905, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15800894&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.17" />Leach MO, Boggis CR, Dixon AK, et al.: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (9473): 1769-78, 2005 May 21-27. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15910949&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.18" />Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (11): 1317-25, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15367553&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.19" />O'Driscoll D, Warren R, MacKay J, et al.: Screening with breast ultrasound in a population at moderate risk due to family history. J Med Screen 8 (2): 106-9, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11480440&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.20" />Dooley WC, Ljung BM, Veronesi U, et al.: Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93 (21): 1624-32, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11698566&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.21" />O'Shaughnessy JA, Ljung BM, Dooley WC, et al.: Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 94 (2): 292-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11900214&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.22" />Shtern F: Digital mammography and related technologies: a perspective from the National Cancer Institute. Radiology 183 (3): 629-30, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1584908&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.23" />Lewin JM, D'Orsi CJ, Hendrick RE, et al.: Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am J Roentgenol 179 (3): 671-7, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12185042&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.24" />Colditz GA, Rosner BA, Speizer FE: Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J Natl Cancer Inst 88 (6): 365-71, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8609646&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.25" />Narod S, Lynch H, Conway T, et al.: Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet 341 (8852): 1101-2, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8097005&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.26" />Narod SA, Goldgar D, Cannon-Albright L, et al.: Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64 (6): 394-8, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8550241&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.27" />McCredie M, Paul C, Skegg DC, et al.: Family history and risk of breast cancer in New Zealand. Int J Cancer 73 (4): 503-7, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9389563&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.28" />Collaborative Group on Hormonal Factors in Breast Cancer.: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.29" />Jernström H, Lubinski J, Lynch HT, et al.: Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96 (14): 1094-8, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15265971&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.30" />Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347 (9017): 1713-27, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8656904&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.31" />Ursin G, Henderson BE, Haile RW, et al.: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57 (17): 3678-81, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9288771&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.32" />Narod SA, Dubé MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (23): 1773-9, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12464649&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.33" />Olsson H, Jernström H, Alm P, et al.: Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Treat 40 (2): 187-96, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8879685&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.34" />Olson JE, Sellers TA, Iturria SJ, et al.: Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detect Prev 28 (5): 357-60, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15542261&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.35" />Struewing JP, Watson P, Easton DF, et al.: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr  (17): 33-5, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8573450&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.36" />Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (17): 1475-9, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10469748&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.37" />Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.38" />Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.39" />Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339 (7): 424-8, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9700175&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.40" />Chen CL, Weiss NS, Newcomb P, et al.: Hormone replacement therapy in relation to breast cancer. JAMA 287 (6): 734-41, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11851540&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.41" />Writing Group for the Women's Health Initiative Investigators.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-33, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.42" />Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (24): 3243-53, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.43" />Schuurman AG, van den Brandt PA, Goldbohm RA: Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control 6 (5): 416-24, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8547539&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.44" />Steinberg KK, Thacker SB, Smith SJ, et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265 (15): 1985-90, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1826136&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.45" />Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168 (5): 1473-80, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8498430&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.46" />Sellers TA, Mink PJ, Cerhan JR, et al.: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127 (11): 973-80, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412302&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.47" />Stanford JL, Weiss NS, Voigt LF, et al.: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274 (2): 137-42, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7596001&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.48" />Gorsky RD, Koplan JP, Peterson HB, et al.: Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 83 (2): 161-6, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8290175&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.49" />Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371-88, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9747868&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.50" />Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122): 93-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672273&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.51" />Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98-101, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672274&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.52" />King MC, Wieand S, Hale K, et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286 (18): 2251-6, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11710890&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.53" />Ariyan S: Prophylactic mastectomy for precancerous and high-risk lesions of the breast. Can J Surg 28 (3): 262-4, 266, 1985. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3995424&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.54" />Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.55" />Hartmann LC, Sellers TA, Schaid DJ, et al.: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 (21): 1633-7, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11698567&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.56" />Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 (3): 159-64, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11463009&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.57" />Rebbeck TR, Friebel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 (6): 1055-62, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14981104&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.58" />Kauff ND, Brogi E, Scheuer L, et al.: Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97 (7): 1601-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12655515&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.59" />Hoogerbrugge N, Bult P, de Widt-Levert LM, et al.: High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21 (1): 41-5, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12506168&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.60" />Scott CI, Iorgulescu DG, Thorne HJ, et al.: Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 64 (2): 111-21, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12859406&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.61" />Adem C, Reynolds C, Soderberg CL, et al.: Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97 (1): 1-11, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12491499&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.62" />Lerman C, Hughes C, Croyle RT, et al.: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31 (1): 75-80, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896846&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.63" />Stefanek ME, Helzlsouer KJ, Wilcox PM, et al.: Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 24 (4): 412-9, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7479633&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.64" />Schrag D, Kuntz KM, Garber JE, et al.: Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336 (20): 1465-71, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9148160&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.65" />Unic I, Stalmeier PF, Verhoef LC, et al.: Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer. Med Decis Making 18 (3): 268-77, 1998 Jul-Sep. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9679991&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.66" />Grann VR, Panageas KS, Whang W, et al.: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16 (3): 979-85, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9508180&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.67" />Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al.: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 (9220): 2015-20, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10885351&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.68" />King MC, Marks JH, Mandell JB, et al.: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (5645): 643-6, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14576434&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.69" />Dørum A, Kristensen GB, Abeler VM, et al.: Early detection of familial ovarian cancer. Eur J Cancer 32A (10): 1645-51, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8983269&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.70" />Tailor A, Bourne TH, Campbell S, et al.: Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 21 (4): 378-85, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12704748&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.71" />Karlan BY, Platt LD: Ovarian cancer screening. The role of ultrasound in early detection. Cancer 76 (10 Suppl): 2011-5, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8634993&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.72" />Karlan BY, Raffel LJ, Crvenkovic G, et al.: A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 169 (3): 494-501, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8372851&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.73" />NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273 (6): 491-7, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7837369&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.74" />Kramer BS, Gohagan J, Prorok PC, et al.: A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71 (2 Suppl): 589-93, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8420681&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.75" />Van Nagell JR Jr, DePriest PD, Puls LE, et al.: Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 68 (3): 458-62, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2065264&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.76" />Fleischer AC, Cullinan JA, Peery CV, et al.: Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am J Obstet Gynecol 174 (1 Pt 1): 101-6, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8571991&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.77" />Weiner Z, Beck D, Shteiner M, et al.: Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 12 (7): 387-93, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8355333&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.78" />Muto MG, Cramer DW, Brown DL, et al.: Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 51 (1): 12-20, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8244166&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.79" />Greene MH , Gynecologic Oncology Group: Prospective Screening Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA 125 Screening in Participants at Increased Genetic Risk of Ovarian Cancer, GOG-0199, Clinical trial, Active. 
			<A href="/search/viewclinicaltrials.aspx?version=&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;healthprofessional&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&amp;cdrid=257695"><span class="Summary-Citation-PUBMED">[PDQ Clinical Trial]</span></A><br /><br /></li><li><a name="Reference4.80" />Skates SJ, Menon U, MacDonald N, et al.: Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. J Clin Oncol 21 (10 Suppl): 206-10, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743136&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.81" />Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (23): 1774-86, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9839517&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.82" />Hankinson SE, Colditz GA, Hunter DJ, et al.: A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76 (2): 284-90, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8625104&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.83" />Vachon CM, Mink PJ, Janney CA, et al.: Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology 13 (1): 66-71, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11805588&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.84" />Godard B, Foulkes WD, Provencher D, et al.: Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 179 (2): 403-10, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9731846&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.85" />Kerber RA, Slattery ML: The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 155 (9): 905-12, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7726698&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.86" />Lacey JV Jr, Mink PJ, Lubin JH, et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (3): 334-41, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117398&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.87" />Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357 (9267): 1467-70, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11377596&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.88" />Rutter JL, Wacholder S, Chetrit A, et al.: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95 (14): 1072-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12865453&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.89" />Miracle-McMahill HL, Calle EE, Kosinski AS, et al.: Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 145 (4): 349-57, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9054239&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.90" />Whittemore AS, Balise RR, Pharoah PD, et al.: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 (11): 1911-5, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15545966&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.91" />McGuire V, Felberg A, Mills M, et al.: Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160 (7): 613-8, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15383404&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.92" />Modan B, Hartge P, Hirsh-Yechezkel G, et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 (4): 235-40, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11474660&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.93" />Grabrick DM, Hartmann LC, Cerhan JR, et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284 (14): 1791-8, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11025831&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.94" />Milne RL, Knight JA, John EM, et al.: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14 (2): 350-6, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15734957&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.95" />Leeper K, Garcia R, Swisher E, et al.: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87 (1): 52-6, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12468342&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.96" />Olivier RI, van Beurden M, Lubsen MA, et al.: Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90 (8): 1492-7, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15083174&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.97" />Colgan TJ, Murphy J, Cole DE, et al.: Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25 (10): 1283-9, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11688463&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.98" />Powell CB, Kenley E, Chen LM, et al.: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23 (1): 127-32, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15625367&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.99" />Piek JM, van Diest PJ, Zweemer RP, et al.: Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195 (4): 451-6, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11745677&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.100" />Paley PJ, Swisher EM, Garcia RL, et al.: Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80 (2): 176-80, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11161856&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.101" />Rose PG, Shrigley R, Wiesner GL: Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 77 (2): 319-20, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10785486&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.102" />Zweemer RP, van Diest PJ, Verheijen RH, et al.: Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 76 (1): 45-50, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10620440&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.103" />Piek JM, Torrenga B, Hermsen B, et al.: Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer 2 (2): 73-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14574155&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.104" />Levine DA, Argenta PA, Yee CJ, et al.: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 (22): 4222-7, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14615451&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.105" />Aziz S, Kuperstein G, Rosen B, et al.: A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80 (3): 341-5, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11263928&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.106" />Hornreich G, Beller U, Lavie O, et al.: Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 75 (2): 300-4, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10525392&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.107" />Chen KT, Schooley JL, Flam MS: Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66 (3 Suppl): 93S-94S, 1985. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4022524&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.108" />Lynch HT, Bewtra C, Lynch JF: Familial ovarian carcinoma. Clinical nuances. Am J Med 81 (6): 1073-6, 1986. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3799638&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.109" />Lynch HT, Watson P, Bewtra C, et al.: Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 67 (5): 1460-6, 1991. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1991314&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.110" />Tobacman JK, Greene MH, Tucker MA, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (8302): 795-7, 1982. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6126666&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.111" />Truong LD, Maccato ML, Awalt H, et al.: Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 21 (1): 99-110, 1990. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1688545&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.112" />Piver MS, Jishi MF, Tsukada Y, et al.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (9): 2751-5, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8467455&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.113" />Casey MJ, Synder C, Bewtra C, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 97 (2): 457-67, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15863145&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.114" />Armstrong K, Schwartz JS, Randall T, et al.: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22 (6): 1045-54, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14981106&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference4.115" />Hendrix SL, Cochrane BB, Nygaard IE, et al.: Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 (8): 935-48, 2005. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15728164&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li></ol></p></a></a><a name="Section_271">
        <Span class="Summary-SummarySection-Title-Level1">Psychosocial Issues in Inherited Breast Cancer Syndromes</Span><br /><br />

<a name="Section_272"><Span class="Summary-SummarySection-Title-Level2">Introduction</Span>
<a name="Section_273" /><P __id="_273">Psychosocial research in the context of cancer genetic testing helps to define
psychological outcomes, interpersonal and familial effects, and cultural and
community reactions.  It also identifies behavioral factors that encourage or
impede surveillance and other health behaviors.  It can enhance decision-making
about risk-reduction interventions, evaluate psychosocial interventions to
reduce distress and/or other negative sequelae related to risk notification and
genetic testing, provide data to help resolve ethical concerns, and predict the
interest in testing of various groups. 
</P>

<a name="Section_275" /><P __id="_275">Research in these areas includes few randomized controlled trials, and many
reports are based on uncontrolled studies of selected high-risk populations. 
Research is likely to expand considerably with access to larger populations of
at-risk individuals.
</P>
<a name="Section_593" /><P __id="_593">There have been a number of descriptions of cancer genetics programs that provide <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=256553&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000256553&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic susceptibility</a> testing.<a href="#Reference5.1">1</a> <a href="#Reference5.2">2</a><a href="#Reference5.3">3</a><a href="#Reference5.4">4</a><a href="#Reference5.5">5</a><a href="#Reference5.6">6</a><a href="#Reference5.7">7</a><a href="#Reference5.8">8</a><a href="#Reference5.9">9</a> The development of such programs was encouraged by federal funding of multidisciplinary research programs that offered intensive <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=44961&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044961&amp;version=HealthProfessional&amp;language=English');  return(false);">genetic counseling</a> for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339343&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339343&amp;version=HealthProfessional&amp;language=English');  return(false);">hereditary cancer syndromes</a>, psychological assessment and back-up, and physician involvement.<a href="#Reference5.10">10</a></P></a>
<a name="Section_276"><Span class="Summary-SummarySection-Title-Level2">Anticipated and Actual Interest in Genetic Testing</Span>


<a name="Section_279" /><P __id="_279">Anticipated interest in breast cancer genetic testing has overestimated uptake rates for <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> testing.  Interest ranged from 41% to 93%.<a href="#Reference5.11">11</a><a href="#Reference5.12">12</a><a href="#Reference5.13">13</a><a href="#Reference5.14">14</a><a href="#Reference5.15">15</a><a href="#Reference5.16">16</a><a href="#Reference5.17">17</a><a href="#Reference5.18">18</a><a href="#Reference5.19">19</a> Among samples of women at higher-than-average breast cancer risk seen in clinical and research settings, uptake of testing was lower, ranging from 26% to 78%.<a href="#Reference5.20">20</a><a href="#Reference5.21">21</a><a href="#Reference5.22">22</a><a href="#Reference5.23">23</a><a href="#Reference5.24">24</a><a href="#Reference5.25">25</a><a href="#Reference5.26">26</a><a href="#Reference5.27">27</a> The discrepancy between interest and uptake on genetic testing for breast cancer is consistent with the literature on colorectal cancer and Huntington’s disease.<a href="#Reference5.28">28</a><a href="#Reference5.29">29</a><a href="#Reference5.30">30</a><a href="#Reference5.31">31</a></P>

<a name="Section_281" /><P __id="_281">The level of uptake of genetic testing in research studies is variable, ranging from 26% to 78%.<a href="#Reference5.20">20</a><a href="#Reference5.21">21</a><a href="#Reference5.24">24</a><a href="#Reference5.25">25</a><a href="#Reference5.26">26</a><a href="#Reference5.27">27</a> Accrual statistics in different populations are
difficult to compare because there are many points in the genetic
<a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460214&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460214&amp;version=HealthProfessional&amp;language=English');  return(false);">risk assessment</a> process at which a family member can decline, and no standard
method of reporting these rates has been developed.<a href="#Reference5.32">32</a>   With the advent of clinical testing, it is impossible to measure uptake rates because patients are self-referred.  Factors that may influence uptake of testing include:</P>
<a name="Section_594" /><a name="ListSection" /><UL __id="_594" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Cost of genetic testing.</LI><LI class="Protocol-IL-Bullet">How informative testing would be (e.g., presence of a known <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=46063&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=HealthProfessional&amp;language=English');  return(false);">mutation</a> in the family or ethnic group vs. lack of an identified mutation).</LI><LI class="Protocol-IL-Bullet">Extent to which genetic test results are likely to influence clinical decision-making.<a href="#Reference5.27">27</a></LI></UL><a name="END_ListSection" /><a name="Section_629" /><P __id="_629">Limited data are available about the characteristics of at-risk individuals who decline to be or have never been tested.  It is difficult to access samples of test decliners since they are people who also may be reluctant to participate in research studies. Studies of testing are difficult to compare because people may decline at different points and with different amounts of pretest education and counseling. One study found that 43% of affected and unaffected individuals from hereditary breast/ovarian cancer families completing a baseline interview regarding testing declined. Most individuals declining testing chose not to participate in educational sessions. Decliners were more likely to be male and unmarried and had fewer relatives affected with breast cancer. Those decliners who had high levels of cancer-related stress had higher levels of depression. Decliners lost to follow-up were significantly more likely to be affected with cancer.<a href="#Reference5.25">25</a> Another study looked at a small number (n = 13) of women decliners who carry a 25% to 50% probability of harboring a <Span Class="Protocol-GeneName">BRCA</Span> mutation and found that these nontested women were more likely to be childless and have a higher educational level. This study showed that most women had decided not to undergo the test after serious deliberation about the risks and benefits. Satisfaction with frequent surveillance was given as 1 reason for nontesting in most of these women.<a href="#Reference5.33">33</a> Other reasons for declining included having no children and becoming acquainted with breast/ovarian cancer in the family relatively early in their lives.<a href="#Reference5.25">25</a><a href="#Reference5.33">33</a> A third study evaluated characteristics of 34 individuals who declined <Span Class="Protocol-GeneName">BRCA1/2</Span> testing in a large multicenter study in the United Kingdom. Decliners were younger compared with a national sample of test acceptors, and female decliners had lower mean scores on a measure of cancer worry. Although 78% of test decliners/deferrers felt that their health was at risk, they reported that learning about their <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation status would cause them to worry about:</P><a name="Section_875" /><a name="ListSection" /><UL __id="_875" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Their children's health (76%).</LI><LI class="Protocol-IL-Bullet">Their life insurance (60%).</LI><LI class="Protocol-IL-Bullet">Their own health (56%).</LI><LI class="Protocol-IL-Bullet">Loss of their job (5%).</LI><LI class="Protocol-IL-Bullet">Receiving less <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460216&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460216&amp;version=HealthProfessional&amp;language=English');  return(false);">screening</a> if they did not carry a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation (62%).</LI></UL><a name="END_ListSection" /><a name="Section_877" /><P __id="_877">Apprehension about the impact of the test result was a more important factor in the reason to decline than concrete burdens such as time to travel to a genetics clinic and time away from work, family, and social obligations.<a href="#Reference5.34">34</a></P><a name="Section_595" /><P __id="_595">Participation in breast cancer risk counseling among family relatives of breast
cancer patients is positively associated with higher levels of education,
income, and positive health behaviors (nonsmokers, any current alcohol use,
recent clinical breast exam), and perceived and objective risk perception.<a href="#Reference5.17">17</a><a href="#Reference5.35">35</a> Other predictors of
participation are being married, having a <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=302456&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000302456&amp;version=HealthProfessional&amp;language=English');  return(false);">family history</a> of cancer, presence of a
daughter, fear of stigma, and believing there are more reasons to be tested
than not to be tested.<a href="#Reference5.36">36</a></P><a name="Section_282" /><P __id="_282">  Women recruited from high-risk clinics, i.e., women
who have expressed their concern about breast cancer by seeking specialized
medical attention, are more likely than women recruited from registry sources
to attend counseling and educational sessions about cancer genetics and genetic
testing.<a href="#Reference5.37">37</a><a href="#Reference5.38">38</a> Genetic testing uptake was influenced by eligibility for free testing, history of breast or ovarian cancer, and <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460127&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460127&amp;version=HealthProfessional&amp;language=English');  return(false);">Ashkenazi Jewish</a> heritage.<a href="#Reference5.27">27</a>  Interest in testing declines sharply if it is not immediately available.<a href="#Reference5.37">37</a> Knowledge about the details of cancer genetic testing is not associated with the decision to be tested,<a href="#Reference5.12">12</a> suggesting a need for improved education about cancer genetics.  Several studies suggest that interest in cancer genetic testing is generally high despite respondents' relative lack of knowledge regarding the pros and cons of attempting to learn one's mutation status.<a href="#Reference5.35">35</a> There are limited data on uptake among nonwhite populations, and further research will be needed to define factors influencing uptake in these populations.<a href="#Reference5.38">38</a></P>

<a name="Section_284" /><P __id="_284">Motivations for testing include the belief that testing positive would increase
one’s motivation to get regular clinical breast examinations, to do breast
self-exams, and to get recommended mammograms.<a href="#Reference5.39">39</a>  Women known to be at
increased risk do not necessarily adhere to screening recommendations at higher
rates than women at population risk, nor do they necessarily pursue or complete
genetic testing, though the data on this subject are contradictory.<a href="#Reference5.37">37</a><a href="#Reference5.40">40</a><a href="#Reference5.41">41</a> 
An additional motivation for testing is to receive information that would
benefit other family members.<a href="#Reference5.26">26</a> Lastly, other motivators for testing may include recommendation by a physician.  In a retrospective study of 335 women considering genetic testing, 77% reported that they wanted the opinion of the genetics physician about whether they should be tested, and 49% wanted the opinion of their primary care provider.<a href="#Reference5.42">42</a></P>
</a>
<a name="Section_285"><Span class="Summary-SummarySection-Title-Level2">What People Bring to Genetic Testing: Impact of Risk Perception, Health Beliefs, and Personality Characteristics</Span>
<a name="Section_286" /><P __id="_286">The emerging literature in this area suggests that risk perceptions,
health beliefs, psychological status, and personality characteristics are important factors in
decision-making about breast/ovarian cancer genetic testing.  Many women
presenting at academic centers for <Span Class="Protocol-GeneName">BRCA1/2</Span> testing arrive with a strong belief
that they have a mutation, having decided they want genetic testing, but
possessing little information about the risks or limitations of testing.<a href="#Reference5.43">43</a> Most mean scores of psychological functioning at baseline for subjects in genetic counseling studies were within normal limits.<a href="#Reference5.44">44</a>  Nonetheless, a subset of subjects in many genetic counseling studies present with elevated anxiety, depression, or cancer worry.  Identification of these individuals is essential to prevent adverse outcomes.
</P>
<a name="Section_287" /><P __id="_287">A general tendency to overestimate inherited risk of breast and ovarian cancer
has been noted in at-risk populations,<a href="#Reference5.45">45</a><a href="#Reference5.46">46</a> in cancer patients,<a href="#Reference5.19">19</a><a href="#Reference5.46">46</a><a href="#Reference5.47">47</a> in spouses of breast and ovarian cancer patients,<a href="#Reference5.48">48</a> and among
women in the general population.<a href="#Reference5.49">49</a><a href="#Reference5.50">50</a><a href="#Reference5.51">51</a>  This tendency may encourage a belief that
<Span Class="Protocol-GeneName">BRCA1/2</Span> genetic testing will be more informative than it is currently thought
to be.  There is some evidence that even counseling does not dissuade women at
low to moderate risk from the belief that <Span Class="Protocol-GeneName">BRCA1</Span> testing could be valuable.<a href="#Reference5.38">38</a> 
 Overestimation of both breast and ovarian cancer risk has been associated with nonadherence to physician-recommended screening practices.<a href="#Reference5.52">52</a><a href="#Reference5.53">53</a> A meta-analysis of 12 studies of outcomes of genetic counseling for breast/ovarian cancer showed that counseling improved the accuracy of risk perception.<a href="#Reference5.54">54</a></P>
<a name="Section_288" /><P __id="_288">Women appear to be the prime communicators within families about the family
history of breast cancer.<a href="#Reference5.55">55</a>  Higher numbers of maternal versus paternal
transmission cases are reported, likely due to family communication
patterns, to the misconception that breast cancer risk can only be transmitted
through the mother, and to the greater difficulty in recognizing paternal
family histories because of the need to identify more distant relatives with
cancer.  Physicians and counselors taking a family history are encouraged to
elicit paternal as well as maternal family histories of breast, ovarian, or
other associated cancers.<a href="#Reference5.55">55</a> 
</P>
<a name="Section_289" /><P __id="_289">The accuracy of reported family history of breast or ovarian cancer varies;
some studies found levels of accuracy above 90%,<a href="#Reference5.56">56</a><a href="#Reference5.57">57</a> with others finding
more errors in the reporting of cancer in second-degree or more distant
relatives.<a href="#Reference5.58">58</a>  Less accuracy has been found in the reporting of cancers other
than breast cancer.  Ovarian cancer history was reported with 60% accuracy in
one study compared with 83% accuracy in breast cancer history.<a href="#Reference5.59">59</a>  Providers
should be aware that there are a few published cases of Munchausen syndrome in
reporting of false family breast cancer history.<a href="#Reference5.60">60</a>  Much more common is
erroneous reporting of family cancer history due to unintentional errors or
gaps in knowledge, related in some cases to the early death of potential
maternal informants about cancer family history.<a href="#Reference5.55">55</a>
(Refer to the <SummaryRef href="CDR0000062865#_18">Taking a Family History</SummaryRef> section of the <SummaryRef href="CDR0000062865">Elements of Cancer Genetics Risk Assessment and Counseling</SummaryRef> summary.)</P><a name="Section_403" /><P __id="_403">Targeted written,<a href="#Reference5.61">61</a> video, CD-ROM, interactive computer program,<a href="#Reference5.62">62</a><a href="#Reference5.63">63</a><a href="#Reference5.64">64</a> and culturally targeted educational materials <a href="#Reference5.65">65</a> may be an effective and efficient means of increasing knowledge about the pros and cons of genetic testing.  Such supplemental materials may allow more efficient use of the time allotted for pretest education and counseling by genetics and primary care providers and may discourage ineligible individuals from seeking genetic testing.<a href="#Reference5.61">61</a> </P>
</a>
<a name="Section_290"><Span class="Summary-SummarySection-Title-Level2">Genetic Counseling for Hereditary Predisposition to Breast Cancer</Span>
<a name="Section_291" /><P __id="_291">Counseling for breast cancer risk typically involves individuals with family
histories that are potentially attributable to <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span>.  It also, however,
may include individuals with family histories of Li-Fraumeni Syndrome, ataxia-telangiectasia, Cowden’s disease, or Peutz-Jeghers syndrome.<a href="#Reference5.66">66</a>  (See the <SummaryRef href="CDR0000062855#_88">Major
Genes</SummaryRef> section of this summary.)
</P>
<a name="Section_292" /><P __id="_292">Management strategies for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460132&amp;version=HealthProfessional&amp;language=English');  return(false);">carriers</a> may involve decisions about the nature, frequency, and
timing of screening and surveillance procedures, chemoprevention, risk-reducing surgery, and use of
hormone replacement therapy. The utilization of breast conservation and
radiation as cancer therapy for women who are carriers may be influenced by knowledge of mutation status.  (See the <SummaryRef href="CDR0000062855#_575">Interventions</SummaryRef> section of this summary.)
</P>
<a name="Section_293" /><P __id="_293">Counseling also includes consideration of related psychosocial concerns and
discussion of planned family communication and the responsibility to warn other
family members about the possibility of having an increased risk of breast,
ovarian, and other cancers.  Data are emerging that individual responses to being tested as adults are influenced by the results status of other family members.<a href="#Reference5.24">24</a><a href="#Reference5.67">67</a> Management of anxiety and distress are important
not only as quality-of-life factors, but also because high anxiety may
interfere with the understanding and integration of complex genetic and medical
information as well as adherence to screening.<a href="#Reference5.40">40</a><a href="#Reference5.41">41</a><a href="#Reference5.68">68</a>  The limited number of
medical interventions with proven benefit to mutation carriers provides further
basis for the expectation that mutation carriers may experience increased
anxiety, depression, and continuing uncertainty following disclosure of genetic
test results.<a href="#Reference5.69">69</a>  Formal, objective evaluation of these outcomes are now
emerging.  (Refer to the sections below on <SummaryRef href="CDR0000062855#_298">Emotional Outcomes</SummaryRef> and <SummaryRef href="CDR0000062855#_332">Behavioral Outcomes</SummaryRef>.)
</P>

<a name="Section_295" /><P __id="_295">Published descriptions of counseling programs for <Span Class="Protocol-GeneName">BRCA1</Span> (and subsequently for
<Span Class="Protocol-GeneName">BRCA2</Span>) testing include strategies for gathering a family history, assessing
eligibility for testing, communicating the considerable volume of relevant
information about breast/ovarian cancer genetics and associated medical and
psychosocial risks and benefits, and discussion of specialized ethical
considerations about confidentiality and family communication.<a href="#Reference5.3">3</a><a href="#Reference5.70">70</a><a href="#Reference5.71">71</a><a href="#Reference5.72">72</a><a href="#Reference5.73">73</a><a href="#Reference5.74">74</a><a href="#Reference5.75">75</a><a href="#Reference5.76">76</a> 
Participant distress, intrusive thoughts about cancer, coping style, and social
support were assessed in many prospective testing candidates.  The psychosocial
outcomes evaluated in these programs have included changes in knowledge about
the genetics of breast/ovarian cancer after counseling, risk comprehension,
psychological adjustment, family and social functioning, and reproductive and
health behaviors.<a href="#Reference5.77">77</a>  
</P>
<a name="Section_296" /><P __id="_296">Many of the psychosocial outcome studies involve specialized, highly selected
research populations, some of which were utilized to map and clone <Span Class="Protocol-GeneName">BRCA1</Span> and
<Span Class="Protocol-GeneName">BRCA2</Span>.  One such example is K2082, an extensively studied <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460158&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460158&amp;version=HealthProfessional&amp;language=English');  return(false);">kindred</a> of more than 800
members of a Utah Mormon family in which a <Span Class="Protocol-GeneName">BRCA1</Span> mutation accounts for the
observed increased rates of breast and ovarian cancer.  A study of the
understanding that members of this kindred have about breast/ovarian cancer
genetics found that, even in breast cancer research populations, there was
incomplete knowledge about associated risks of colon and prostate cancer, the
existence of options for risk-reducing mastectomy and risk-reducing oophorectomy,
and the complexity of existing psychosocial risks.<a href="#Reference5.3">3</a>  
A meta-analysis of 21 studies found that genetic counseling was effective in increasing knowledge and improved the accuracy of perceived risk. Genetic counseling did not have a statistically significant long-term impact on affective outcomes including anxiety, distress, or cancer-specific worry and the behavioral outcome of cancer surveillance activities.<a href="#Reference5.44">44</a> These prospective studies, however, were characterized by a heterogeneity of measures of cancer-specific worry and inconsistent findings in effects of change from baseline.<a href="#Reference5.44">44</a></P>
<a name="Section_297" /><P __id="_297">It is not yet clearly established to what extent findings derived from special
research populations, at least some of which have long awaited genetic testing
for breast/ovarian cancer risk, are generalizable to other populations.  For
example, there are data to suggest that the <Span Class="Protocol-GeneName">BRCA1/2</Span> <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339344&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339344&amp;version=HealthProfessional&amp;language=English');  return(false);">penetrance</a> estimates
derived from these dramatically affected families are substantial overestimates
and do not apply to most families presenting for counseling and
possible testing.<a href="#Reference5.78">78</a></P>
</a>
<a name="Section_298"><Span class="Summary-SummarySection-Title-Level2">Emotional Outcomes of Individuals</Span>
<a name="Section_299" /><P __id="_299">The few studies conducted to date of psychological outcomes associated with
genetic testing for mutations in breast/ovarian cancer <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460208&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460208&amp;version=HealthProfessional&amp;language=English');  return(false);">predisposition genes</a>  have shown
low levels of distress among those found to be carriers and even lower levels
among noncarriers.<a href="#Reference5.21">21</a><a href="#Reference5.61">61</a><a href="#Reference5.79">79</a><a href="#Reference5.80">80</a>  A systematic review found that the studies assessing
measures of distress (9 of 11 studies) found no change, or a decrease, in those
parameters (including anxiety, depression, general distress, and situation
distress) in people who had undergone testing at assessments done at 1 month or
less, and 3 to 6 months later.<a href="#Reference5.81">81</a> Few studies have conducted longer term
follow-up.  One long-term study of 65 female participants explored the psychosocial consequences of carrying a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation 5 years after genetic testing.  Carriers did not differ from noncarriers on several distress measures. Although both groups showed significant increases in depression and anxiety compared with one year postdisclosure, these scores remained within normal limits for the general population.<a href="#Reference5.82">82</a> Caution is advised by authors of these studies in interpretation of
the results as they are all from programs in which results disclosure was
preceded by extensive genetic counseling about risks and benefits of <Span Class="Protocol-GeneName">BRCA1/2</Span>
testing, psychological assessment, and even, occasionally, exclusion of a few
individuals who appeared highly distressed.<a href="#Reference5.3">3</a>  Intrusive thoughts (measured
by the Impact of Event Scale [IES]) <a href="#Reference5.83">83</a> about cancer diminished after results
disclosure for both mutation-positive and mutation-negative individuals in 1
Dutch study.<a href="#Reference5.84">84</a> </P>
<a name="Section_660" /><P __id="_660">Despite generally positive findings regarding diminished distress in tested individuals, most studies also report increased distress among small subsets of tested individuals.  Most, but not all, of these increases are within the normal range of distress.  Increased distress has been noted by individuals receiving both positive and negative test results. Studies suggest that the psychological impact of an individual test result is highly influenced by the test result status of other family members. A 1999 study found that an individual’s response to learning his or her own <Span Class="Protocol-GeneName">BRCA1/2</Span> test result was significantly influenced by his or her gender and by the genetic test result status of other family members. Adverse, immediate outcomes were experienced by male carriers who were the first tested in their family or by noncarrier men whose siblings were all positive. In addition, female carriers who were the first in their families to be tested or whose siblings were all negative had significantly higher distress than other female carriers.<a href="#Reference5.24">24</a> Another study found that spousal anxiety about genetic testing and supportiveness differentiated the impact of <Span Class="Protocol-GeneName">BRCA1/2</Span> test results. When the spouse was highly anxious and nonsupportive in style, the mutation carrier had significantly higher levels of distress. These studies illustrate that genetic test results are not received in a vacuum, and that researchers need to consider the context of the tested individual in determining which individuals applying for genetic testing may require additional emotional support.<a href="#Reference5.67">67</a>  </P><a name="Section_300" /><P __id="_300">In another study, depression rates postdisclosure were unchanged for mutation
carriers and markedly decreased for noncarriers.<a href="#Reference5.25">25</a>  An analysis of the
distress of individuals receiving <Span Class="Protocol-GeneName">BRCA1</Span> results in the context of their siblings'
results, however, revealed patterns of response suggesting that certain
subgroups of tested individuals have markedly increased levels of distress
after disclosure that were not apparent when the analysis focused only on
comparing the mean scores for carriers versus noncarriers.<a href="#Reference5.24">24</a>  Early
optimistic findings may not sufficiently reflect the true complexity of
response to disclosure of <Span Class="Protocol-GeneName">BRCA1/2</Span> test results.  Female carriers who had no
carrier siblings had distress scores (IES) similar to those found in cancer
patients 10 weeks after their diagnosis.  The distress of male subjects was
highly correlated with the status of their siblings’ test results or lack
thereof.<a href="#Reference5.24">24</a>  One pilot study suggested that women diagnosed more recently were
more distressed after counseling.<a href="#Reference5.85">85</a>  A survey of women enrolled in a high-risk clinic found that heightened levels of distress may be more related to living with the awareness of a familial risk for cancer than with the genetic testing process itself.  Obtaining genetic testing may be less stressful than living with the awareness of familial risk for cancer.<a href="#Reference5.86">86</a> (Note: For more detailed information about depression and anxiety associated with a cancer diagnosis, refer to the PDQ Supportive Care summaries on <SummaryRef href="CDR0000062790">Anxiety Disorder</SummaryRef>; <SummaryRef href="CDR0000062739">Depression</SummaryRef>; and <SummaryRef href="CDR0000062891">Normal Adjustment and the Adjustment Disorders</SummaryRef>.) Case descriptions have supported the
importance of family relationships and test outcomes in shaping the distress of
tested individuals.<a href="#Reference5.87">87</a><a href="#Reference5.88">88</a> 
</P><a name="Section_404" /><P __id="_404">Although there are not yet reports of large-scale studies of the reactions of affected individuals to genetic testing, there are indications from several smaller studies that affected individuals who undergo genetic counseling and testing experience more distress than had been expected by professionals <a href="#Reference5.89">89</a><a href="#Reference5.90">90</a> and are less able themselves to anticipate the intensity of their reactions following result disclosure.<a href="#Reference5.91">91</a> Female mutation carriers who have had breast cancer are often surprised by their high level of risk for ovarian cancer. Women mutation carriers who have had breast cancer worried more than unaffected women about developing ovarian cancer, though, in general, worry about ovarian cancer risk was found to be unrealistically low.<a href="#Reference5.90">90</a> In addition, some distress related to the burden of conveying genetic information to relatives has been noted among those who are the first in their families to be tested.<a href="#Reference5.89">89</a><a href="#Reference5.92">92</a></P>
<a name="Section_630" /><P __id="_630">Several studies have compared the provision of breast cancer genetics services by different providers and the psychological impact on women at high and low risk for cancer. In a study of 735 women at all levels of risk for hereditary breast/ovarian cancer, the services of a multidisciplinary team of genetics specialists was compared with services provided by surgeons. There were no significant differences between groups in anxiety, cancer worry, or perceived risk.<a href="#Reference5.93">93</a> In a Scottish study of 373 participants, an alternative model of cancer genetics services using genetics nurse specialists in community-based services was compared with standard genetics regional services. There was no difference in cancer worry or change in health behaviors between the 2 groups. Cancer worry decreased for both groups over a 6-month period. Women who dropped out of the study tended to be in the nurse provider arm or were at low risk of breast cancer.<a href="#Reference5.94">94</a> In a small U.S. study, an evaluation of nurses and genetic counselors as providers of education about breast cancer susceptibility testing was conducted to compare outcomes of pretest education about breast cancer susceptibility. Four genetic counselors and 2 nurses completed specialized training in cancer genetics. Women receiving pretest education from nurses were as satisfied with information received and had equal degrees of perceived autonomy and partnership. The study findings suggest that with proper training and supervision, both genetic counselors and nurses can be effective in providing pretest education to women considering genetic susceptibility testing for breast cancer risk.<a href="#Reference5.95">95</a></P><a name="Section_301" /><P __id="_301">There has been little empirical research in the communication of risk
assessments to individuals at risk of breast/ovarian cancer syndromes.  When
asked to choose a preferred method, individuals undergoing genetic counseling
for breast and ovarian cancer appear to prefer quantitative to qualitative
presentation of risk information.<a href="#Reference5.96">96</a><a href="#Reference5.97">97</a>  One study indicated that most women wanted information given both ways.<a href="#Reference5.19">19</a>  Information about the risk of
developing breast cancer among women with a family history of breast cancer may
be more accurately recalled when presented as odds ratios rather than in other
forms.<a href="#Reference5.98">98</a> Other studies explored the use of decision aids as an adjunct to standard genetic counseling to assist patients in decisions about cancer risk management (mastectomy vs. surveillance).  One study showed that the use of a decision aid consisting of  individualized value assessment and cancer risk management information after receiving positive <Span Class="Protocol-GeneName">BRCA1/2</Span> test results was associated with fewer intrusive thoughts and lower levels of depression at the 6-month follow-up in unaffected women.  The usage of the decision aid did not alter cancer risk management intentions and behaviors. Slightly detrimental effects on well-being and several decision-related outcomes, however, were noted among affected women.<a href="#Reference5.99">99</a>
</P>
<a name="Section_302" /><P __id="_302">Preferences for delivery of breast cancer genetic testing are reported in 1
study <a href="#Reference5.97">97</a> to include counseling conducted by a genetic counselor (42%) or
oncologist (22%) rather than by a primary care physician (6%), nurse (12%), or
gynecologist (5%).  Patients in that study preferred results disclosure by an
oncologist.  Younger women especially expressed a need for individual
consideration of their personal values and goals or potential emotional
reactions to testing; 67% believed emotional support and counseling were a
necessary part of posttest counseling.  Most women (82%) wanted to
be able to self-refer for genetic testing, without a physician referral.
</P>
</a>
<a name="Section_303"><Span class="Summary-SummarySection-Title-Level2">Family Effects</Span>
<a name="Section_977" /><P __id="_977">Family communication about genetic testing for cancer susceptibility, and 
specifically about the results of <Span Class="Protocol-GeneName">BRCA1/2</Span> genetic testing, is complex; there are
few systematic data available on this topic.  Gender appears to be an important variable in family communication and psychological outcomes.  One
study documents that female carriers are more likely to disclose their status
to other family members (especially sisters and children aged 14-18 years) than
are male carriers.<a href="#Reference5.100">100</a>  Among males, noncarriers were more likely than carriers
to tell their sisters and children the results of their tests.  <Span Class="Protocol-GeneName">BRCA1/2</Span>
carriers who disclosed their results to sisters had a slight decrease in
psychological distress, compared with a slight increase in distress for carriers
who chose not to tell their sisters.</P><a name="Section_978" /><P __id="_978">Family communication of <Span Class="Protocol-GeneName">BRCA1/2</Span> test results to relatives is another factor affecting participation in testing. For example, it has been observed that in some families in which a mutation is detected, no relatives come forward for predictive genetic testing, and distant relatives pursue genetic testing less frequently.  There have been more studies of communication with first-degree and second-degree relatives than with more distant family members. One study investigated the process and content of communication among sisters about <Span Class="Protocol-GeneName">BRCA1/2</Span> test results.<a href="#Reference5.101">101</a> Study results suggest that both mutation carriers and women with uninformative results communicate with sisters to provide them with genetic risk information. Among relatives with whom genetic test results were not discussed, the most important reason given was that the affected women were not close to their relatives. Other studies found that women with a <Span Class="Protocol-GeneName">BRCA</Span> mutation more often shared their results with their adult sisters and daughters than with their adult brothers and sons;<a href="#Reference5.102">102</a> and another study found that disclosure was limited mainly to first-degree relatives, and dissemination of information to distant relatives was problematic.<a href="#Reference5.103">103</a> Age was a significant factor in informing distant relatives with younger patients being more willing to communicate their genetic test result.<a href="#Reference5.101">101</a><a href="#Reference5.102">102</a><a href="#Reference5.103">103</a></P><a name="Section_979" /><P __id="_979">A few in-depth qualitative studies have looked at issues associated with family communication about genetic testing. Although the findings from these studies may not be generalizable to the larger population of at-risk persons, they illustrate the complexity of issues involved in conveying hereditary cancer risk information in families.<a href="#Reference5.104">104</a>  On the basis of 15 interviews conducted with women attending a familial cancer genetics clinic, the authors concluded that while women felt a sense of duty to discuss genetic testing with their relatives, they also experienced conflicting feelings of uncertainty, respect, and isolation.  Decisions on whom in the family to inform and how to inform them about hereditary cancer and genetic testing may be influenced by tensions between women's need to fulfill social roles and their responsibilities toward themselves and others.<a href="#Reference5.104">104</a></P><a name="Section_980" /><P __id="_980">There is a small but growing body of literature regarding psychological effects in men who have a family history of breast cancer and who are considering or have had <Span Class="Protocol-GeneName">BRCA</Span> testing. A qualitative study of 22 men from 16 high-risk families in Ireland revealed that more men in the study with daughters were tested than men without daughters.  These men reported little communication with relatives about the illness, with some men reporting being excluded from discussion about cancer among female family members.  Some men in the study also reported actively avoiding open discussion with daughters and other relatives.<a href="#Reference5.105">105</a> In contrast, a study of 59 men testing positive for a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation found that most men participated in family discussions about breast and/or ovarian cancer. However, fewer than half of the men participated in family discussions about risk-reducing surgery. The main reason given for having <Span Class="Protocol-GeneName">BRCA</Span> testing was concern for their children and a need for certainty about whether they could have transmitted the mutation to their children. In this study, 79% of participating men had at least one daughter. Most of these men described how their relationships had been strengthened after receipt of <Span Class="Protocol-GeneName">BRCA</Span> results, helping communication in the family and greater understanding.<a href="#Reference5.106">106</a> Men in both studies expressed fears of developing cancer themselves.  Irish men especially reported fear of cancer in sexual organs.</P><a name="Section_981" /><P __id="_981">A study of Dutch men at increased risk of having inherited a <Span Class="Protocol-GeneName">BRCA1</Span> mutation reported a tendency for the men to deny or minimize the emotional effects of their risk status, and to focus on medical implications for their female relatives. Men in these families, however, also reported considerable distress in relation to their female relatives.<a href="#Reference5.107">107</a>  In another study of male psychological functioning during breast cancer testing, 28 men belonging to 18 different high-risk families (with a 25% or 50% risk of having inherited a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation) participated.  The study purpose was to analyze distress in males at risk of carrying a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation who 
applied for genetic testing.  Of the men studied, most had low 
pretest distress; scores were lowest for men who were optimistic or who did not have daughters. Most mutation carriers had normal levels of anxiety and depression and reported no guilt, though some anticipated increased distress and feelings of responsibility if their daughters developed breast or ovarian cancer. None of the noncarriers reported feeling guilty.<a href="#Reference5.108">108</a> In one study,<a href="#Reference5.106">106</a>  adherence to recommended screening guidelines after testing was analyzed.  In this study, more than half of male carriers of mutations did not adhere to the screening guidelines recommended after disclosure of genetic test results. These findings are consistent with those for female carriers of <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations.<a href="#Reference5.106">106</a><a href="#Reference5.109">109</a></P><a name="Section_982" /><P __id="_982">Testing for <Span Class="Protocol-GeneName">BRCA1/2</Span> has been almost universally limited to adults older than 18
years.  The risks of testing children for adult-onset disorders (such as breast
and ovarian cancer), as inferred from developmental data on children’s medical 
understanding and ability to provide informed consent, have been outlined in
several reports.<a href="#Reference5.110">110</a><a href="#Reference5.111">111</a><a href="#Reference5.112">112</a>  Surveys of parental interest in testing children
for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=339332&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000339332&amp;version=HealthProfessional&amp;language=English');  return(false);">late-onset</a> hereditary cancers suggest that parents are more eager to
test their children than to be tested themselves for a breast cancer gene,
suggesting potential conflicts for providers.<a href="#Reference5.113">113</a><a href="#Reference5.114">114</a>  In a general population
survey in the United States, 71% of parents said that it was moderately, very,
or extremely likely that if they carried a breast-cancer predisposing mutation,
they would test a 13-year-old daughter now to determine her breast cancer
gene status.<a href="#Reference5.113">113</a>  To date, no data exist on the testing of children for
<Span Class="Protocol-GeneName">BRCA1/2</Span>, though some researchers believe it is necessary to test the validity
of assumptions underlying the general prohibition of testing of children for
breast/ovarian cancer and other adult-onset disease genes.<a href="#Reference5.115">115</a><a href="#Reference5.116">116</a><a href="#Reference5.117">117</a> In 1 study,  20 children (aged 11-17 years) of a selected group of mothers undergoing genetic testing (80% of whom previously had breast cancer and all of whom had discussed <Span Class="Protocol-GeneName">BRCA1/2</Span> testing with their children) completed self-report questionnaires on their health beliefs and attitudes toward cancer, feelings related to cancer, and behavioral problems.<a href="#Reference5.118">118</a> Ninety percent of children thought they would want cancer risk information as adults; half worried about themselves or a family  member developing cancer. There was no evidence of emotional distress or behavioral problems. Another study by this group <a href="#Reference5.119">119</a> found that 1 month after disclosure of <Span Class="Protocol-GeneName">BRCA1/2</Span> genetic test results, 53% of 42 enrolled mothers of children aged 8–17 years had discussed their result with 1 or more of their children. Age of the child rather than mutation status of the mother influenced whether they were told, as did family health communication style.</P><a name="Section_983" /><P __id="_983">In one study, participants
who told children younger than 13 years about their carrier status had
increased distress, and those who did not tell their young children experienced
a slight decrease in distress. Communication with young children was found to be influenced by developmental variables such as age and style of parent/child communication.<a href="#Reference5.119">119</a></P><a name="Section_984" /><P __id="_984">Prenatal diagnosis of breast/ovarian cancer predisposition is generally
discouraged.<a href="#Reference5.120">120</a>  Adult age at onset, good prognosis for many breast cancer
patients, and the expectation of greater medical progress by the time disease
onset might be expected decades into the future make the prospect of prenatal
diagnosis an uncomfortable one for many geneticists, leading potentially to
charges of eugenics.<a href="#Reference5.113">113</a><a href="#Reference5.121">121</a> Limited data on the use of this technology are available.  In a small series, 26 mutation carriers indicated that pregnancy termination based on mutation status would not be acceptable.  Interestingly, a small percentage of non–mutation carriers felt termination of a pregnancy where the fetus was a mutation carrier was acceptable.<a href="#Reference5.122">122</a> Historically, in Huntington’s disease, the uptake of prenatal diagnosis and termination is low.<a href="#Reference5.123">123</a> <a href="#Reference5.124">124</a></P>
</a>
<a name="Section_308"><Span class="Summary-SummarySection-Title-Level2">Cultural/Community Effects</Span>
<a name="Section_309" /><P __id="_309">The recognition that <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations are prevalent, not only in
breast/ovarian cancer families but also in some ethnic groups,<a href="#Reference5.125">125</a> has led to
considerable discussion of the ethical, psychological, and other implications of
having one’s ethnicity be a factor in determination of disease predisposition. 
Fears of genetic reductionism and the creation of a genetic underclass <a href="#Reference5.126">126</a>
have been voiced.  Questions about the impact on the group of being singled out
as having genetic vulnerability to breast cancer have been raised.  There is
also confusion about who gives or withholds permission for the group to be
involved in studies of their genetic identity.  These issues challenge
traditional views on informed consent as a function of individual autonomy.<a href="#Reference5.127">127</a> 
 </P>
<a name="Section_791" /><P __id="_791">A growing literature on the unique factors influencing a variety of cultural subgroups suggests the importance of developing culturally specific genetic counseling and educational approaches.<a href="#Reference5.65">65</a><a href="#Reference5.128">128</a><a href="#Reference5.129">129</a><a href="#Reference5.130">130</a><a href="#Reference5.131">131</a></P><a name="Section_792" /><P __id="_792">The above data are associated with the subgroups that have been most intensively studied to date, but there will be an emerging literature on this topic.</P></a>
<a name="Section_310"><Span class="Summary-SummarySection-Title-Level2">Ethical Concerns </Span>
<a name="Section_311" /><P __id="_311">The human implications of the ethical issues raised by the advent of genetic
testing for breast/ovarian cancer susceptibility are described in case studies,<a href="#Reference5.132">132</a> essays,<a href="#Reference5.69">69</a><a href="#Reference5.133">133</a> and research reports.  Issues about rights and
responsibilities in families concerning the spread of information about genetic
risk promise to be major ethical and legal dilemmas in the coming decades. 
</P>
<a name="Section_312" /><P __id="_312">Studies have shown that 62% of studied family members were aware of the family
history, and that 88% of hereditary breast/ovarian cancer family members
surveyed have significant concerns about privacy and confidentiality. 
Expressed concern about cancer in third-degree relatives, or relatives farther
removed, was about the same as that for <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460150&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460150&amp;version=HealthProfessional&amp;language=English');  return(false);">first-</a> or second-degree relatives of
the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460211&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460211&amp;version=HealthProfessional&amp;language=English');  return(false);">proband</a>.<a href="#Reference5.134">134</a>  Only half of surveyed first-degree relatives of women with
breast or ovarian cancer felt that written permission should be required to
disclose <Span Class="Protocol-GeneName">BRCA1/2</Span> test results to a spouse or immediate family member. 
Attitudes toward testing varied by ethnicity, previous exposure to genetic
information, age, optimism, and information style.  Altruism is a factor
motivating genetic testing in some people.<a href="#Reference5.37">37</a>  Many
professional groups have made recommendations regarding informed
consent.<a href="#Reference5.35">35</a><a href="#Reference5.37">37</a><a href="#Reference5.73">73</a><a href="#Reference5.135">135</a><a href="#Reference5.136">136</a>  There is some evidence that not all practitioners are
aware of or follow these guidelines.<a href="#Reference5.39">39</a>  Research shows that many <Span Class="Protocol-GeneName">BRCA1/2</Span>
genetic testing consent forms do not fulfill recommendations by professional
groups about the 11 areas that should be addressed,<a href="#Reference5.135">135</a> and they omit highly
relevant points of information.<a href="#Reference5.39">39</a>  In a study of women with a history of breast or ovarian cancer, the interviews yielded that the women reported feeling  inadequately prepared for the ethical dilemmas they encountered when imparting genetic information to family members.<a href="#Reference5.137">137</a> These data suggest that more preparation about disclosure to family members before testing reduces the emotional burden of disseminating genetic information to family members.  Patients and health care providers would benefit from enhanced consideration of the ethical issues of warning family members about hereditary cancer risk.
</P>
</a>
<a name="Section_313"><Span class="Summary-SummarySection-Title-Level2">Psychological Aspects of Medical Interventions</Span>
<a name="Section_314" /><P __id="_314">Risk-reducing mastectomy is 1 of the options for risk reduction recommended for
discussion with women who have an increased risk of developing breast cancer
due to inherited cancer predisposition.<a href="#Reference5.136">136</a>  It is also offered to some women
with a strong family history of breast cancer who have had, or who are
contemplating, removal of 1 breast because of the presence of tumor,<a href="#Reference5.138">138</a> and
to women with premalignant breast disease or extreme cancer fear.<a href="#Reference5.139">139</a> Recommendation for risk-reducing mastectomy has been controversial because of the lack of clarity in criteria for its appropriate use <a href="#Reference5.140">140</a> and limited data on the emotional and social ramifications.<a href="#Reference5.141">141</a> Reports of &gt;90% risk reduction for women at high and moderate risk for breast cancer strengthen the likelihood that providers will discuss risk-reducing mastectomy with women at increased hereditary risk.<a href="#Reference5.23">23</a><a href="#Reference5.142">142</a>  
</P>


<a name="Section_317" /><P __id="_317">Caution is advised in interpreting the value and advisability of risk-reducing
mastectomy among women at increased genetic risk because of the need to
consider the psychological and other costs of surgery.<a href="#Reference5.143">143</a>  
  
</P>
<a name="Section_596" /><P __id="_596">On the other hand, many women found to be mutation carriers express interest in risk-reducing mastectomy in hopes of minimizing their risk of breast cancer.  In 1 study of a number of unaffected women with no previous risk-reducing surgery who received results of <Span Class="Protocol-GeneName">BRCA1</Span> testing following genetic counseling, 17% of carriers (2/12) intended to have mastectomies and 33% (4/12) intended to have oophorectomies.<a href="#Reference5.21">21</a> In a later study of the same population, risk-reducing mastectomy was considered an important option by 35% of women who tested positive, whereas risk-reducing oophorectomy was considered an important option by 76%.  Initial interest does not always translate into the decision for surgery.  One study found that only 3% (1 out of 29) of mutation carriers had a risk-reducing mastectomy in the year following result disclosure.<a href="#Reference5.109">109</a>  In a study of patients in the United Kingdom, data were collected during observations of genetic consultations and in semistructured interviews with 41 women following their attendance at genetic counseling.<a href="#Reference5.144">144</a> The option of risk-reducing surgery was raised in 29 consultations and discussed in 35 of the postclinic interviews.  Fifteen women said they would consider having an oophorectomy in the future, and 9 said they would consider having a mastectomy.  The implications of undergoing oophorectomy and mastectomy were discussed in postclinic interviews.  Risk-reducing surgery was described by the <a Class="Summary-GlossaryTermRef" href="/Common/PopUps/popDefinition.aspx?id=460230&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000460230&amp;version=HealthProfessional&amp;language=English');  return(false);">counselees</a> as providing individuals with a means to (a) fulfill their obligations to other family members and (b) reduce risk and contain their fear of cancer.  The costs of this form of risk management were described by the respondents as:</P><a name="Section_597" /><a name="ListSection" /><UL __id="_597" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Compromising social obligations.</LI><LI class="Protocol-IL-Bullet">Upsetting the natural balance of the body.</LI><LI class="Protocol-IL-Bullet">Not receiving protection from cancer.</LI><LI class="Protocol-IL-Bullet">Operative and postoperative complications.</LI><LI class="Protocol-IL-Bullet">The onset of menopause.</LI><LI class="Protocol-IL-Bullet">The effects of body image, gender, and personal identity.</LI><LI class="Protocol-IL-Bullet">Potential effects on sexual relationships.<a href="#Reference5.144">144</a></LI></UL><a name="END_ListSection" /><a name="Section_598" /><P __id="_598">A number of women choose to undergo risk-reducing mastectomy and risk-reducing oophorectomy without genetic testing because:</P><a name="Section_599" /><a name="ListSection" /><UL __id="_599" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Testing is not readily accessible.</LI><LI class="Protocol-IL-Bullet">They do not wish exposure to the psychosocial risks of genetic testing.</LI><LI class="Protocol-IL-Bullet">They do not trust that a negative genetic test result means they are not at increased risk.</LI><LI class="Protocol-IL-Bullet">They find any level of risk, even baseline population risk, unacceptable.<a href="#Reference5.145">145</a><a href="#Reference5.146">146</a></LI></UL><a name="END_ListSection" /><a name="Section_600" /><P __id="_600">Among first-degree relatives of breast cancer patients attending a surveillance clinic, women who expressed an interest in prophylactic mastectomy and/or had undergone surgery were found to have significantly more breast cancer biopsies (<i>P</i> &lt;.05) and higher subjective 10-year breast cancer risk estimates (<i>P</i> &lt;.05) than women not interested in prophylactic mastectomy. Cancer worry at the time of entry into the clinic was highest among women who subsequently underwent prophylactic mastectomy compared with  women who expressed interest but had not yet had surgery, as well as women who did not intend to have surgery (<i>P</i> &lt;.001).<a href="#Reference5.147">147</a>  </P><a name="Section_601" /><P __id="_601">For the woman having her breasts removed prophylactically, the decision about whether to have reconstruction is often difficult.  Despite assurances that reconstruction will not interfere with detection of any cancer that might develop, some women choose no reconstruction to avoid any continuing worry about a cancer hidden under a reconstructed breast or because of fears about health problems which might develop due to ruptured or leaking implants.</P>







</a>
<a name="Section_602">

<Span class="Summary-SummarySection-Title-Level2">Psychosocial Outcome Studies</Span>


<a name="Section_603" /><P __id="_603">A prospective study conducted in the Netherlands found that among 26 <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers, the 14 women who chose mastectomy had higher distress both before test result disclosure and 6 and 12 months later, compared with the 12 carriers who chose surveillance and compared with 53 nonmutation carriers. Overall, however, anxiety declined in women undergoing prophylactic mastectomy; at 1 year, their anxiety scores were closer to those of women choosing surveillance and to the scores of nonmutation carriers.<a href="#Reference5.148">148</a> Interestingly, women opting for prophylactic mastectomy had lower pretest satisfaction with their breasts and general body image than carriers who opted for surveillance or noncarriers of <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations. Of the women who had a prophylactic mastectomy, all but 1 did not regret the decision at 1 year posttest disclosure, but many had difficulties with body image, sexual interest and functioning, and self-esteem. The perception that doctors had inadequately informed them about the consequences of prophylactic mastectomy was associated with regret.<a href="#Reference5.148">148</a> At 5-year follow-up, women who had undergone risk-reducing mastectomy had less favorable body image and changes in sexual relationships, but also had a significant reduction in the fear of developing cancer.<a href="#Reference5.82">82</a></P>
<a name="Section_604" /><P __id="_604">Mixed psychosocial outcomes were reported in a follow-up study (mean 14 years) of 609 women who received prophylactic mastectomies at the Mayo Clinic.  Seventy percent were satisfied with prophylactic mastectomy, 11% were neutral, and 19% were dissatisfied.  Eighteen percent believed that if they had the choice to make again, they probably or definitely would not have a prophylactic mastectomy.  About three quarters said their worry about cancer was diminished by surgery.  Half reported no change in their satisfaction with body image; 16% reported improved body image following surgery.  Thirty-six percent said they were dissatisfied with their body image following prophylactic mastectomy.  About a quarter of the women reported adverse impact of prophylactic mastectomy on their sexual relationships and sense of femininity, and 18% had diminished self-esteem.  Factors most strongly associated with satisfaction with prophylactic mastectomy were postsurgical satisfaction with appearance, reduced stress, no reconstruction or lack of problems with implants, and no change or improvement in sexual relationships.  Women who cited physician advice as the primary reason for choosing prophylactic mastectomy tended to be dissatisfied following prophylactic mastectomy.<a href="#Reference5.149">149</a></P><a name="Section_690" /><P __id="_690">Quality of life in 59 women who underwent risk-reducing oophorectomy was assessed at 24 months postprocedure.<a href="#Reference5.150">150</a> Overall quality of life was similar to the general population and breast cancer survivors, with approximately 20% reporting depression. The 30% of subjects reporting vaginal dryness and dyspareunia were more likely to report dissatisfaction with the procedure.</P><a name="Section_793" /><P __id="_793">Very little is known about how the results of genetic testing affect treatment decisions at the time of cancer diagnosis.  Two studies explored genetic counseling and <Span Class="Protocol-GeneName">BRCA1/2</Span> genetic testing at the time of breast cancer diagnosis.<a href="#Reference5.151">151</a><a href="#Reference5.152">152</a>  One of these studies found that genetic testing at the time of diagnosis significantly altered surgical decision making, with more mutation carriers than noncarriers opting for bilateral mastectomy.  Bilateral prophylactic mastectomy was chosen by 48% of mutation-positive women <a href="#Reference5.151">151</a> and by 100% of mutation-positive women in a smaller series <a href="#Reference5.152">152</a> of women undergoing testing at the time of diagnosis.  Of women in whom no mutation was found, 24% also opted for bilateral mastectomy.<a href="#Reference5.151">151</a> Physician recommendation was an important determinant of surgical decisions.  </P></a>
<a name="Section_327"><Span class="Summary-SummarySection-Title-Level2">Interventions: Psychological</Span>
<a name="Section_328" /><P __id="_328">Several psychological interventions have been proposed for women who may
have hereditary risk of breast cancer, but few of these have been rigorously
tested.  Issues faced by these women include the following:
</P>
<a name="Section_329" /><a name="ListSection" /><UL __id="_329" class="Protocol-UL"><LI class="Protocol-IL-Bullet">Confronting the meaning of one’s risk status, as well as venting strong
feelings of fear of harm, disfigurement, pain, or death.</LI>
<LI class="Protocol-IL-Bullet">Addressing guilt about passing on genetic risk or not doing enough for
loved ones.</LI>
<LI class="Protocol-IL-Bullet">Managing stress, cancer-related worry, and intrusive thoughts.</LI>
<LI class="Protocol-IL-Bullet">Coaching in problem-solving.</LI>
<LI class="Protocol-IL-Bullet">Facilitating effective decision-making strategies and teaching positive,
active coping behaviors.</LI>
</UL><a name="END_ListSection" />
<a name="Section_330" /><P __id="_330">Psychotherapy for women interested in prophylactic mastectomy is discussed in 1
report.<a href="#Reference5.153">153</a>  Another recommends rehearsal of affective state in the context of
all potential outcomes of cancer genetic testing for <Span Class="Protocol-GeneName">BRCA1/2</Span>.<a href="#Reference5.154">154</a>  As genetic
testing programs grow and the psychological outcomes and behavioral impact of
testing are further defined, there will be an increasing demand for
interventions to maximize the benefits of cancer genetic testing and minimize
the risks to carriers and family members.
</P>
<a name="Section_331" /><P __id="_331">A pilot study demonstrated the usefulness of a 6-session psychoeducational
support group for women at high genetic risk of breast cancer who were
considering prophylactic mastectomy.  The themes for the group sessions
included overestimation of and anxiety about risk, desire for hard data,
emotional impact of watching a mother die of breast cancer, concerns about
spouse reactions, self-image and body image, the decision-making process, and
confusion over whom to trust in decision-making.  Both the participants and the
multidisciplinary leaders concluded that as a supplement to individual
counseling, a support group is a beneficial and cost-effective treatment
modality.<a href="#Reference5.155">155</a>
</P>
</a>
<a name="Section_332"><Span class="Summary-SummarySection-Title-Level2">Behavioral Outcomes</Span>
<a name="Section_333" /><P __id="_333">A study <a href="#Reference5.156">156</a> of screening behaviors of 216 self-referred, high-risk (&gt;10% risk of carrying a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation) women who are members of hereditary breast cancer families found a range of screening practices.  Even the  presence of known mutations in their families was not associated with good adherence to recommended screening practices.  Sixty-nine percent of women aged 50 to 64 years and 83% of women aged 40 to 49 years had had a screening mammogram in the previous year.  Twenty percent of participants had ever had a CA 125 test and 31% had ever had a pelvic or transvaginal ultrasound. Further analysis of this study population <a href="#Reference5.156">156</a> looking specifically at 107 women with informative <Span Class="Protocol-GeneName">BRCA</Span> test results found good use of breast cancer screening, though the uptake rate in younger carriers is lower. The reason for the lower uptake rate was not explored in this study.<a href="#Reference5.157">157</a> One survey of screening behaviors among women at increased risk of breast/ovarian cancer identified physician recommendations as a significant factor in adherence to screening.<a href="#Reference5.158">158</a> While motivations cited for pursuing genetic testing often include increased adherence to breast and/or ovarian screening recommendations,<a href="#Reference5.14">14</a><a href="#Reference5.17">17</a><a href="#Reference5.36">36</a><a href="#Reference5.156">156</a> limited data exist about how much participants in genetic testing alter their screening behaviors over time and about other variables that may influence those behaviors, such as insurance coverage and physician recommendations or attitudes.
</P>
<a name="Section_334" /><P __id="_334">This is a critical issue not only for women testing positive, but also for
adherence to screening for those testing negative as well as those who have
received indeterminate results or choose not to receive their results.  It is
possible that adherence actually diminishes with a decrease in the perceived
risk that may result from a negative genetic test result.
</P>
<a name="Section_335" /><P __id="_335">In addition, while there is still some question regarding the link between
cancer-related worry and breast cancer screening behavior, accumulating
evidence appears to support a linear rather than a curvilinear relationship. 
That is, for some time, the data were not consistent; some data supported the
hypothesis that mild-to-moderate worry may increase adherence, while excessive
worry may actually decrease the utilization of recommended screening practices. 
Other reports support the notion that a linear relationship is more likely;
that is, more worry increases adherence to screening recommendations.  Few
studies, however,  have followed women to assess their health behaviors
following genetic testing.  Thus, a negative test result leading to decreased
worry could theoretically result in decreased screening adherence.  A large study found that patient compliance with screening practices was not related to general or screening-specific anxiety—with the exception of breast self-exam, for which compliance is negatively associated with procedure-specific anxiety.<a href="#Reference5.52">52</a> Further
research designed to clarify this potential concern would highlight the need
for comprehensive genetic counseling to discuss the need for follow-up
screening.  
 </P>
<a name="Section_336" /><P __id="_336">Further complicating this area of research are issues such as the baseline rate
of mammography adherence among women older than 40 or 50 years prior to genetic
testing.  More specifically, the ability to note a significant difference in
adherence on this measure may be affected by the high adherence rate to this
screening behavior before genetic testing by women undergoing such testing.   It
may be easier to find significant changes in mammography use among women with a
family history of breast cancer who test positive.  Finally, adherence over
time will likely be affected by how women undergoing genetic
testing and their caregivers perceive the efficacy of many of the screening options
in question, such as mammography for younger women, breast self-examination,
and ovarian cancer screening (periodic vaginal ultrasound and serum CA 125
measurements), along with the value of preventive interventions.
</P>
<a name="Section_337" /><P __id="_337">The issue of screening decision-making and adherence among women undergoing
genetic testing for breast and ovarian cancer is the subject of several ongoing
trials, and an area of much needed ongoing study.
</P>

</a>        


       <a name="ReferenceSection"><p><Span Class="Summary-ReferenceSection">
							References
						</Span><ol><li><a name="Reference5.1" />Lynch HT, Fitzsimmons ML, Lynch J, et al.: A hereditary cancer consultation clinic. Nebr Med J 74 (12): 351-9, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2608150&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.2" />Eeles RA, ed.: Genetic Predisposition to Cancer. London, England: Chapman and Hall Medical, 1996 
			<A /><br /><br /></li><li><a name="Reference5.3" />Baty BJ, Venne VL, McDonald J, et al.: BRCA1 testing: genetic counseling protocol development and counseling issues. J Genet Couns  6(2): 223-244, 1997 
			<A /><br /><br /></li><li><a name="Reference5.4" />Hoskins IA: Genetic counseling for cancer patients and their families. Oncology (Huntingt) 3 (1): 84-92; discussion 92, 95-8, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2701404&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.5" />Lynch HT, Lynch J: Genetic counseling for hereditary cancer. Oncology (Huntingt) 10 (1): 27-34, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8924364&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.6" />McKinnon WC, Guttmacher AE, Greenblatt MS, et al.: The Familial Cancer Program of the Vermont Cancer Center: development of a cancer genetics program in a rural area. J Genet Couns  6(2): 131-145, 1997 
			<A /><br /><br /></li><li><a name="Reference5.7" />Offit K: Clinical Cancer Genetics: Risk Counseling and Management. New York, NY: John Wiley and Sons, 1998 
			<A /><br /><br /></li><li><a name="Reference5.8" />Peters JA: Familial cancer risk, part II: breast cancer risk counseling and genetic susceptibility testing. J Oncol Manag  3 (6): 14-22, 1994 
			<A /><br /><br /></li><li><a name="Reference5.9" />Ponder BA: Setting up and running a familial cancer clinic. Br Med Bull 50 (3): 732-45, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7987652&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.10" />Collins FS, Thomson EJ: Findings from the cancer genetic studies consortium. Cancer Epidemiol Biomarkers Prev  8 (special issue): 325, 1999 
			<A /><br /><br /></li><li><a name="Reference5.11" />Gwyn K, Vernon SW, Conoley PM: Intention to pursue genetic testing for breast cancer among women due for screening mammography. Cancer Epidemiol Biomarkers Prev 12 (2): 96-102, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12582018&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.12" />Durfy SJ, Bowen DJ, McTiernan A, et al.: Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 8 (4 Pt 2): 369-75, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207642&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.13" />Kash KM, Ortega-Verdejo K, Dabney MK, et al.: Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. Semin Surg Oncol 18 (4): 333-8, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10805955&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.14" />Lerman C, Seay J, Balshem A, et al.: Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 57 (3): 385-92, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7677139&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.15" />Lipkus IM, Iden D, Terrenoire J, et al.: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 8 (6): 533-9, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10385144&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.16" />Richards CS, Ward PA, Roa BB, et al.: Screening for 185delAG in the Ashkenazim. Am J Hum Genet 60 (5): 1085-98, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9150156&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.17" />Struewing JP, Lerman C, Kase RG, et al.: Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 4 (2): 169-73, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7742725&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.18" />Lerman C, Daly M, Masny A, et al.: Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 12 (4): 843-50, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8151327&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.19" />Bluman LG, Rimer BK, Berry DA, et al.: Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 17 (3): 1040-6, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10071299&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.20" />Biesecker BB, Ishibe N, Hadley DW, et al.: Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 93 (4): 257-63, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10946349&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.21" />Lerman C, Narod S, Schulman K, et al.: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275 (24): 1885-92, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8648868&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.22" />Lerman C, Schwartz MD, Lin TH, et al.: The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol 65 (3): 414-20, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9170764&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.23" />Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al.: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 (9220): 2015-20, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10885351&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.24" />Smith KR, West JA, Croyle RT, et al.: Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev 8 (4 Pt 2): 385-92, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207644&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.25" />Lerman C, Hughes C, Lemon SJ, et al.: What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 16 (5): 1650-4, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9586874&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.26" />Armstrong K, Calzone K, Stopfer J, et al.: Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 9 (11): 1251-4, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11097234&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.27" />Lee SC, Bernhardt BA, Helzlsouer KJ: Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer 94 (6): 1876-85, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11920551&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.28" />Bloch M, Fahy M, Fox S, et al.: Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet 32 (2): 217-24, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2522735&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.29" />Craufurd D, Dodge A, Kerzin-Storrar L, et al.: Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 2 (8663): 603-5, 1989. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2570293&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.30" />Lerman C, Hughes C, Trock BJ, et al.: Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281 (17): 1618-22, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10235155&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.31" />Quaid KA, Morris M: Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 45 (1): 41-5, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8418657&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.32" />Bowen DJ, Patenaude AF, Vernon SW: Psychosocial issues in cancer genetics: from the laboratory to the public. Cancer Epidemiol Biomarkers Prev 8 (4 Pt 2): 326-8, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207636&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.33" />Lodder L, Frets PG, Trijsburg RW, et al.: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet 119A (3): 266-72, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12784290&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.34" />Foster C, Evans DG, Eeles R, et al.: Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Test 8 (1): 23-9, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15140371&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.35" />Rimer BK, Schildkraut JM, Lerman C, et al.: Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. Cancer 77 (11): 2348-55, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8635106&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.36" />Jacobsen PB, Valdimarsdottier HB, Brown KL, et al.: Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 59 (5): 459-66, 1997 Sep-Oct. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9316177&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.37" />Geller G, Doksum T, Bernhardt BA, et al.: Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions. Cancer Epidemiol Biomarkers Prev 8 (4 Pt 2): 377-83, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207643&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.38" />Lerman C, Hughes C, Benkendorf JL, et al.: Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol Biomarkers Prev 8 (4 Pt 2): 361-7, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207641&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.39" />Durfy SJ, Buchanan TE, Burke W: Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing. Am J Med Genet 75 (1): 82-7, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9450863&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.40" />Kash KM, Holland JC, Halper MS, et al.: Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 84 (1): 24-30, 1992. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1738170&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.41" />Lerman C, Schwartz M: Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Res Treat 28 (2): 145-55, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8173067&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.42" />Armstrong K, Stopfer J, Calzone K, et al.: What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test 6 (2): 115-8, 2002 Summer. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12215250&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.43" />Winer E, Winer N, Bluman L, et al.: Attitudes and risk perceptions of women with breast cancer considering testing for BRCA1/2. [Abstract] Proceedings of the American Society of Clinical Oncology  16: A1937, 537a, 1997 
			<A /><br /><br /></li><li><a name="Reference5.44" />Braithwaite D, Emery J, Walter F, et al.: Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 96 (2): 122-33, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14734702&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.45" />Hallowell N, Statham H, Murton F: Women's understanding of their risk of developing breast/ovarian cancer before and after genetic counseling. J Genet Couns  7(4): 345-364, 1998 
			<A /><br /><br /></li><li><a name="Reference5.46" />MacDonald DJ, Choi J, Ferrell B, et al.: Concerns of women presenting to a comprehensive cancer centre for genetic cancer risk assessment. J Med Genet 39 (7): 526-30, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12114489&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.47" />Iglehart JD, Miron A, Rimer BK, et al.: Overestimation of hereditary breast cancer risk. Ann Surg 228 (3): 375-84, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9742920&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.48" />Bluman LG, Rimer BK, Regan Sterba K, et al.: Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology 12 (5): 410-27, 2003 Jul-Aug. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12833555&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.49" />McCaul KD, O'Donnell SM: Naive beliefs about breast cancer risk. Womens Health 4 (1): 93-101, 1998 Spring. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9520608&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.50" />Huiart L, Eisinger F, Stoppa-Lyonnet D, et al.: Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. J Clin Epidemiol 55 (7): 665-75, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12160914&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.51" />Davis S, Stewart S, Bloom J: Increasing the accuracy of perceived breast cancer risk: results from a randomized trial with Cancer Information Service callers. Prev Med 39 (1): 64-73, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15207987&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.52" />Lindberg NM, Wellisch D: Anxiety and compliance among women at high risk for breast cancer. Ann Behav Med 23 (4): 298-303, 2001 Fall. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11761347&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.53" />Ritvo P, Irvine J, Robinson G, et al.: Psychological adjustment to familial-genetic risk assessment for ovarian cancer: predictors of nonadherence to surveillance recommendations. Gynecol Oncol 84 (1): 72-80, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11748980&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.54" />Meiser B, Halliday JL: What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med 54 (10): 1463-70, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12061481&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.55" />Green J, Richards M, Murton F, et al.: Family communication and genetic counseling: the case of hereditary breast and ovarian cancer. J Genet Couns  6(1): 45-60, 1997 
			<A /><br /><br /></li><li><a name="Reference5.56" />Theis B, Boyd N, Lockwood G, et al.: Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev 3 (4): 321-7, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7950886&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.57" />Breuer B, Kash KM, Rosenthal G, et al.: Reporting bilaterality status in first-degree relatives with breast cancer: a validity study. Genet Epidemiol 10 (4): 245-56, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8224805&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.58" />Parent ME, Ghadirian P, Lacroix A, et al.: The reliability of recollections of family history: implications for the medical provider. J Cancer Educ 12 (2): 114-20, 1997 Summer. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9229275&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.59" />Kerber RA, Slattery ML: Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146 (3): 244-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9247008&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.60" />Kerr B, Foulkes WD, Cade D, et al.: False family history of breast cancer in the family cancer clinic. Eur J Surg Oncol 24 (4): 275-9, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9724992&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.61" />Schwartz MD, Peshkin BN, Hughes C, et al.: Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20 (2): 514-20, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11786581&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.62" />Green MJ, Biesecker BB, McInerney AM, et al.: An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. Am J Med Genet 103 (1): 16-23, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11562929&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.63" />Green MJ, McInerney AM, Biesecker BB, et al.: Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor. Am J Med Genet 103 (1): 24-31, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11562930&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.64" />Dabney MK, Huelsman K: Counseling by computer: breast cancer risk and genetic testing. Developed by the University of Wisconsin-Madison Department of Medicine and the Program in Medical Ethics. Genet Test 4 (1): 43-4, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10794359&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.65" />Baty BJ, Kinney AY, Ellis SM: Developing culturally sensitive cancer genetics communication aids for African Americans. Am J Med Genet 118A (2): 146-55, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12655495&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.66" />Calzone KA: Predisposition testing for breast and ovarian cancer susceptibility. Semin Oncol Nurs 13 (2): 82-90, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9114475&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.67" />Wylie JE, Smith KR, Botkin JR: Effects of spouses on distress experienced by BRCA1 mutation carriers over time. Am J Med Genet 119C (1): 35-44, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12704636&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.68" />Kelly PT: Understanding Breast Cancer Risk. Philadelphia, Pa: Temple University Press, 1991 
			<A /><br /><br /></li><li><a name="Reference5.69" />Hubbard R, Lewontin RC: Pitfalls of genetic testing. N Engl J Med 334 (18): 1192-4, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602190&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.70" />Richards MP, Hallowell N, Green JM, et al.: Counseling families with hereditary breast and ovarian cancer: a psychosocial perspective. J Genet Couns  4(3): 219-233, 1995 
			<A /><br /><br /></li><li><a name="Reference5.71" />Hoskins KF, Stopfer JE, Calzone KA, et al.: Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 273 (7): 577-85, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7837392&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.72" />Schneider KA: Genetic counseling for BRCA1/BRCA2 testing. Genet Test 1 (2): 91-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10464632&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.73" />McKinnon WC, Baty BJ, Bennett RL, et al.: Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA 278 (15): 1217-20, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333247&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.74" />Cummings S, Olopade O: Predisposition testing for inherited breast cancer. Oncology (Huntingt) 12 (8): 1227-41; discussion 1241-2, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11236312&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.75" />Lipkus IM, Klein WM, Rimer BK: Communicating breast cancer risks to women using different formats. Cancer Epidemiol Biomarkers Prev 10 (8): 895-8, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11489757&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.76" />Butow PN, Lobb EA: Analyzing the process and content of genetic counseling in familial breast cancer consultations. J Genet Couns 13 (5): 403-24, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15604639&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.77" />Lerman C, Audrain J, Croyle RT: DNA-testing for heritable breast cancer risks: lessons from traditional genetic counseling. Ann Behav Med  16(4): 327-333, 1994 
			<A /><br /><br /></li><li><a name="Reference5.78" />Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (20): 1401-8, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9145676&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.79" />Croyle RT, Smith KR, Botkin JR, et al.: Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 16 (1): 63-72, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9028816&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.80" />Reichelt JG, Heimdal K, Møller P, et al.: BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample. Fam Cancer 3 (1): 21-8, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15131402&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.81" />Broadstock M, Michie S, Marteau T: Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 8 (10): 731-8, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11039571&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.82" />van Oostrom I, Meijers-Heijboer H, Lodder LN, et al.: Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21 (20): 3867-74, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14551306&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.83" />Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: a measure of subjective stress. Psychosom Med 41 (3): 209-18, 1979. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=472086&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.84" />DudokdeWit AC, Tibben A, Duivenvoorden HJ, et al.: Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. J Med Genet 35 (9): 745-54, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9733033&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.85" />Wood ME, Mullineaux L, Rahm AK, et al.: Impact of BRCA1 testing on women with cancer: a pilot study. Genet Test 4 (3): 265-72, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11142757&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.86" />Coyne JC, Kruus L, Racioppo M, et al.: What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? Am J Med Genet 116A (3): 222-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12503096&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.87" />DudokdeWit AC, Tibben A, Frets PG, et al.: BRCA1 in the family: a case description of the psychological implications. Am J Med Genet 71 (1): 63-71, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9215771&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.88" />Macke E: A family history of breast and ovarian cancer. In: Marteau T, Richards M, eds.: The Troubled Helix: Social and Psychological Implications of the New Human Genetics. Cambridge, England: Cambridge University Press, 1996, pp 31-37 
			<A /><br /><br /></li><li><a name="Reference5.89" />Bonadona V, Saltel P, Desseigne F, et al.: Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev 11 (1): 97-104, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11815406&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.90" />Bish A, Sutton S, Jacobs C, et al.: Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer 86 (1): 43-50, 2002 Jan  7. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11857010&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.91" />Dorval M, Patenaude AF, Schneider KA, et al.: Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 18 (10): 2135-42, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10811679&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.92" />Hallowell N, Foster C, Ardern-Jones A, et al.: Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. Genet Test 6 (2): 79-87, 2002 Summer. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12215246&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.93" />Brain K, Norman P, Gray J, et al.: A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. Br J Cancer 86 (2): 233-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11870512&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.94" />Fry A, Cull A, Appleton S, et al.: A randomised controlled trial of breast cancer genetics services in South East Scotland: psychological impact. Br J Cancer 89 (4): 653-9, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12915873&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.95" />Bernhardt BA, Geller G, Doksum T, et al.: Evaluation of nurses and genetic counselors as providers of education about breast cancer susceptibility testing. Oncol Nurs Forum 27 (1): 33-9, 2000 Jan-Feb. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10660921&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.96" />Hallowell N, Statham H, Murton F, et al.: "Talking about chance": the presentation of risk information during genetic counseling for breast and ovarian cancer. J Genet Couns  6(3): 269-286, 1997 
			<A /><br /><br /></li><li><a name="Reference5.97" />Audrain J, Rimer B, Cella D, et al.: Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 16 (1): 133-8, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440734&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.98" />Watson M, Duvivier V, Wade Walsh M, et al.: Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet 35 (9): 731-8, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9733031&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.99" />van Roosmalen MS, Stalmeier PF, Verhoef LC, et al.: Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. J Clin Oncol 22 (16): 3293-301, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310772&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.100" />Lerman C, Peshkin BN, Hughes C, et al.: Family disclosure in genetic testing for cancer susceptibility: determinants and consequences. Journal of Health Care Law and Policy  1(2): 353-373, 1998 
			<A /><br /><br /></li><li><a name="Reference5.101" />Hughes C, Lerman C, Schwartz M, et al.: All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 107 (2): 143-50, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11807889&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.102" />Wagner Costalas J, Itzen M, Malick J, et al.: Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet 119C (1): 11-8, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12704633&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.103" />Claes E, Evers-Kiebooms G, Boogaerts A, et al.: Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet 116A (1): 11-9, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12476445&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.104" />Foster C, Eeles R, Ardern-Jones A, et al.: Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing. Psychol Health  19 (4): 439-55, 2004 
			<A /><br /><br /></li><li><a name="Reference5.105" />McAllister MF, Evans DG, Ormiston W, et al.: Men in breast cancer families: a preliminary qualitative study of awareness and experience. J Med Genet 35 (9): 739-44, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9733032&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.106" />Liede A, Metcalfe K, Hanna D, et al.: Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 67 (6): 1494-504, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11063672&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.107" />DudokdeWit AC, Tibben A, Frets PG, et al.: Males at-risk for the BRCA1 gene, the psychological impact. Psychooncology
  5(3): 251-257, 1996 
			<A /><br /><br /></li><li><a name="Reference5.108" />Lodder L, Frets PG, Trijsburg RW, et al.: Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet 9 (7): 492-500, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11464240&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.109" />Lerman C, Hughes C, Croyle RT, et al.: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31 (1): 75-80, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896846&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.110" />Patenaude AF: Cancer susceptibility testing: risks, benefits, and personal beliefs. In: Clarke A, ed.: The Genetic Testing of Children. Oxford, England: BIOS Scientific, 1998, pp 145-156 
			<A /><br /><br /></li><li><a name="Reference5.111" />Richards M: The genetic testing of children: adult attitude's and children's understanding. In: Clarke A, ed.: The Genetic Testing of Children. Oxford, England: BIOS Scientific, 1998, pp 169-179 
			<A /><br /><br /></li><li><a name="Reference5.112" />Wertz DC, Fanos JH, Reilly PR: Genetic testing for children and adolescents. Who decides? JAMA 272 (11): 875-81, 1994. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8078166&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.113" />Wertz DC: International perspectives. In: Clarke A, ed.: The Genetic Testing of Children. Oxford, England: BIOS Scientific, 1998, pp 271-287 
			<A /><br /><br /></li><li><a name="Reference5.114" />Benkendorf JL, Reutenauer JE, Hughes CA, et al.: Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. Am J Med Genet 73 (3): 296-303, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9415688&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.115" />Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 57 (5): 1233-41, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7485175&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.116" />Michie S, Marteau TM: Predictive genetic testing in children: the need for psychological research. In: Clarke A, ed.: The Genetic Testing of Children. Oxford, England: BIOS Scientific, 1998, pp 169-182 
			<A /><br /><br /></li><li><a name="Reference5.117" />MacDonald DJ, Lessick M: Hereditary cancers in children and ethical and psychosocial implications. J Pediatr Nurs 15 (4): 217-25, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10969494&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.118" />Tercyak KP, Peshkin BN, Streisand R, et al.: Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psychooncology 10 (4): 336-46, 2001 Jul-Aug. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11462232&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.119" />Tercyak KP, Peshkin BN, DeMarco TA, et al.: Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns 47 (2): 145-53, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12191538&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.120" />Wagner TM, Ahner R: Prenatal testing for late-onset diseases such as mutations in the breast cancer gene 1 (BRCA1). Just a choice or a step in the wrong direction? Hum Reprod 13 (5): 1125-6, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9647529&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.121" />Dickens BM, Pei N, Taylor KM: Legal and ethical issues in genetic testing and counseling for susceptibility to breast, ovarian and colon cancer. CMAJ 154 (6): 813-8, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8634959&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.122" />Lodder LN, Frets PG, Trijsburg RW, et al.: Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands. J Med Genet 37 (11): 883-4, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11185074&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.123" />Tibben A, Frets PG, van de Kamp JJ, et al.: On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. Am J Med Genet 48 (2): 103-11, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8362926&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.124" />Adam S, Wiggins S, Whyte P, et al.: Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet 30 (7): 549-56, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8411026&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.125" />Struewing JP, Abeliovich D, Peretz T, et al.: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11 (2): 198-200, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7550349&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.126" />Rothenberg KH: Breast cancer, the genetic "quick fix," and the Jewish community. Ethical, legal, and social challenges. Health Matrix Clevel 7 (1): 97-124, 1997 Winter. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10167180&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.127" />Foster MW, Bernsten D, Carter TH: A model agreement for genetic research in socially identifiable populations. Am J Hum Genet 63 (3): 696-702, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9718343&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.128" />Burhansstipanov L, Bemis LT, Dignan MB: Native American cancer education: genetic and cultural issues. J Cancer Educ 16 (3): 142-5, 2001 Autumn. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11603876&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.129" />Hughes C, Fasaye GA, LaSalle VH, et al.: Sociocultural influences on participation in genetic risk assessment and testing among African American women. Patient Educ Couns 51 (2): 107-14, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14572939&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.130" />Julian-Reynier CM, Bouchard LJ, Evans DG, et al.: Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92 (4): 959-68, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11550171&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.131" />Phillips KA, Warner E, Meschino WS, et al.: Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet 57 (5): 376-83, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10852372&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.132" />Freedman TG: Genetic susceptibility testing: ethical and social quandaries. Health Soc Work 23 (3): 214-22, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9702553&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.133" />Parens E: Glad and terrified: on the ethics of BRACA1 and 2 testing. Cancer Invest 14 (4): 405-11, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8689437&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.134" />Winter PR, Wiesner GL, Finnegan J, et al.: Notification of a family history of breast cancer: issues of privacy and confidentiality. Am J Med Genet 66 (1): 1-6, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8957501&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.135" />Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14 (5): 1730-6; discussion 1737-40, 1996. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8622094&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.136" />Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277 (12): 997-1003, 1997. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9091675&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.137" />Hallowell N, Foster C, Eeles R, et al.: Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics 29 (2): 74-9; discussion 80-3, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12672886&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.138" />Goin MK, Goin JM: Psychological reactions to prophylactic mastectomy synchronous with contralateral breast reconstruction. Plast Reconstr Surg 70 (3): 355-9, 1982. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7111487&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.139" />Perez FM: Subcutaneous mastectomy: a review. Am Surg 45 (1): 21-5, 1979. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=426367&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.140" />Nemecek JR, Young VL, Lopez MJ: Indications for prophylactic mastectomy. Mo Med 90 (3): 136-40, 1993. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8446090&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.141" />Stefanek M, Hartmann L, Nelson W: Risk-reduction mastectomy: clinical issues and research needs. J Natl Cancer Inst 93 (17): 1297-306, 2001. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11535704&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.142" />Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.143" />Eisen A, Weber BL: Prophylactic mastectomy--the price of fear. N Engl J Med 340 (2): 137-8, 1999. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887166&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.144" />Hallowell N: 'You don't want to lose your ovaries because you think 'I might become a man". Women's perceptions of prophylactic surgery as a cancer risk management option. Psychooncology 7 (3): 263-75, 1998 May-Jun. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9638787&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.145" />Schneider KA, Stopfer JE, Peters JA, et al.: Complexities in cancer risk counseling: presentation of three cases. J Genet Couns  6(2): 147-168, 1997 
			<A /><br /><br /></li><li><a name="Reference5.146" />Tarkan L: My Mother's Breast: Daughters Face Their Mothers' Cancer. Dallas, TX: Taylor Publishing, 1999 
			<A /><br /><br /></li><li><a name="Reference5.147" />Stefanek ME, Helzlsouer KJ, Wilcox PM, et al.: Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 24 (4): 412-9, 1995. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7479633&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.148" />Lodder LN, Frets PG, Trijsburg RW, et al.: One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73 (2): 97-112, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12088120&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.149" />Frost MH, Schaid DJ, Sellers TA, et al.: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284 (3): 319-24, 2000. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10891963&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.150" />Robson M, Hensley M, Barakat R, et al.: Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89 (2): 281-7, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12713992&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.151" />Schwartz MD, Lerman C, Brogan B, et al.: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22 (10): 1823-9, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15067026&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.152" />Weitzel JN, McCaffrey SM, Nedelcu R, et al.: Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138 (12): 1323-8; discussion 1329, 2003. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14662532&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.153" />Massie MJ, Muskin PR, Stewart DE: Psychotherapy with a woman at high risk for developing breast cancer. Gen Hosp Psychiatry 20 (3): 189-97, 1998. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9650038&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.154" />Shoda Y, Mischel W, Miller SM, et al.: Psychological interventions and genetic testing: facilitating informed decisions about BRCA1/2 cancer susceptibility. J Clin Psychol Med Settings  5(1): 3-17, 1998 
			<A /><br /><br /></li><li><a name="Reference5.155" />Karp J, Brown KL, Sullivan MD, et al.: The prophylactic mastectomy dilemma: a support group for women at high genetic risk for breast cancer. J Genet Counsel 8 (3): 163-73, 1999 
			<A /><br /><br /></li><li><a name="Reference5.156" />Isaacs C, Peshkin BN, Schwartz M, et al.: Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat 71 (2): 103-12, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11881908&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.157" />Peshkin BN, Schwartz MD, Isaacs C, et al.: Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11 (10 Pt 1): 1115-8, 2002. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12376518&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li><li><a name="Reference5.158" />Tinley ST, Houfek J, Watson P, et al.: Screening adherence in BRCA1/2 families is associated with primary physicians' behavior. Am J Med Genet A 125 (1): 5-11, 2004. 
			<A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14755459&amp;dopt=Abstract"><span class="Summary-Citation-PUBMED">[PUBMED Abstract]</span></A><br /><br /></li></ol></p></a></a><a name="Section_591">
<Span class="Summary-SummarySection-Title-Level1">Disclaimer</Span>

<a name="Section_592" /><P __id="_592">The designations in PDQ that treatments are “standard” or “under clinical evaluation” are not to be used as a basis for reimbursement determinations.</P>
</a><a name="Section_589">



<Span class="Summary-SummarySection-Title-Level1">Changes to This Summary (01/11/2006)</Span><a name="Section_580" /><P __id="_580">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.
</P><a name="Section_919" /><P __id="_919"><b><SummaryRef href="CDR0000062855#_6">Family History as a Risk Factor for Breast Cancer</SummaryRef></b></P><a name="Section_938" /><P __id="_938">Revised text about the number of female relatives in the family and its influence on the family history as a risk assessment tool, and the genetic susceptibility to breast or other female cancers in families with few women.</P><a name="Section_920" /><P __id="_920"><b><SummaryRef href="CDR0000062855#_11">Family History as a Risk Factor for Ovarian Cancer</SummaryRef></b></P><a name="Section_939" /><P __id="_939">Revised text to include the 2005 U.S. ovarian cancer estimates of 22,220 new cases and 16,210 deaths.</P><a name="Section_921" /><P __id="_921"><b><SummaryRef href="CDR0000062855#_15">Autosomal Dominant Inheritance of Breast/Ovarian Cancer Predisposition</SummaryRef></b></P><a name="Section_940" /><P __id="_940">Revised text about the 50% risk to offspring of inheriting a predisposing genetic alteration.</P><a name="Section_941" /><P __id="_941">Revised text about incomplete penetrance and gender-related expression.</P><a name="Section_942" /><P __id="_942">Revised text to include the possible increased risk of benign features as a family characteristic that suggests a hereditary breast and ovarian cancer predisposition.</P><a name="Section_922" /><P __id="_922"><b><SummaryRef href="CDR0000062855#_25">Other Risk Factors for Breast Cancer</SummaryRef></b></P><a name="Section_943" /><P __id="_943">Added text to state that in 2 of the largest population-based series of breast cancer patients from the United Kingdom, 5.9% of 234 women diagnosed younger than age 35 had a <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutation, and 4.1% of those diagnosed between ages 36 to 45 were positive (cited Peto et al.).</P><a name="Section_944" /><P __id="_944">Added text about a study of women with <Span Class="Protocol-GeneName">BRCA1</Span> or <Span Class="Protocol-GeneName">BRCA2</Span> mutations, in whom parity was not associated with breast cancer risk in <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, but women with more than 4 children had a 38% lower risk compared with nulliparous carriers (cited Cullinane et al.); in contrast, among <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50, and this increase was greatest in the 2-year period following a pregnancy. </P><a name="Section_945" /><P __id="_945">Added text to state that early menarche has been associated with increased risk among <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers but appeared not to influence risk in <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers (cited Kotsopoulos et al.).</P><a name="Section_946" /><P __id="_946">Revised text to state that oral contraceptives are sometimes recommended for ovarian cancer prevention in <Span Class="Protocol-GeneName">BRCA1</Span> and <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers, but studies of their effect on breast cancer risk have been inconsistent.</P><a name="Section_947" /><P __id="_947">Added text to state that in contrast, a population-based study of 47 <Span Class="Protocol-GeneName">BRCA1</Span>- and 36 <Span Class="Protocol-GeneName">BRCA2</Span>-mutation carriers with breast cancer, matched to population controls without mutations, found no increased risk associated with current use of low-dose contraceptive pills for <Span Class="Protocol-GeneName">BRCA2</Span>, and a significantly reduced risk for <Span Class="Protocol-GeneName">BRCA1</Span>.</P><a name="Section_948" /><P __id="_948">Added text to state that one study (cited Brunet et al.) found a reduced risk of breast cancer among <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation carriers who smoked, but an expanded, follow-up study failed to find an association (Ghadirian et al.).</P><a name="Section_923" /><P __id="_923"><b><SummaryRef href="CDR0000062855#_110">Mutations in BRCA1 and BRCA2</SummaryRef></b></P><a name="Section_949" /><P __id="_949">Added Bunyan et al. as reference 19.</P><a name="Section_924" /><P __id="_924"><b><SummaryRef href="CDR0000062855#_117">Penetrance of Mutations</SummaryRef></b></P><a name="Section_950" /><P __id="_950">Added Carcangiu et al. as reference 53.</P><a name="Section_951" /><P __id="_951">Added text about  a case series of 491 women with stage I or stage II breast cancer and a known or suspected deleterious <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation was reviewed for incidence of ovarian cancer; the actuarial risk of developing ovarian cancer at 10 years following diagnosis of breast cancer was 12.7% for <Span Class="Protocol-GeneName">BRCA1</Span> mutation carriers, and 6.8% for <Span Class="Protocol-GeneName">BRCA2</Span> mutation carriers; 8 of 83 cancer deaths in this series were because of ovarian cancer, and systemic treatment for the primary breast cancer did not alter these findings (cited Metcalfe et al.).</P><a name="Section_925" /><P __id="_925"><b><SummaryRef href="CDR0000062855#_79">Models for Prediction of the Likelihood of a BRCA1 or BRCA2 Mutation</SummaryRef></b></P><a name="Section_952" /><P __id="_952">Added text about the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model that was developed to assess both breast and ovarian cancer risks and the probabilities of carrying a <Span Class="Protocol-GeneName">BRCA1/2</Span> mutation (cited Antoniou et al.); this model appears to perform well, particularly in the situation of a family history of breast cancer, compared to the Claus and BRCAPRO models, but because of its complexity, it is not readily applied in a clinical setting and is not included in <SummaryRef href="CDR0000062855#_678">Table 4</SummaryRef>.</P><a name="Section_926" /><P __id="_926"><b><SummaryRef href="CDR0000062855#_136">Pathology/Prognosis of Breast Cancer</SummaryRef></b></P><a name="Section_953" /><P __id="_953">Added text to state that a  population-based case control study of ductal carcinoma <i>in situ</i> patients also found the prevalence of <Span Class="Protocol-GeneName">BRCA</Span> mutations to be similar in these women as previously reported in studies of invasive breast cancer patients (cited Claus et al.), and it appears that ductal carcinoma <i>in situ</i> is a component of the hereditary breast ovarian cancer syndrome.</P><a name="Section_954" /><P __id="_954">Added Palacios et al. as reference 132 and Cavaciuti et al. as reference 194.</P><a name="Section_927" /><P __id="_927"><b><SummaryRef href="CDR0000062855#_177">Breast Cancer</SummaryRef></b></P><a name="Section_955" /><P __id="_955">The <SummaryRef href="CDR0000062855#_858">Magnetic Resonance Imaging</SummaryRef> section was extensively revised  (cited Kuhl et al., Kriege et al., Lehman et al., Leach et al., and Warner et al.).</P><a name="Section_956" /><P __id="_956">Added text to state that in a study of 680 women and who were at various levels of familial risk, from the Mayo Clinic who had bilateral oophorectomy before age 60, the likelihood of breast cancers developing was reduced for all risk groups (cited Olson et al.).</P><a name="Section_928" /><P __id="_928"><b><SummaryRef href="CDR0000062855#_389">Ovarian Cancer</SummaryRef></b></P><a name="Section_957" /><P __id="_957">Revised text about conficting data regarding the effect of oral contraceptives on breast cancer risk, and added that a population-based study found a reduced risk among <Span Class="Protocol-GeneName">BRCA1</Span>-mutation carriers (cited Milne et al.).</P><a name="Section_958" /><P __id="_958">Revised text to state that numerous studies have found that women at inherited risk of breast and ovarian cancer have a decreased risk of ovarian cancer following risk-reducing oophorectomy.</P><a name="Section_959" /><P __id="_959">Added text to state that among 238 individuals in the Creighton Registry with <Span Class="Protocol-GeneName">BRCA1/2</Span> mutations who underwent risk-reducing oophorectomy, 5 subsequently developed intra-abdominal carcinomatosis, and that all 5 of these women had  <Span Class="Protocol-GeneName">BRCA1</Span> mutations (cited Casey et al.).</P><a name="Section_929" /><P __id="_929"><b><SummaryRef href="CDR0000062855#_276">Anticipated and Actual Interest in Genetic Testing</SummaryRef></b></P><a name="Section_960" /><P __id="_960">Revised text to state that limited data are available about the characteristics of at-risk individuals who decline to be or have never been tested.</P><a name="Section_930" /><P __id="_930"><b><SummaryRef href="CDR0000062855#_285">What People Bring to Genetic Testing: Impact of Risk Perception, Health Beliefs, and Personality Characteristics</SummaryRef></b></P><a name="Section_961" /><P __id="_961">Added Davis et al. as reference 51.</P><a name="Section_931" /><P __id="_931"><b><SummaryRef href="CDR0000062855#_298">Emotional Outcomes of Individuals</SummaryRef></b></P><a name="Section_962" /><P __id="_962">Added Reichelt as reference 80.</P></a> 
  <a name="Section_ForMoreInfo_14">
<Span class="Summary-SummarySection-Title-Level1">More Information</Span>

<a name="Section_ForMoreInfo_15" /><P __id="_ForMoreInfo_15"><b>About PDQ</b></P><a name="Section_ForMoreInfo_3" /><a name="ListSection" /><UL __id="_ForMoreInfo_3" class="Protocol-UL"><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/cancerdatabase">PDQ® - NCI's Comprehensive Cancer Database</a>.<a name="Section_ForMoreInfo_4" /><a name="ListSection" /><DL __id="_ForMoreInfo_4"><DD>Full description of the NCI PDQ database.</DD></DL><a name="END_ListSection" /></LI></UL><a name="END_ListSection" /><a name="Section_ForMoreInfo_16" /><P __id="_ForMoreInfo_16"><b>Additional PDQ Summaries</b></P><a name="Section_ForMoreInfo_6" /><a name="ListSection" /><UL __id="_ForMoreInfo_6" class="Protocol-UL"><LI class="Protocol-IL-Bullet"> <a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/adulttreatment">PDQ® Cancer Information Summaries: Adult Treatment</a><a name="Section_ForMoreInfo_7" /><a name="ListSection" /><DL __id="_ForMoreInfo_7"><DD>Treatment options for adult cancers.</DD></DL><a name="END_ListSection" />
 
  </LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/pediatrictreatment">PDQ® Cancer Information Summaries: Pediatric Treatment</a><a name="Section_ForMoreInfo_8" /><a name="ListSection" /><DL __id="_ForMoreInfo_8"><DD>Treatment options for childhood cancers. 
  </DD></DL><a name="END_ListSection" />
</LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/supportivecare">PDQ® Cancer Information Summaries: Supportive Care</a>
<a name="Section_ForMoreInfo_9" /><a name="ListSection" /><DL __id="_ForMoreInfo_9"><DD>Side effects of cancer treatment, management of cancer-related complications and  pain, and psychosocial concerns. 
</DD></DL><a name="END_ListSection" /></LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/screening">PDQ® Cancer Information Summaries: Screening/Detection (Testing for Cancer)</a>
<a name="Section_ForMoreInfo_10" /><a name="ListSection" /><DL __id="_ForMoreInfo_10"><DD>Tests or procedures that detect specific types of cancer. 
  </DD></DL><a name="END_ListSection" /></LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/prevention">PDQ® Cancer Information Summaries: Prevention
</a><a name="Section_ForMoreInfo_11" /><a name="ListSection" /><DL __id="_ForMoreInfo_11"><DD>Risk factors and methods to increase chances of preventing specific types of cancer.</DD></DL><a name="END_ListSection" /> 
  </LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/genetics">PDQ® Cancer Information Summaries: Genetics
</a><a name="Section_ForMoreInfo_12" /><a name="ListSection" /><DL __id="_ForMoreInfo_12"><DD>Genetics of specific cancers and inherited cancer syndromes, and ethical, legal, and social concerns.</DD></DL><a name="END_ListSection" /> 
  </LI><LI class="Protocol-IL-Bullet"><a Class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/cam">PDQ® Cancer Information Summaries: Complementary and Alternative Medicine
</a><a name="Section_ForMoreInfo_13" /><a name="ListSection" /><DL __id="_ForMoreInfo_13"><DD>Information about complementary and alternative forms of treatment for patients with cancer.</DD></DL><a name="END_ListSection" /> 
  </LI></UL><a name="END_ListSection" /><a name="Section_ForMoreInfo_19" /><P __id="_ForMoreInfo_19"><b>Important:</b></P><a name="Section_ForMoreInfo_20" /><P __id="_ForMoreInfo_20"> 

This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at <b>1-800-4-CANCER (1-800-422-6237)</b>.</P></a> 
  </Summary>